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ABSTRACT

Intracellular Ca 2+ ([Ca 2+]i)plays a key role in metabolic disorders associated with obesity
and insulin resistance. Previous data from this laboratory demonstrated that increasing
[Ca2+]i via stimulation of either receptor or voltage-mediated calcium channels stimulates
the expression and activity of fatty acid synthase (FAS), a key enzyme in de nova
lipogenesis, and inhibits basal and agonist-stimulated lipolysis in both human and murine
adipocytes. Therefore, increasing [Ca2+]iappears to promote adipocyte triglyceride
accumulation by exerting a coordinated control over stimulation of lipogenesis and
inhibition of lipolysis. These data suggest that adipocyte [Ca2+]iis a logical target for
pharmacological/nutritional regulation of adiposity. However, the role of [Ca2+]i in
human adipocyte differentiation, an important contributor to adiposity, is unknown.
Moreover, specific adipocyte [Ca2+]itargets need to be further explored. Accordingly, our
studies were designed to (1) determine the role of [Ca2+]i in human adipocyte
differentiation, and (2) identify adipocyte targets which regulate [Ca2+]i and determine
strategies for modulating these targets. We demonstrated that increasing preadipocyte
[Ca2+]i in early stages of differentiation suppresses human adipocyte differentiation,
while increasing [Ca 2+]i late promotes human adipocyte differentiation. To antagonize
adipocyte Ca 2 + influx by blocking Ca2+ channels, we identified a potential receptor target,
the adipocyte sulfonylurea receptor (SUR), which mediates adipocyte [Ca2+]i signaling
and corresponding increased lipogenesis and decreased lipolysis. Antagonism of this
receptor reverses all these actions. We further extended this approach to dietary
regulation of adipocyte [Ca2+]i.We demonstrated that la,25-(0H)2-D

3,

which is regulated

by dietary calcium, also stimulates adipocyte [Ca2+]i,promotes lipogenesis, and inhibits
IV

lipolysis, thereby resulting in triglyceride accumulation, via a rapid non-genomic action
mediated by a putative membrane vitamin D receptor (mVDR). These actions can be
mimicked by la,25-(0H)z-lumisteroh,

a specific agonist for mVDR, and completely

prevented by l/j,25-(0H)z-D 3, a specific antagonist for the mVDR. This led to a
hypothesis that dietary calcium suppression of la.,25-(0H)z-D 3 would reduce adipocyte
[Ca2+]i and thereby inhibit triglyceride accumulation by coordinated control over
lipogenesis and lipolysis. We further confirmed this hypothesis in transgenic mice overexpressing the agouti gene specifically in adipose tissue, similar to the pattern of human
expression. Our data demonstrated that suppression of la.,25-(0H) 2 -D 3by increasing
dietary calcium decreases adipocyte [Ca2+]i, stimulates lipolysis, inhibits lipogenesis in
aP2-agouti transgenic mice and that dietary calcium not only attenuated diet-induced
obesity but also accelerated weight loss and fat mass reduction secondary to caloric
restriction. Notably, high calcium diets also increased white adipose tissue uncoupling
protein 2 (UCP2) expression and core temperature. To determine whether this upregulation ofUCP2 is a direct effect of inhibition of la.,25-(0H) 2-D 3, we evaluated the
role of la.,25-(0H)2-D 3 in regulating human adipocyte UCP2 expression. We
demonstrated that la.,25-(0H)i-D 3 exerts an inhibitory effect on white adipocyte UCP2
expression and that this effect is mediated via a genomic action (nuclear vitamin D
receptor; nVDR). Accordingly, these data demonstrate that SUR-mediated Ca 2+ signaling
and la.,25-(0H)2-D3-mediated genomic and non-genomic pathways play important roles
in regulation of adipocyte lipid and energy metabolism, thereby contributing to
modulation of adiposity, and that antagonism of adipocyte [Ca2+]i by blocking these

V

pathways may represent an effective approach for development of therapeutic
intervention in obesity.
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PARTl
INTRODUCTION

1

INTRODUCTION
Obesity is an increasingly prevalent, costly and serious medical problem in most of the
world. The third National Health and Nutrition Examination Survey (1988-1994) shows
that more than half of American adults are overweight and nearly one-fourth are
clinically obese, with 97 million overweight or obese adults in the U.S (1). Obesity
results from an interaction between genetics and environment (such as diet and physical
activity) (1 ). Unfortunately, strategies to modify the environment factors have met with
little success. Two-thirds of patients who lose weight initially regain weight in one year,
and almost all do so in five years (2). Therefore, modulation of body weight is apparently
resisted by biological mechanisms.

Intracellular Ca 2+ ([Ca 2+]i) plays a key role in metabolic disorders associated with obesity
and insulin resistance (3-5). Recent data from this laboratory demonstrate a pivotal role
for [Ca 2+]i in the regulation of adipocyte lipid metabolism (6, 7). The studies of the
mechanism of action of the agouti gene in obesity have demonstrated that recombinant

agouti protein acts on a novel response element to stimulate the expression and activity of
fatty acid synthase (FAS), a key enzyme in de novo lipogenesis, and inhibit basal and
agonist stimulated lipolysis in a Ca 2+-dependent manner (8-11 ). These effects of agouti in
promoting lipogenesis and suppressing lipolysis can be mimicked by Ca 2+ channel
activation and reversed by Ca 2+ channel antagonism (9-11 ). Therefore, increasing
adipocyte [Ca 2+]i appears to promote triglyceride accumulation by exerting a coordinated
control over stimulation oflipogenesis and inhibition oflipolysis,

2

resulting in an obese

phenotype. These data suggest that adipocyte [Ca2 +]i is a logic target for
pharmacological/nutritional regulation of adiposity.

Although the role of [Ca2 +]i in adipocyte lipid metabolism has been investigated, several
issues still need to be further addressed. [Ca2+]i has also been implicated in regulation of
murine adipocyte differentiation (12). However, the role of [Ca2+]i in human adipocyte
differentiation, an important contributor to human adiposity in vivo (13-16), is not
known. Moreover, exploiting adipocyte [Ca2+]i as a potential target for the development
of intervention in obesity needs to be explored.

Antagonism of [Ca2+]i by either blocking Ca2+ channels or inhibiting Ca2+ agonists is a
logical approach for development of therapeutic intervention in obesity. Indeed, calcium
channel blockade has been proven to reduce body weight and fat pad mass effectively in
several animal studies (17-19). Previous data from this laboratory demonstrated that
treating transgenic mice over-expressing agouti with a Ca2+ channel antagonist
(nifendipine) resulted in significant decreases in adipocyte lipogenesis and corresponding
adipose tissue mass (17). Similarly, Ca2+ channel antagonists, such as nifendipine,
verapamil and felodipine, caused decreases in body weight and fat pad mass in obese
SHHF/Mcc-facp rats (18, 19).

Sulfonylureas, such as glibenclamide, are insulin secretagogues widely used to stimulate
insulin secretion in the treatment of type II diabetes mellitus. These drugs bind to
sulfonylurea receptor (SUR) of pancreatic

p cells and then block the conductance ofKATP
3

channels, thereby resulting in depolarization and secondary Ca2+ influx via L-type Ca2+
channels, which in tum triggers insulin release (20). The

p cell receptor

for sulfonylureas,

sulfonylurea receptor!, has been cloned (20).

Patients using sulfonylureas for type II diabetes develop obesity, while diazoxide, a drug
that activates the

p cell KATP

channel and inhibits sulfonylureas, exerts an anti-obesity

effect in hyperinsulinemic obese human (21) and Zucker rats (22). However, these effects
were previously attributed to direct actions of diazoxide on

p cells, rather than direct

effects of diazoxide on adipocyte metabolism. Nonetheless, these SUR agonists and
antagonist may also exert direct effect on adipocyte [Ca2+]i and lipid metabolism,
resulting in body weight regulation.

On the other hand, identifying and characterizing hormones that modulate [Ca2+]i is a
logical approach for elucidating novel mechanism underlying the modulation of
adipocyte. la,25-dihyroxyvitamin D 3 (la,25-(OH)i-D

3)

was originally believed to solely

function via a nuclear vitamin D receptor (nVDR) to generate genomic action (23).
However, this concept was challenged by recent studies revealing that it also generates
rapid, non-genomic signal transductions including stimulation of [Ca2+]i via a putative
membrane vitamin D receptor (mVDR) in a wide variety of cells (24-28). Although the
role of la,25-(OH) 2 -D3 in modulating adipocyte Ca2+ signaling and lipid metabolism has
not been explored, several lines of evidence demonstrate that circulating la,25-(OH)i-D
levels are elevated in obese humans (29-32).

4
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During the course of a previous clinical trial investigating the anti-hypertensive effect of
calcium in obese African-Americans, it was noted that increasing daily calcium intake
from 400-1000 mg/day for 1 year resulted in a 4.9 Kg reduction in body fat (33). This led
to a hypothesis that increasing la,25-(OH)z-D 3 secondary to low calcium diets stimulates
adipocyte Caz+ influx and thereby increase lipid storage. If this is correct, then increasing
dietary calcium should be able to suppress la,25-(OH)z-D 3 and thereby inhibit adipocyte
[Caz+]i and lipid storage.

Accordingly, our studies were designed to:
I. Determine the role of [Caz+]iin human adipocyte differentiation.
II. Determine the physiological regulation of adipocyte Caz+ influx and its impact on
adipocyte metabolism, as follows:
{A) Sulfonylurea receptor {SUR): This study was designed to determine direct
role of the human adipocyte SUR in regulating adipocyte Caz+ signaling and
i

metabolism, and develop approaches for the selective modulation of this
adipocyte Caz+channel.
{B) lg,25-{OH)z-D 1~ This study was designed to (a) determine the role of la,25(OH)z-D3 in modulation of adipocyte Caz+ signaling and lipid metabolism and
whether this modulation is via novel rapid non-genomic action mediated by the
putative mVDR and (b) determine the role of dietary calcium suppression of
la,25-(OH)z-D3 in attenuating diet-induced obesity and accelerating weight loss
secondary to caloric restriction.
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III. Determine the role of la,25-(0H) 2-D3 in regulating human adipocyte uncoupling
protein 2 (UCP2) expression and whether this regulation is via the classic genomic action
mediated by the nVDR.

•
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I.

OBESITY: AN EPIDEMIC DISEASE

A. PREY ALENCE OF OBESITY
Obesity, defined as body mass index (BMI) greater than 30 kg/m 2 , is an increasingly
prevalent, costly and serious medical problem in the developed countries (1 ). National
surveys in the United States have shown a striking population-wide increase in
prevalence of overweight (BMI ~5 .0) and obesity (BMI ;;80.0) over the short period of
time between 1980 and 1994 (1). The third National Health and Nutrition Examination
Survey (1988-1994) shows that more than half of American adults are overweight and
nearly one-fourth are clinically obese, with 97 million overweight or obese adults in U.S.
( 1). This survey also demonstrates that the number of overweight children and
adolescents in the United States has markedly increased, and that 11% of children and
adolescents are overweight (2). Moreover, the prevalence in developing countries is also
increasing at an alarming rate (3).

B. OBESITY AS A MEDICAL PROBLEM
Obesity is closely associated with the development of other serious chronic diseases,
including diabetes mellitus, hypertension, dyslipidemia, coronary heart disease and
several forms of cancer. Obesity-related diseases cause more than 300,000 deaths
annually in the United States alone (1).

a. Effect of Obesity on Mortality
Life insurance data first demonstrated the relationship of increased body weight and
central fat to high death rate (4). Subsequent epidemiological studies confirmed that
13

increasing degrees of overweight and obesity are important predictors of decreased
longevity (5). The overall relationship between mortality and BMI adjusted for age shows
an acceleration of the mortality risk above a BMI of 30 kg/m 2 ( 6). This is further
illustrated by the work of Manson et al. who demonstrated the association between BMI
and both overall mortality and mortality from specific diseases in a cohort study, showing
that the risk of death was 1.3 in those with a BMI 25-26.9, 1.6 in those with a BMI 2728.9 and doubled for those with a BMI of29.0-31.9 (7). Moreover, recent evidence
indicates that a weight loss of more than 9 kg is associated with a 25% reduction in all
causes of mortality (8).

Regional fat distribution has an important additional role in excess death (9). The
relationship of body fat distribution to overall mortality was demonstrated by the
Gothenburg study showing that mortality was increased with a high ratio of waist
circumference to hip circumference as the index of central fatness (10).

b. Obesity-Associated Morbidity
Obesity and overweight are associated with increased risk of insulin resistance/type II
diabetes, coronary heart disease (CHD), dyslipidemia, hypertension, respiratory disease,
gall bladder disease and several types of cancer (1).

1. Obesity and Insulin Resistance/Type II Diabetes
The association of obesity with type II diabetes has been recognized for decades. More
than 80% of type II diabetics are obese (1). Both prospective and retrospective studies
14

have demonstrated that the risk of type II diabetes increases as BMI increases in both
genders and in populations at high risk for both conditions (11, 12, 13). Moreover, body
fat distribution exerts a marked influence on the risk of type II diabetes, as abdominal
visceral obesity has a strong association with type II diabetes (14, 15).

Type II diabetes is preceded by insulin resistance, a defect in the response of muscle,
adipose tissue and liver to insulin-mediated glucose transport, metabolism, and storage.
Insulin resistance in obesity is manifested by decreased insulin-stimulated glucose
transport and metabolism in insulin-sensitive tissues (16). These functional defects in
obesity may result from impaired insulin signaling, including insulin binding to its
receptor, receptor phosphorylation and kinase activity, phosphorylation of insulin
receptor substrate (IRS), and activation of PI-3 kinase, and subsequent down-regulation
of GLUT4, the major insulin-responsive glucose transporter (16). Indeed, the expression
of various insulin signaling molecules is reduced in skeletal muscle in morbid obesity
(17). Moreover, adipocytes from obese humans exhibit reduced insulin receptor
substrate-I (IRS-1) expression, resulting in decreased PB-kinase activity (18). In
addition, decreased expression of GLUT4 or impaired GLUT4 translocation, docking,
and vesicle fusion is evident in skeletal muscle and adipocytes from obese subjects (19).

The mechanism whereby increased energy storage in adipocyte promotes insulin
resistance in the other tissue such as skeletal muscle and liver is not clear. However,
adipose tissue functions as an endocrine organ that expresses and secretes several
molecules that exert multiple endocrine effects. Several of these, including free fatty
15

acids (FF As) (20), tumor necrosis factor alpha (TNF-a) (21), resistin (22, 23), and
adiponectin (24-26), may contribute to insulin resistance in obesity, as follows.

•

Free Fatty Acids

Elevated FF As impair insulin-stimulated glucose transport by inhibiting GLUT4
expression (27). FF As also inhibit glucose oxidation (28, 29) and glycogen synthase
activity (30) in skeletal muscle, thereby reducing glucose utilization. Moreover, FFAs
stimulate hepatic gluconeugenesis and thereby increase glucose output (31 ). Intraabdominal adipocytes are more lipolytically active due to their abundant adrenergic
receptors mediating vigorous response to noradrenaline. This would contribute to an
exaggerated release ofFFAs from abdominal adipocytes into portal system (32, 33),
thereby promoting insulin resistance. This is thought to explain why abdominal fat depots
are much more strongly linked to insulin resistance than are peripheral
(gluteal/subcutaneous) fat depots.

•

TNF-a

TNF-a is over-expressed in obese humans and animals (34). This cytokine stimulates
lipolysis and the resulting increases in FFAs may thereby contribute to insulin resistance
(35). Moreover, TNF-a has been shown to impair insulin signaling through
phosphorylation of IRS-1 at serine residues (36). In addition, TNF-a is able to downregulate GLUT4 expression, thereby decreasing insulin-stimulated glucose transport (37,
38). This is supported by the studies demonstrating that TNF-a knockout mice exhibit
improved insulin sensitivity (39).
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•

Resistin

Recently, Steppan et al. identified an adipocyte-derived hormone named resistin which
exerts an effect on insulin resistance and potentially links obesity to diabetes (22).
Resistin gene expression is induced during adipocyte differentiation, and the resistin
protein is specifically expressed and secreted by adipocytes (22). Circulating resistin
level is markedly increased in both genetic and diet-induced obesity mice (22). Moreover,
administration of resistin impairs glucose tolerance and insulin action in normal mice
(22). By contrast, immunoneutralizaton of resistin improves blood glucose and insulin
action in the animal models of type II diabetes (22). In addition, thiazolidinediones
(TZDs), a class of anti-diabetic drugs, have been demonstrated to inhibit resistin
expression and thereby exert their anti-diabetic effects (22).

•

Adiponectin

Another adipocyte-derived hormone adiponectin, also known as Acrp30, plays an
important role in insulin resistance (24-26). Decreased expression and circulating levels
of adiponectin correlate with insulin resistance in diabetic animal models (24).
Conversely, caloric restriction increases the levels of this protein (25). In contrast to
resistin, TZDs increase adiponectin expression in adipocytes (24), indicating that this
protein may also mediate the anti-diabetic effects of TZDs. Adiponectin decreases insulin
resistance by decreasing triglyceride content in muscle and liver in obese mice (24). This
effect results from increased expression of molecules involved in both fatty acid
combustion and energy dissipation in muscle (24). Moreover, insulin resistance in
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lipoatrophic mice was completely reversed by the combination of physiological dose of
adiponectin and leptin (24).

2. Obesity and Other Metabolic Disorders
In addition to type II diabetes, obesity is also strongly associated with other metabolic

disorders, including coronary heart disease (CHD), hypertension, and dyslipidemia,
which are closely related and interact with each other (1).

Data from the Nurse Health Trial demonstrate that risk for CHD is increased 3.3-fold in
women with a BMI greater than 29 kg/m 2 , compared with the risk for women with a BMI
less than 21 kg/m 2 ( 40). Similar relationship between increased BMI and CHD risk has
been observed in men (41 ). A weight gain of 5-8 Kg may be translated to an increased
CHD risk of 25% (41). Physiologically, the increased fat mass could increase circulating
blood volume which in tum contributes to an increase in the left ventricular preload and a
subsequent increase in cardiac output (42). The volume expansion and increased cardiac
output may further lead to an increase in wall stress and structural changes of the heart
such as an enlarged left ventricular cavity dimension and myocardial hypertrophy (42).

It is well known that dyslipidemia plays an important role in the development ofCHD.

Dyslipidemia is manifested by high total cholesterol, high triglycerides, low high-density
lipoprotein cholesterol (HDL), and elevated low-density lipoprotein cholesterol (LDL)
(1). A positive correlation between BMI and high total cholesterol, high triglycerides and
high LDL has been demonstrated repeatedly (1 ). Moreover, an inverse relationship
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between BMI and HDL has also been well documented (1). A meta-analysis shows that 1
Kg weight loss corresponds to a 1% reduction of total cholesterol and LDL, a 1%
increase ofHDL, and a 3% reduction oftriglyerides (43). It is noteworthy that obesityrelated insulin resistance contributes to the pathological development of dyslipidemia,
which may further cause CHD (44).

Obesity and hypertension are significant risk factors for the development of
cardiovascular disease. A large number of population-based studies have documented a
strong association between obesity and hypertension in both sexes, in all age groups, and
for virtually every geographic and ethnic group (45). Data from NHANES III show that
the age-adjusted prevalence of high blood pressure increases progressively with higher
levels of BMI in both men and women. The large international study of salt
(INTERSAL T) carried out in more than 10,000 people reported that a 10 Kg higher body
weight is associated with 3.00 mm Hg higher systolic and 2.3 mm Hg higher diastolic
blood pressure (46). The pathophysiology underlying the development of hypertension
associated with obesity includes associated increases in vascular resistance, blood
volume, cardiac output, and sodium retention. These cardiovascular abnormalities
associated obesity are believed to be related to a combination of obesity-related insulin
resistance/hyperinsulinemia,

increased sympathetic nervous system activity, and

alterations of the rennin-angiotensin system ( 1).
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II.

GENETICS OF OBESITY

A. OVERVIEW
Obesity is a multifactorial disease with a potent genetic component. Several mutations in
rodent obesity genes that segregate as mendelian traits have been cloned; subsequently,
corresponding homologous mutations have been identified as rare causes of human
obesity (4 7). Phenotypes shared between the human and animals with homologous
obesity mutations exhibit conserved physiological pathways. Cloning and
characterization of these obesity genes and gene products reveal novel molecular and
biochemical mechanisms underlying the obesity development and thereby provides
potential targets for therapeutic interventions in obesity. On the other hand, quantitative
genetic approaches for human population-based genetic studies and mouse-inbred strains
have led to the genetic maps for obesity in humans and mice. This assists in not only
identifying those genetic loci that fail to display a mendelian inheritance pattern and
function in a gene-gene or gene-environment interaction manner to contribute to a
polygenic trait, but also in identifying the human population with a genetic susceptibility
to obesity.

a. Genetics of Obesity in Humans
Human obesity is a polygenic trait, a quantitative phenotype that fails to display
mendelian inheritance pattern because it is controlled by many different loci (47).
Whether or not these genetic propensities are expressed may depend on appropriate
environmental variables. It is believed that human obesity results from interaction
between genes and environment. Several lines of evidence support a model in which
20

susceptibility to obesity is determined largely by genetic factors, but the environment
determines phenotype expression (4 7).

Genetic factors account for a substantial portion of variation in human obesity. This is
supported by numerous studies of genetic epidemiology of human obesity (48-52). The
most convincing evidence for the genetic transmission of human obesity comes from twin
studies. If the heritability quotient value 0.0 indicates no inheritance and 1.0 represents
complete inheritance for twin study data, the heritability quotients from twin studies of
human obesity range from 0.4 to as high as 0.98 (48-50). Family studies and adoption
studies have also consistently shown that 40-70% of the variation in obesity-related
phenotypes, such as BMI, skinfold thickness and fat mass, is heritable (51). Moreover,
many segregation analyses, which evaluate the evidence and pattern of transmission for a
major gene based on observed patterns of phenotypic inheritance, demonstrate that major
genes that influence the obesity-related phenotypes account for as much as 40% of the
variation in BMI and fat mass (51, 52).

Emphasis on human genetics of obesity has shifted from the question of whether human
obesity has genetic components to which specific genes are responsible for specific
obesity phenotypes. The search for human obesity genes is a challenging task. Two
strategies, the candidate gene approach and the genome scan approach, are now used to
identify human obesity gene (47, 51). The candidate gene approach is used to screen
obese human patients for mutations in candidate genes selected on the basis of the mouse
genetic studies. Using this strategy, two children with defects in leptin have been
21

identified; these patients are homozygous for loss of function mutations and exhibit
phenotypes of morbid obesity and hyperphasia (53, 54). Similarly, a leptin receptor
mutation has also been reported (55). Moreover, the importance of the melanocortin
pathway in the control of energy homeostasis in human has been demonstrated by
identification of obese patients with mutations in pro-opiomelanocortin (POMC) and
melanocortin-4 receptor (MC4R). Two children with loss of function mutations in POMC
gene exhibit impaired melanocortin signaling and display obesity and altered
pigmentation phenotypes (56). In addition, several groups have reported MC4R
mutations, including base deletion-induced frameshift and base substitution missense
mutations, as well as haploinsufficiencymutations (57-61). The metabolic phenotypes
caused by MC4R mutations in human are similar to those caused by impaired
melanocortin signaling in mice. Other mutations of candidate genes identified in human
obesity include PPARy (62) and prohormone convertase 1 (PCl) (63).

Single gene mutations as causes of obesity in humans is so rare that identification of
these mutations is unable to address genetic causes in population as a whole. Therefore,
genetic linkage and association analyses of candidate genes with obesity are more
effective in this regard. The statistical support for linkage has been presented in the form
of a LOD score (logarithm of the likelihood ratio for linkage) (47, 51). This has yielded
intriguing insights into the genetics of human obesity. Numerous DNA polymorphisms at
or near candidate genes have been identified to be associated with the quantitative trait of
BMI or other measures of body fatness (51 ).
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Genetic determinants of variation in human obesity and related phenotypes are likely to
be multiple and interacting, with most single variants generating a moderate effect on
obesity (51 ). Therefore, the genome scan approach is an effective approach to identify
these individual genetic loci contributing to obesity. In a whole genome scan, linkage
analysis is conducted using a series of DNA markers or polymorphisms, spaced at
relatively constant intervals over the whole genome, to identify quantitative trait loci
(QTL) associated with the obesity phenotypes. This approach offers the potentials to
identify previously unknown genes affecting the phenotypes of interest. Results from four
reported genome-wide linkage studies that examined obesity and related phenotypic traits
in Mexican-Americans, Pima-Indians and African-Americans have identified several loci
that show positive evidence for linkage (47, 64-66). For instance, significant linkage of
serum leptin levels and fat mass to short arm (p) of chromosome 2 at band 21 (2p21) was
demonstrated in Mexican-Americans (64, 65). However, no obvious candidate genes
have been so far mapped to any chromosome QTL regions.

b. Genetics of Obesity in Animal Models
1. Single Genes
The genes responsible for mutations which produce well characterized obesity in rodent
models have been cloned and characterized. These genetic obese animal models include
yellow (AY/a)obese mouse, obese (ob/ob) mouse, diabetic (db/db) mouse, Zucker fatty

(fa/fa) rat, Tubby (tub/tub), Fat (fat/fat or cpefat/cpefa1) mouse.
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1.1 Obese (ob/ob) Mouse. Diabetic (db/db) Mouse. and Fatty (fa/fa) Rat
The phenotypic expression of the obese syndrome is similar across three mutations that
cause obesity in the ob/ob mouse, db/db mouse, and the fa/fa rat. These animals exhibit
hyperphasia, morbid early-onset obesity, decreased energy expenditure, insulin
resistance/hyperinsulinemia (67). Coleman conducted an elegant parabiosis experiment
with ob/ob and db/db mice, suggesting that ob/ob mouse lacks a weight-regulating factor
and db/db mouse lacks a molecule responding to this factor (68). Parabiosis studies
suggested that the fa/fa rat was similar to the db/db mouse in its failure to respond to a
circulating factor.

Using positional cloning strategy, the mouse ob gene was cloned (69) and shown to
encode a 4.5 kilobase mRNA transcript with a highly conserved 167 amino acid.
Analysis of this gene product revealed characteristics consistent with a secretory peptide,
which is also classified as a cytokine-like protein without homology with other known
cytokines. The mutation was identified as a base substitution that introduces a stop
codon, resulting in a premature-truncated protein. Leptin is primarily expressed in white
adipose tissue, but also in placenta and gastric epithelium at lower levels. Leptin
circulates as a 16-kDa protein and plasma leptin levels are highly correlated with adipose
tissue mass. Administration of leptin via either intraperitoneal or intracerebroventricular
injection results in a significant correction in obese and diabetic syndrome in ob/ob but
not db/db mice (70). Accordingly, leptin appears to function as a body weight modulator.
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The complete non-response of db mouse to leptin and identical phenotype of ob and db
mouse suggest that db locus encodes the leptin receptor (ob-R). The ob-R was first
isolated from mouse choroid plexus cDNA library by expression cloning strategy (71).
This receptor belongs to a single transmemberane receptor of class I cytokine family and
binds leptin with nanomolar affinity. Alternative splicing results in at least 5 different
isoforms of ob-R (ob-Ra, ob-Rb, ob-Re, ob-Rd, ob-Re) (72-74). All these isoforms share
identical extracellular ligand binding domain, but only ob-Rb encodes all intracellular
motifs capable of activating JAK (janus kinase)-STAT (signal transducers and activators
of transcription) signal transduction (72-74). A base substitution mutation of db gene in
db/db mouse introduces a stop codon that prevents translation of the long intracellular
domain of the receptor (72-74 ). A similar mutation is present in the fa/fa rat (73, 74).
Thus, these studies confirm the original prediction from parabiosis studies that there was
a circulating factor to which the db/db and fa/fa rat could not respond.

The leptin receptor is expressed at high levels in hypothalamic neurons (72). Therefore,
the hypothalamus is the primary target tissue which leptin act upon to exert its energyregulatory effects (73, 74). Leptin responsive neurons in hypothalamus express
neuropeptides that are modulated by leptin and interact with each other in controlling
feeding behavior and energy balance.

1.2 Fat (fat/fat or cpera1/cpera1) Mouse
The homozygous fat mouse with recessive fat gene mutation, unlike the ob/ob mouse, the

db/db mouse, and the fa/fa rat, exhibits late-onset obesity. These mice develop marked
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hyperinsulinemia prior to the development of obesity (75, 76). Therefore, the fat mouse is
an interesting animal model for studying the insulin resistance/hyperinsulinemia and
obesity interrelationship (75, 76). The fat gene, located on mouse chromosome 8, has
been shown to encode carboxypeptidase E (77). A single base mutation that results in a
serine to proline substitution at position 202 severely reduces the activity of
carboxypeptidase E in both pancreas and pituitary (77). This enzyme is required for
cleavage of two arginine residues from the B chain of proinsulin during pro-enzyme
processing. The impairment in processing of proinsulin causes hyperproinsulinemia in
the fat mouse. In addition, a number of prohormones and proneuropeptides, including
POMC, require carboxypeptidase E for cleavage of paired dibasic residues from carboxy
terminus to yield the biologically active form of peptides. Accordingly, the obesity
phenotype of fat mouse is likely to result from a complex pattern of alterations in activity
or secretion ofneuropeptides, such as POMC, in hypothalamus (75-78).

1.3 Tubby (tub/tub) Mouse
Homozygous mice with a mutation at the tub locus develop late-onset obesity and insulin
resistance (75- 78). Using positional cloning, tub gene has been cloned and mapped to
mouse chromosome 7 (79). Tubby mice have a naturally occurring slicing site mutation
at the junction of the 3' coding exon. A recent study show that tubby proteins localize to
the plasma membrane by binding to phosphatidylinositol 4,5-bisphosphate (PIP2) and
function as transcriptional factors that translocate to the nucleus in response to receptormediated activation of G protein aq (Gaq) (80).
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2. Polygenic Obesity in Animal Models
Unlike the single-gene mutations in the aforementioned animal models, human obesity is
polygenic, likely to have significant genetic heterogeneity, and clearly involves
environmental factors (50). Thus, animal models of polygenic obesity may be used to
investigate the genetic mechanisms underlying the development of obesity involved in
gene-gene interaction and gene-environment interaction.

Using polymorphic genetic markers covering the whole mouse genome, quantitative trait
loci (QTL) mapping is performed to identify the genetic loci associated with specific
traits involved in obesity or obesity-related phenotype in inbred mouse strains (47, 51).
These inbred strains of mice are useful, as different strains encompass a wide range of
adiposity. Thus, these strains can be intercrossed to generate an Fl generation, and the
segregation of the trait in Fl backcross or in Fl intercross can be followed and linked to
the segregation of polymorphic genetic markers (47, 81, 82). QTL mapping can be used
to target the specific obesity phenotypes caused by gene-gene interaction or geneenvironment interaction. For instance, West et al. used two strains of mice (AKR/J x
SWR/J) that differ in their sensitivity to diet-induced obesity (83, 84), while Warden et
al. used BSB model (C57BL/6J x Mus spretus strain) whose body fat composition varies
from 1% to 50% (85, 86). Both studies have mapped QTLs on chromosomes
corresponding to specific phenotypes. So far, over 70 loci for polygenic obesity have
been identified from more than 15 different crosses (4 7).
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B. THE MOUSE AGOUTI GENE AND ITS ROLE IN OBESITY
a. Agouti Gene and Its Mutation
Agouti gene was the first obesity gene cloned (87). This gene, mapped to mouse
chromosome 2, encodes a 131-amino acid protein with a consensus signal peptide (8790). The agouti gene is normally involved in coat color regulation in mice, with transient
expression in neonates, resulting in a pigmentation pattern classically called agouti (8890). Agouti is transiently expressed in neonatal skin, secreted by follicular cells, and
exerts a paracrine action on melanocytes. This results in a competitive antagonism of amelanocyte-stimulating hormone (a-MSH) binding to the melanocortin-1 receptor (MClR), which in tum causes a switch from the synthesis of a-MSH-stimulated black pigment
(eumelanin) to that of default yellow pigment (phaeomelanin) (91, 92). This produces
the characteristic pigmentation pattern of wild-type mice, a predominantly black hair
shaft with a subapical yellow segment.

A number of dominant mutations at agouti locus results in ectopic expression in all
tissues throughout the life of the mouse (89-91). These mutations result in not only an
altered pigmentation pattern, but also a pleiotropic syndrome characterized by adultonset obesity, hyperphagia, hyperinsulinemia, insulin resistance, impaired glucose
tolerance, and decreased thermogenesis (89-91). Molecular analysis of dominant agouti
alleles, such as lethal yellow (AY)and viable yellow (Avy),demonstrates that mutations in
promoter regions result in ubiquitous expression of normal agouti protein (88, 89). This
was confirmed by overexpressing agouti cDNA under control of a ubiquitous promoter in
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transgenenic mice (93). These animals recapitulated the phenotypes of dominant mutants
(93).

b. Agouti Signaling
Although the genetic defect in the agouti yellow mouse syndrome clearly involves
ectopic expression of the agouti gene, the actual mechanism whereby the overexpressed
agouti causes the yellow obese syndrome is not clear. Both central and peripheral effects
of agouti on obesity syndrome have been extensively explored. Several lines of evidence
suggest that both central effects of agouti on energy intake, mediated by melanocortin
signaling pathway, and peripheral effects of agouti on adipocyte lipid metabolism and
pancreatic 13cell insulin/amylin secretion, mediated by intracellular

ca2+,
may contribute

to agouti yellow mouse syndrome.

1. Central Actions of Agouti: Role ofMelanocortin Receptor
The initial observation that agouti modulation of pigmentation is mediated by antagonism
ofMC-lR (87, 92) has led to the hypothesis that melanocortin receptor antagonism may
be responsible for the metabolic effects of agouti in yellow obese syndrome.

MCl-R belongs to melanocortin receptor family of7-transmanbrane G protein coupled
receptors, which includes 5 members (94, 95). MC-lR, the a-MSH receptor, is primarily
expressed in melanocytes and regulates pigmentation. MC2-R, the adrenocorticotropin
hormone (ACTH) receptor, is expressed in adrenal cortex and in adipose tissue (96).
MC3-R is expressed in hypothalamus and limbic system, as well as in placenta and gut
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(97). MC4-R is expressed widely in the brain, with a high expression in region of
hypothalamus involved in regulation of energy intake and body weight (98). MC5-R is
expressed ubiquitously and appears to be involved in thermoregulation and
immunomodulation (99-101 ). Lu et al investigated the potential of agouti to antagonize
the binding of a-MSH to each of these melanocortin receptors. They demonstrated that
agouti protein potently antagonizes MCl-R, MC2-R and MC4-R, but exerts little or no
effect on MC3-R and MC5-R (92). Of these receptors antagonized by agouti, both loss
and gain of function mutations targeting MC-lR affect coat color without producing
significant metabolic effects (94), whereas disruption of MC2-R results in familial
glucocorticoid deficiency (102). Therefore, only MC4-R remains as a likely target to
mediate agouti-induced obesity syndrome.

The role ofmelanocortin/MC4-R signaling pathway in regulation of food intake and
energy homeostasis had not been explored until the cloning and characterization of the
agouti gene. MC4-R is abundantly expressed in the hypothalamic paraventricular
nucleus, dorsomedial nucleus and ventromedial mucleus, major hypothalamus regions
involved in regulating feeding behavior, body weight and energy homeostasis ( 103-106).
Huszar et al (107) reported that disruption ofMC4-R in mice resulted in an adult-onset
obesity syndrome associated with hyperphagia, hyperinsulinemia/insulin resistance,
which recapitulated several characteristic features of dominant agouti mutation.
Moreover, Fan et al (108) demonstrated that intracerebroventricular administration of
MTII, a potent MC4-R agonist, caused a dose-dependent inhibition of food intake in four
murine models of obesity and hyperphagia. This inhibition was reversed by
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coadministration of SHU9119, a potent melanocortin antagonist. The effect of MC4-R on
feeding was confirmed by the study demonstrating that MC4-R knockout mice did not
respond to the anorectic actions ofMTII (109). Further evidence from Harrold et al (110)
showed that food restriction caused a selective up-regulation ofMC4-R density in rat
hypothalamus, whereas diet-induce obesity resulted in a down-regulation ofMC4-R,
suggesting that MC4-R plays an important role in the control of feeding behavior.

Several studies demonstrate that MC4-R may also play a role in human obesity. Recent
data from Chagnon et al (57) demonstrated a significant association between restriction
fragment polymorphisms ofMC4-R and obesity phenotype, including body mass index
(BMI), fat mass, and percent body fat, in the Quebec family study. Moreover, Yeo et al
(58) and Vaisse et al (59) described a severely obese child and adult, respectively, with a
base deletion or insertion induced frameshift mutation in MC4-R gene. Both patients are
heterozygous. In addition, three allelic variants at MC4-R locus have been identified in
obese human by polymorphism analysis (60). One variant from extremely obese person
was cloned and found to be severely impaired in ligand binding and signaling (60),
raising the possibility that this variant ofMC4-R gene may contribute to development of
obesity. Hinney et al (61) screened the coding region ofMC4-R gene in both extremely
obese and normal-weight people. Several mutations, including base deletion induced
frameshift, base substitution (both mutations yield truncated MC4-R), and missense
mutation, have been identified in extremely obese subjects with BMis above 99 th
percentile. Further study from the same group (111) detected a haploinsufficiency
mutation in MC4-R gene, which was believed to be responsible for the extreme obesity.
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Although agouti is not normally expressed in the central nervous system, agouti related
protein (AGRP) (also known as agouti related transcript, ART), a homolog of agouti, was
identified as an endogenous antagonist for MC4-R (112). AGRP is abundantly expressed
in arcuate neurons and its expression is markedly elevated in obese mouse model (112).
Ubiquitous expression of AGRP in transgenic mice recapitulates the phenotypes of
obesity syndrome found in MC4-R knockout mice (113, 114). AGRP exhibits 25%
identity to agouti, with the highest degree of identity in the cysteine-rich carboxyl
terminus ( 112). As carboxyl terminus of agouti was believed to act as functional domain
for antagonizing MC4-R (115, 116), a similarity between carboxyl terminal regions of the
two proteins suggests similar functions for this domain in interacting with MC4-R. This
was verified by demonstrations that carboxyl terminus of AGRP was critical for its
antagonism of a-MSH at MC4-R (117, 118). Consistent this, intracerebroventricular
administration of a carboxyl-terminal fragments of AGRP increased food intake in rats
(119). This effect was mimicked by the MC4-R antagonist SHU9119.

The endogenous ligand for MC4-R is a-MSH, a peptide derived from
proopiomelanocortin (POMC) (sequential cleavage of this protein also generates
melanocortin peptides ACTH, 13and y MSH as well as opioid-receptor ligand 13
endorphin) (103). a-MSH appears to bind to MC4-R with a high affinity and act as a
strong agonist in regulation of food intake and body weight. POMC gene is expressed in
arcuate nucleus and then projects a-MSH to MC4-R-expressing cells, such as the
paraventricular nucleus, resulting in a decreased food intake (104). Yaswen et al (120)
recently generated a POMC-knockout mouse that developed severe obesity, similar to
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that of the MC4-R knockout mouse. 2-week treatment of these POMC-null mice with aMSH agonist caused more than 40% of weight loss. Consistent with this, a patient with
severe early-onset obesity caused by POMC gene mutation was recently reported (56).
The phenotype of this patient is similar to that found in POMC-null mice.

2. Peripheral Actions of Agouti: Role of Intracellular Ca 2+ ([Ca 2+h)
In addition to the central effects of agouti on food intake and body weight regulation,
available evidence also demonstrate that agouti protein also exerts potent pleiotropic
effects in peripheral tissue, particularly in adipocytes and pancreatic 13cells (121, 125,
126, 131). Although chronic antagonism of central MC4-R may be responsible for the
hyperphasia in yellow agouti mutants, the efficiency of energy utilization, such as
preferential energy partitioning into adipose tissue, is also markedly increased in these
mice (121 ). For example, adipose tissue expression of fatty acid synthase (FAS), the key
enzyme in de novo lipogenesis, is significantly elevated in yellow obese mice (121).
Moreover, MC4-R is expressed in several peripheral tissues, including adipose tissue
(57). It is therefore possible that agouti-induced obesity syndrome may also involve its
action at peripheral melanocortin receptors. In addition, transgenic mice specifically
overexpressing agouti in adipose tissue under the control of aP2 promoter become obese
in response to a concomitant hyperinsulinemia induced by either exogenous insulin
administration (122) or a high sucrose diet (123), while their non-transgenic littermates
do not. Recent data indicate that these peripheral actions of agouti in preferential energy
partitioning in adipose tissue are mediated by modulation of [Ca2+]i.
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Agouti protein contains a cysteine-rich carboxyl terminus, which bears functional activity
equivalent to the full-length agouti in melanocortin receptor antagonism (124). All 10
cysteines at this domain are involved in forming disulfide bonds (124). The spacing and
pattern of disulfide bonds is highly homologous to that of spider and snail neurotoxin
venoms, which primarily target Caz+channels. Therefore, the structural similarity of Cterminus between agouti and these venoms suggests a similar function of Caz+ channel
modulation for the agouti C-terminal domain. Indeed, A vymice exhibit increased steadystate [Caz+]iand Caz+ influx in adipose tissue and skeletal muscle (125, 126). There is a
strong correlation between [Caz+]ilevels and the degree of agouti expression and body
weight (126) in these mice. Since adipocyte lipogenesis is markedly elevated in Avymice,
it is tempted to speculate that agouti may modulate adipocyte lipid metabolism via
modulating [Caz+]i.

Recombinant agouti protein causes a dose-responsive increase in [Caz+]i in a variety of
cells, including both human and murine adipocytes (125, 126). Although the agouti
stimulation of [Caz+]irequires a functional melanocortin receptors, which are expressed
in both human adipocytes and 3T3-Ll (57), this action is not mediated by MCR
antagonism (125). The physiological consequence of this elevation in [Caz+]iwas
addressed by the studies of adipocyte lipogenesis. Agouti stimulates the expression and
activity of fatty acid synthase (FAS) via a Caz+-dependent manner, and this action can be
mimicked by Caz+ channel activation and reversed by Caz+ channel antagonism (121).
These actions are mediated by an agouti/Caz+ response element on FAS promoter region
(127). Moreover, recent evidence shows that agouti expression is highly correlated with
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in vivo FAS expression and activity, suggesting that agouti protein, which is normally
expressed in human adipose tissue, may play a role in adipocyte metabolism (128).

Agouti protein inhibits basal and agonist-stimulated lipolysis in human adipocytes via a
Ca 2+-dependent mechanism (129). The mechanism underlying the anti-lipolytic effect of
[Ca2+]i was recently demonstrated to be increased [Ca 2+]i activation of phosphodiesterase
3B, resulting in reduced cAMP levels and, consequently, inhibition of hormone sensitive
lipase activity (130). Accordingly, agouti regulation of adipocyte [Ca 2+]i appears to
promote triglyceride accumulation in adipocyte by exerting a coordinated control over
stimulation of lipogenesis and inhibition of lipolysis, serving to simultaneously stimulate
the former and inhibit the latter.

It is noteworthy that hyperinsulinemia is necessary for complete expression of the obese
phenotype in transgenic mice expressing agouti in adipose tissue under control of the aP2
promoter, indicating an interaction between insulin and agouti in agouti-induced obesity
syndrome. Consistent with this, there is an additive effect of agouti and insulin on FAS
transcription and lipogenesis (127). Since increased [Ca2+]i is the proximate signal for
insulin release and agouti stimulates [Ca2+]i in several cell types, it is possible that agouti
may exert a direct effect on pancreatic

p cells to modulate

Ca 2+ signaling and stimulate

insulin release. Indeed, agouti is expressed in human pancreas and potently stimulates
and insulin release in RIN-5F, HIT-T15 and human pancreatic

p cells via Ca 2+-dependent

mechanism ( 131 ). Therefore, agouti stimulation of insulin release may contribute to the
hyperinsulinemia/insulin resistance commonly present in yellow obese mice, and interact
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with agouti to promote obesity phenotype. Moreover, agouti also stimulates amylin
secretion from pancreatic

p cells (132) via Ca2+-dependent mechanism.

contribute to the development of amyloidogenesis, leading to impaired

This may

p cell function

and diabetes.

Therefore, agouti modulation of adipocyte lipid metabolism via [Ca2+]i, coupled with
pancreatic insulin release via [Ca2+]i,may contribute to the peripheral actions of agouti in
promoting obesity syndrome in yellow obese mouse. This was confirmed by
demonstrating that treatment of agouti-overexpressing transgenic mice with nifedipine, a
Ca 2+ channel antagonist, markedly reduced the fat pad mass and corrected the agoutiinduced hyperinsulinemia (133). Accordingly, antagonism of adipocyte and pancreatic
cell [Ca2+]i may represent a target for the development of therapeutic interventions in
obesity.
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P-

III.

ROLE OF INTRACELLULAR Ca2+ IN OBESITY

A. SYNDROME X: ROLE OF INTRACELLULAR Ca2+

Obesity is closely related to other metabolic disorders, including insulin
resistance/hyperinsulinemia, hypertension and cardiac hypertrophy. These diseases are
integrated into a metabolic syndrome referred to as "Syndrome X" (134). To explain
these tightly interacting abnormalities, Resnick et al (135) proposed a unifying "ionic
hypothesis", in which a common cell lesion underlying these disorders in different tissues
was characterized, in part, by elevations in steady-state intracellular [Ca2 +]i levels.

a. Intracellular Ca2+ and Insulin Resistance/Hyperinsulinemia
[Ca2+]iplays an important role in insulin resistance. Dysregulation of [Ca2+]i in multiple
tissues, including adipose tissue, skeletal muscle and pancreas, may cause insulin
resistance. Sustained increase in [Ca2+]ihave been observed in adipocytes, skeletal
muscle cells, erythrocytes, and platelets in patients with insulin resistance (136-140).
Draznin et al. demonstrated an optimal range of [Ca2+]i for maximizing insulin-stimulated
glucose transport in isolated adipocytes, with increases beyond this range causing marked
decreases in insulin sensitivity (136). Consistent with this, adipocytes isolated from
NIDDM patients exhibit high levels of [Ca2+]i associated with a decreased insulinstimulated glucose uptake (136-138), while pretreatment of these adipocytes with the
Ca2+ channel antagonist verapmil prevented this [Ca2+]i-mediated inhibition of insulinstimulated glucose transport (136). Avymice with marked insulin
resistance/hyperinsulinemia exhibit elevated [Ca2+]iin skeletal muscle, and the degree of
elevation is closely correlated with the degree to which the mutant traits are expressed in
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individual animals (126). Since agouti protein is able to stimulate [Ca2+]i in cultured and
freshly isolated skeletal myocytes, it is reasonable to speculate that agouti promotes
insulin resistance in Avy mice through its ability to increase [Ca2 +]i (126).

Two calcitrophic hormone parathyroid hormone (PTH) and 1,25-(0H)2-D 3, which
respond to suboptimal calcium intake, are also involved in insulin resistance. PTH is
elevated in insulin resistant patients and stimulates Ca2+ influx in adipocytes (141),
suggesting a role for this hormone in insulin signaling in adipocytes. 1,25-(0H) 2-D3 has
been shown to stimulate Ca2+ (142) and insulin release (143, 144) in pancreatic ~-cells,
suggesting that 1,25-( OH) 2 -D3 may play a role in the development of hyperinsulinemia.
This increased [Ca2 +]i induced hyperinsulinemia may further aggravate insulin resistance.

Since increasing [Ca2+]i appears to mediate the development of insulin resistance,
antagonism of [Ca2+]i in the insulin sensitive tissue would be predicted to improve insulin
sensitivity. Indeed, [Ca2+]i antagonism in obese elderly patients markedly increased
insulin sensitivity of adipocytes isolated from abdominal biopsies (145). Similarly,
antagonism of [Ca2+]iwith the L-type calcium channel blocker nirendipine significantly
improved insulin sensitivity and glucose tolerance in spontaneously hypertensive rats
(146). Moreover, antagonism of [Ca2+]iwith Ca2+ channel blockers (nitrendipine,
diltiazem, or ampodipine) improved glucose tolerance and reduced fasting and glucosestimulated circulating insulin levels in patients with insulin resistance, obesity and
hypertension (147-149).
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The mechanisms whereby dysregulation of [Ca2+]i causes insulin resistance are not well
defined. There is an association between decreased GLUT4 and increased [Ca2+]iin
skeletal muscle in type II diabetic patients (150). GLUT4 activity can be modulated by
phosphorylation at serine residue. Phosphorylation of GLUT4 results in inactivation of
GLUT4, while dephosphorylation of GLUT4 leads to activation of this protein.
Therefore, increased [Ca 2+]imay contribute to insulin resistance by inhibiting the
dephosphorylation ofGLUT4 and thereby decreasing its activity (151). This was
confirmed by demonstration that increasing Ca 2 + influx by either membrane
depolarization or parathyroid hormone treatment increased phosphorylation of GLUT4,
whereas antagonism of Ca 2 + influx with L-type calcium channel blocker nitrendipine
maintained active and dephosphorylated state of GLUT4 (151). These effects of
increased [Ca 2+]i on hyperphosphorylation of GLUT4 appeared to be mediated by [Ca2+]iinduced phosphorylation and activation of inhibitor 1, which in tum inhibited
phosphoserine phosphorylase l(PPl) (152). This inactivation of PPl by increased [Ca2+]i
therefore caused hyperphosphorylation of GLUT4 and inhibited its activity.

In addition to the effects of [Ca 2+]iregulation of GLUT 4 on insulin resistance, Ca 2+regulated calmodulin has been shown to interact with IRS-1 and thereby modulate insulin
signaling (153). Alternatively, it is also possible that increased [Ca2+]imay result in
insulin resistance via activation of protein kinase C (PKC). The activation of PKC is
accomplished by the translocation of PKC from the cytosol to the plasma membrane for
association with diacylglycerol (DAG). [Ca 2+]iplays a key role in this process. The
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activated PKC may phosphorylate and inactivate the insulin receptor (IR) {3-subunits,
resulting in an inhibition of insulin signaling (141, 154).

b. Intracellular Ca 2+ and Hypertension
Sustained elevations of [Ca2+]ihave been observed in vascular smooth muscle cells,
platelets, erythrocytes, lymphocytes, aorta, and renal cells in either patients with
hypertension or hypertensive rodents (140, 155-161). Increased [Ca2+]iin platelets has
been demonstrated to augment platelet aggregation in response to epinephrine (162).
Most importantly, the role of [Ca2 +]iin regulating vascular tone and blood pressure has
been well established (135, 163, 164). Depolarization of vascular smooth muscle cell
membrane results in Ca2+ influx via voltage-dependent L or T type of Ca2+ channels.
This, in turn, results in cytosolic Ca2+-induced Ca 2+ release from sarcoplasmic reticulum
(SR) via activating ryanodine-sensitive Ca2+ channels on the SR membrane, thereby
magnifying and spreading the initial, localized [Ca2+]ithroughout the cytosol.
Subsequently, elevated Ca2+ triggers a cascade of molecular reaction of calmodulin and
myosin light-chain kinase, ultimately leading to myofilament shortening and
vasoconstriction (135, 163, 164). It is noteworthy that increased [Ca2+]i induced by the
other cellular events, such as hormonal receptor signaling-mediated generation of inositol
triphosphate (IP3), is also able to cause the similar vasoconstriction (135). Antagonism of
[Ca2+]iin vascular smooth muscle cells causes vasodilation and reduces blood pressure.
L-type Ca 2+ antagonists, such as nitrendipine and nifendipine, are widely used to treat
hypertension clinically. Moreover, thiazolidinediones, a group of insulin sensitizing
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agents, have been demonstrated to block calcium channel in vascular smooth muscle and
reduce blood pressure (165-167).

Factors that regulate [Ca2 +]i in vascular smooth muscle cells may modulate
vasoconstriction and blood pressure. Insulin regulation of vascular smooth [Ca 2+]i is
responsible for insulin regulation of vascular tone (168). Insulin attenuates both voltage
and receptor-mediated Ca 2+ influx in vascular smooth muscle cells (168). Inhibition of
Ca 2+ influx by insulin attenuates vasoconstriction in artery cells (169). Further,
physiological concentrations of insulin inhibit either arginine vasopressin (A VP),
angiotensin II (All), or norepinephrine induced elevation in [Ca2+]i (170). The insulin
inhibition of sarcoplasmic Ca2+ release caused by either AVP, All or norepinephrine is
mediated by insulin stimulation of Ca2+-ATPase activity in smooth muscle cells (171).
Reduced Ca 2+-ATPase activity has been observed in type II diabetic patients (172).
Insulin stimulates Ca 2+-ATPase-mediated Ca 2+ efflux and causes vascular relaxation
(173), and vascular smooth muscle cell Ca2+ efflux is impaired in both insulin resistant
rats and streptozotocin-treated rats (156, 174, 175). This insulin stimulation of Ca 2+ATPase is exerted via the up-regulation of Ca 2+-ATPase expression, as reduced Ca2+ATPase expression has been observed in vascular smooth muscle from insulin resistant
rats (176) and insulin directly stimulates vascular smooth muscle Ca 2+-ATPase
expression (177). These data suggest that impaired insulin action, due to a defect in
insulin signaling caused by insulin resistance, may result in decreased vascular smooth
muscle Ca 2+-ATPase expression and activity (177). This in turn results in decreased
vascular smooth muscle Ca2+ efflux and increased vasoconstriction. Thus, the role of
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insulin in regulation of vascular [Ca2+]i and vascular tone provides the mechanism
whereby insulin resistance and hypertension are closely associated disorders.

PTH and 1,25-(OH)i-D 3 may also play important roles in regulation of vascular tone and
hypertension. 1,25-(OH)i-D 3 stimulates Ca 2+ influx in a variety of cells (178, 179),
including vascular smooth muscle cells (180), via a rapid non-genomic action. This
action is believed to be mediated via a putative membrane vitamin D receptor (mVDR)
rather than the classic nuclear vitamin D receptor (nVDR) (178, 179). Therefore, 1,25(OH)2-D3 exerts a vasoconstrictive effect, serving to increase peripheral vascular
resistance (135, 181, 182). However, the role of PTH in regulation of vascular tone is
more complicated. There are two mechanisms for the action of PTH at cellular level. In
addition to stimulation ofCa 2+ influx, PTH also stimulates synthesis of cAMP by
activating adenylyl cyclase (141). Therefore, although PTH does stimulate Ca2+ influx in
vascular smooth muscle, it also exhibits vasodilatory and hypotensive effects (183, 184).
Resnick (185) proposed that PTH may exert two independent effects on regulation of
vascular tone: an acute vasodilatory effect due to the burst of cAMP generation and a
chronic vasoconstrictory effect due to a persistent increase in [Ca2+]i. Moreover,
parathyroid hypertensive factor (PHF), a circulating hypertensive factor of parathyroid
origin, stimulates vascular smooth muscle Ca2+ influx, potentiates vasoconstrictive
responses to other pressor factors and increases blood pressure (186, 187). The
hyperparathyroidism associated with over-production of these calcitrophic hormones
exerts physically detrimental impacts on vascular smooth muscle cells, due to their
capability of stimulation of Ca2+ influx in these cells. This is manifested with the
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deposition of calcium in the wall of arteries from patients with primary or secondary
hyperparathyroidism ( 188).

Accordingly, low calcium diets, which stimulate the over-production of calcitrophic
hormones, would be expected to stimulate vasoconstriction and increase blood pressure,
while high calcium diets, which suppress the calcitrophic hormone levels, would be
expected to maintain vasodilation and reduce blood pressure. This concept has been
consistently confirmed by numerous epidemiological studies and clinical trials.
McCarron et al. reported that low calcium diet is associated with hypertension and that
dietary calcium intake is inversely correlated with the risk of being hypertensive in
American adults (189, 190). This suggests that dietary calcium intervention is a practical
approach in prevention or treatment of hypertension. Indeed, the DASH (Dietary
Approaches to Stop Hypertension) trial demonstrates that increasing dietary calcium with
low-fat dairy, combined with increased fruit and vegetable consumption, exerted
profound effects on reduction of blood pressure. The effects of this calcium-rich
combination diet in hypertensive group are comparable to those observed in
pharmacological trials in mild hypertension (182, 191). These data indicate that dietary
calcium exerts a potent effect on prevention or treatment of hypertension in the context of
specific dietary patterns.

c. Intracellular Ca2+ and Coronary Heart Disease (CHD)
Dysregulation of [Ca2+]i contributes to the development of insulin resistance and
hypertension, both of which are co-morbidities and high risk factors of CHD. In addition,
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[Ca2+]i per se plays an important role in the pathogenesis of atherosclerosis (141, 193,
194). Sustained elevations of [Ca2+]i have been observed in vascular smooth muscle cells,
platelets, erythrocytes, lymphocytes, aorta, cardiomyocytes, and renal cells in patients
with CHD (135, 155-161), while the elevation in calcitrophic hormones secondary to
suboptimal calcium intake stimulate increases in [Ca2+]i in these cells (141). As a
consequence, increased [Ca2 +]i in these cells promotes smooth muscle cell and
macrophage migration into the intima, facilitates platelet aggregation, enhances
endothelial cell proliferation, stimulates macrophage to become foam cells (141).
Atherosclerosis is initialized by the influx of Ca2+ into atherogensis-involved cells and
accelerated by massive filtration of Ca2+ in vascular smooth muscle cells and completed
by final Ca 2+ deposition and calcification in vascular wall (141, 193). This was confirmed
by clinical evidence that Ca2+ channel blockers are able to prevent arterial calcium
overlaod and atherosclerosis (194). Moreover, formation of coronary plaques induced in
vitamin D-intoxicated rats is highly sensitive to Ca 2+ channel antagonists (141, 194). The
pathogenesis of coronary plaques in this animal model resembles that in humans,
suggesting an important role of [Ca2+]i in the development of human atherosclerosis.
Both cholesterol and LDL stimulate Ca2+ influx via L-type Ca2+ channels in vascular
smooth muscle cells (141, 195, 196), while oxidized LDL, a primary atherogenic factor,
causes a sustained increase of [Ca2+]i in cultured aortic endothelial cells (197). Free
radicals, anther group of atherogenic factors, have also been shown to modulate Ca2+
channels (198), while increased [Ca2+]i in tum stimulates formation of free radicals such
as lipid peroxides (199). Formation of free radicals during ischemia reperfusion,
hyperoxia, and phagocytosis is associated with increased [Ca2+]i (200). Further, the
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detrimental effects of free radicals on cell functions are, at least in part, mediated by their
modulation of [Ca 2+]i (201). Myocardial reperfusion injury is markedly attenuated by
Ca2+channel antagonists (202).

B. ROLE OF INTRACELLULAR Ca2+ IN OBESITY
a. Calcium Homeostasis and Obesity
Obesity is associated with alterations in calcium homeostasis. In a general profile of
plasma calcium composition, 50% of total plasma calcium is ionized, 35% is albuminbound, and the rest is complexed with anions. Serum calcium concentration is typically
2.25-2.5 mM, with 1.25 mM ionized Ca2+. Only the ionized calcium is biologically active
and can be regulated by calcium-homeostatic hormones, including PTH, 1,25-(OH)i-D 3,
and calcitonin. Decreased serum ionized

ca2+,increased urinary calcium excretion,

and

increased calcitrophic hormone PTH and 1,25-(OH)i-D 3 have been frequently observed
in obese humans (203-206). Serum calcium levels are relatively stable. However, serum
albumin, phosphate, and bicarbonate levels are decreased in obesity, while citrate, lactate,
fatty acids and urate levels are increased (204). This causes the concentration of less
readily resorbable anion in the renal ultrafilturate, resulting in increased urinary calcium
excretion and thereby decreased serum ionized Ca2+(207,208). This decreased ionized
Ca 2+ subsequently stimulates calcitrophic hormone synthesis and release (204). An
inverse correlation has been found between serum ionized Ca 2+ levels and BMI/percent
of body weight (204, 209). By contrast, weight reduction results in normalization of
serum phosphate, bicarbonate, lactate, and fatty acid levels, leading to increases in serum
ionized Ca 2+ and corresponding decreases in calcitrophic hormones (210).
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b. Intracellular Ca 2 + and Adipocyte Lipid Metabolism
[Ca2+]iplays an important role in the regulation of adipocyte lipid metabolism. Draznin et
al (136-138) first reported that obese patients exhibited an elevation in basal adipocyte
[Ca2+]i. The physiological consequence of this elevation in [Ca2+]iwas addressed by the
following studies involved in adipocyte lipogenesis and lipolysis. Avasthy et al (211)
demonstrated that treatment of rat adipocytes with A23187, a calcium ionophore, caused
a marked increase in both basal and insulin-stimulated lipogenesis, while this action was
completely prevented by the calcium channel antagonist verapamil and by the calmodulin
inhibitor calmidazolium (211).

In addition to lipogenesis, several lines of evidence demonstrated an inhibitory effect of
[Ca2+]ion adipocyte lipolysis (212-216). Modulation of [Ca2+]iplays a role in mediating
both lipolytic and anti-lipolytic actions of hormones in adipocytes (213-216). The antilipolytic effect of epidermal growth factor (EGF) is mediated by an increase in [Ca2 +]iThe EGF-stimulated [Ca2+]iincreases interaction between Gi and adenylyl cyclase,
resulting in a reduction in cAMP and thereby an inhibition in lipolysis (215,216).
Alternatively, thyroid hormone modulates adipocyte lipolysis by increasing [Ca2+]i,
which involves alterations in phosphodisesterase activity (213). In addition, increasing
[Ca2+]iby the calcium ionophore A23187 in hamster adipocytes stimulates
phosphodisesterase and decreases cAMP levels, resulting in an inhibition of lipolysis
(214).
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[Ca 2+]i mediated increase in lipogenesis and inhibition in lipolysis were further explored
in the studies of agouti. Avymice exhibit increases in both steady-state [Ca2+]i and Ca2+
influx in several tissues (125, 126). The increase in [Ca2+]i is correlated with the degree
of ectopic agouti expression and body weight (125). Moreover, Avymice exhibit elevated
adipocyte fatty acid synthase expression, suggesting that adipocyte de novo lipogenesis is
increased in these animals (121). In addition, in vitro studies show that recombinant
agouti protein causes a dose-responsive increase in [Ca 2+]i in a variety of cells, including
both human and murine adipocytes (125, 126). The physiological consequence of this
elevation in [Ca 2+]i was addressed by the studies of adipocyte lipogenic genes and
activity. Agouti stimulates the expression and activity of fatty acid synthase (FAS) in a
Ca 2+-dependent manner, and this action can be mimicked by Ca2+ channel activation and
reversed by Ca 2+ channel antagonism (121). These actions are mediated by an agouti/Ca 2+
response element on FAS promoter region (127). Moreover, recent evidence shows that
agouti expression is highly correlated with in vivo FAS expression and activity,
suggesting that agouti protein, which is normally expressed in human adipose tissue, may
play a role in human obesity (128).

In addition to the effect of agouti on stimulation of lipogenesis, agouti protein inhibits
basal and agonist-stimulated lipolysis in human adipocytes via a Ca 2+-dependent
mechanism (129). The mechanism underlying the anti-lipolytic effect of [Ca 2+]i was
recently demonstrated to be increased [Ca2+]i activation of phosphodiesterase 3B,
resulting in reduced cAMP levels and, consequently, inhibition of hormone sensitive
lipase activity (130). Accordingly, agouti regulation of adipocyte [Ca 2+]i appears to
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promote triglyceride accumulation in adipocyte by exerting a coordinated control over
stimulation of lipogenesis and inhibition of lipolysis, serving to simultaneously stimulate
the former and inhibit the latter.

Accordingly, antagonism of [Ca 2+]i by either blocking Ca 2+ channels or inhibiting Ca 2+
agonists is a logical approach for development of therapeutic intervention in obesity.
Indeed, calcium channel blockade has been proven to reduce body weight and fat pad
mass effectively in several animal models. Kim et al. previously reported that treating
transgenic mice overexpressing agouti with a Ca 2+ channel antagonist (nifedipine)
resulted in significant decreases in adipocyte lipogenesis and reduction in adipose tissue
mass (133). Similarly, Ca2+ channel antagonists, such as nifendipine, verapamil,
felodipine, and benidipine, caused decreases in body weight and fat pad mass in obese
SHHF /Mcc-facp rats and obese mice (217, 218).

c. Intracellular Ca 2+ Mobilizing Agents in Obesity
There are many nutritional, hormonal, and pharmacological factors that modulate
adipocyte [Ca 2+]i and may, therefore, modulate adipocyte lipid metabolism. In addition to
agouti, these include sulfonylureas (219), calcitrophic hormone PTH (220, 221) and 1,25(OH)2-D3 (220, 222), arginine vasopressin, agiotensin II, and glutamate, etc. Therefore,
identifying and characterizing the factors that modulate adipocyte [Ca 2+]i is a logical
approach for elucidating novel mechanism involved in modulating adiposity and
identifying targets for the development of therapeutic interventions in obesity.
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1. Sulfonylurea and Sulfonylurea Receptor
We recently demonstrated that human adipocytes express a sulfonylurea receptor (SUR),
which mediates adipocyte [Ca2+]i signaling and, consequently, modulates adipocyte lipid
metabolism (219).

Sulfonylureas, such as glibenclamide, are insulin secretagogues widely used to stimulate
insulin secretion in the treatment of non-insulin-dependent diabetes mellitus. These
insulin secretagogues bind to the sulfonylurea receptor (SUR) of pancreatic J3cells and
then block the conductance of an ATP- dependent potassium channel

(KATP

channel)

(223-225). The attenuation of potassium current by blocking this channel depolarizes the
J3cells and thereby induces Ca2+entry via L-type calcium channels (226), leading to

increased insulin secretion (227). The SUR is a member of the ATP- binding cassette
proteins, with multiple membrane-spanning domains and two nucleotide- binding folds
(225). The SUR itself does not form the ion-conducting part of the

KA TP

channel.

However, SUR combines and interacts with an inward-rectifier K+ channel (Kir6.2) to
generate

KA TP channel

(228). Notably, endosulfine, an endogenous ligand of SUR, has

also been cloned and is able to mimic the effects of sulfonylureas and thereby exhibit
physiological functions, including inhibiting

KATP

channels currents and stimulating

insulin release in J3cell (229).

Patients treated with glibenclamide frequently experience weight gain as a side effect.
Conversely, diazoxide, which inhibits SUR by activating

KATP

channels, exerts an

antiobesity effect in obese Zucker rats and hyperinsulinemic obese humans (230-232).
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These effects of glibenclamide and diazoxide on body weight have been attributed to
their effect on circulating insulin rather than to any direct effect on adipocytes (230-232).
However, the identification of SUR expression in human adipocytes suggests that it may
modulate adipocyte [Ca2 +]i and corresponding lipid metabolism (219). Indeed,
Adipocytes exhibited corresponding glibenclamide dose-responsive increase in [Ca2 +]i.
Moreover, glibenclamide exerted lipogenic and antilipolytic effects in human adipocytes,
with a marked increase in fatty acid synthase and glycerol-3-phosphate dehydrogenase
activities and a remarkable decrease in glycerol release, while diazoxide significantly
blunted each of these effects (219). These data demonstrate that SUR in human adipocyte
regulates [Ca2+]i and thereby exerts coordinate control over lipogenesis and lipolysis.
Accordingly, the human adipocyte SUR appears to represent an important target for
further development of therapeutic intervention in obesity.

Consistent with our findings, SUR agonists have previously been demonstrated to exert
direct effects on adipocytes. Draznin et al (136, 233) reported that glibenclamide
increased [Ca2+]i in isolated rat adipocytes in a dose-dependent manner by stimulating
Ca2+influx through voltage-dependent Ca2+ channels, while this effect was blocked by
nitrendipine. Moreover, glibenclamide has been reported to potentiate peripheral insulin
effect in isolated adipocytes (234,235). By contrast, Rajan et al (236) were unable to
identify high affinity SUR in either isolated rat adipocytes or 3T3-Ll adipocytes.
Moreover, they were unable to inhibit 86Rb+ efflux (a surrogate for KATP channel activity)
or increase [Ca2+]i with glibenclamide. The reason for this discrepancy is not clear.
However, several other investigators have reported both specific binding of sulfonylurea
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and specific post-receptor effects in murine and rat adipocytes. For example, rat
adipocytes exhibit specific, saturable glibenclamide binding (Ko of 1-3 µM), which is
displaced by other sulfonylureas, and sulfonylurea treatment of isolated rat adipocytes
potentiates insulin receptor of glucose transport (234,235,237). Further, Muller et al.
(238,239) reported that glimepiride exhibits specific binding to 3T3-Ll and rat
adipocytes, resulting in an insulin-mediated stimulation of glucose transport and nonoxidative glucose disposal. These effects were attributed to sulfonylurea-induced
inhibition of cAMP level and protein kinase A activity. Thus, rodent adipocytes appear to
exhibit SUR binding and functional response to this binding.

Interestingly, the human chromosome region encoding both the SUR and the associated
inward rectifying K+ channel, 1lp15. l (240) also contains the human homolog of Tubby,
a locus responsible for severe obesity in mice (241). Moreover, a significant association
was recently reported between an exon 22 allelic variant of the SUR gene and obesity in
French Caucasians (242). In addition, linkage between the SUR region and a subgroup of
morbidly obese families was also noted (242). Thus, the SUR locus may contribute to
genetic susceptibility to obese (242). Whether this contribution is based on alteration in
insulin secretion or an extrapancreatic role of the SUR is unknown. However, our data
suggest a potential role for the human adipocyte SUR in modulating energy storage and
thereby potentially contribute to obesity.
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It is noteworthy that both electrophysiological and pharmacological evidence

demonstrates that KATP channels present in different tissues, such as pancreas, muscle and
brain, belong to different subtypes and show different binding affinity to sulfonylureas,
thereby resulting in different efficacy (243). Accordingly, it is possible that SURs
expressed in pancreatic

p cells and adipocytes

are also different subtypes and have

different sensitivities to sulfonylureas. If so, it may be possible to exploit these
differences to make adipocyte specific SUR agonists and antagonists.

2. 1.25-(0H)z-D

3

and Dietary Calcium

It is now well recognized that la,25-(0H)

2 -D 3 ,

the biologically active form of the

vitamin D, generates biological responses via both genomic and nongenomic pathways.
la,25-(0H)

2 -D 3

is a highly conformationally flexible molecule and is able to rotate

around its 6, 7 carbon-carbon bond of the B ring. This rotation allows generation of a
continuum of potential ligand shapes ranging from the steroid like 6-s-cis conformation
to the extended 6-s-trans conformation (179, 244). Thus, this conformational flexibility of
la,25-(0H)

2 -D 3

in a structure and function context underlies the mechanism whereby

la,25-(0H)

2 -D 3

generates both genomic and non-genomic cellular responses.

la,25-(0H)

2 -D 3

was originally believed to solely function via a nuclear receptor in a

manner similar to the other members of steroid hormone superfamily, resulting in a
biological response (245). Briefly, la,25-(0H)z-D

3

binds to and activates a specific

nuclear hormone receptor, nVDR. The activated nVDR then interacts with another
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nuclear receptor RXR and forms a heterodimer complex. This complex functions as a
transcriptional factor to act on the direct repeat response element named DR-3 in the
promoter region of target genes, thereby stimulating or suppressing transcription of those
genes encoding for proteins that carry out a variety of functions (245). Indeed, recent
studies ofnVDR knockout mouse showed that mice lacking nVDR exhibit a vitamin D
deficient phenotype, including impaired bone formation and growth retardation (246,
247), demonstrating that nVDR mediated genomic action exhibits an important biological
function. However, a high calcium/phosphorus/lactose diet fed at 16 days of age in
nVDR knockout mice allows normal mineral ion homeostasis and thereby rescues the
vitamin D deficient phenotype (248), suggesting that an alternative pathway may
compensate to preserve intestinal calcium absorption and bone development and
modeling in the absence of a functional nVDR. In fact, several lines of evidence
demonstrated that la,25-(0H)i-D

3

stimulates intestinal transcaltachia (249-253), the

rapid stimulation of Ca2+ transport in intestinal epithelium, which may contribute to the
intestinal calcium absorption in these n VDR ablated mice, although this may not be
sufficient to prevent the phenotype of vitamin D deficiency in these animals fed with
normal calcium diets. Moreover, several studies demonstrated that la,25-(0H)

2-D3

is

able to induce rapid non-genomic effects in nVDR-null cells or cells from nVDR
knockout mice (254, 255), further indicating that the genomic model of la,25-(0H) 2 -D3
action is not complete.

la,25-(0H)z-D

3

also generates rapid, nongenomic signal transduction via a putative

membrane vitamin D receptor (mVDR) in a wide variety of cells (178), including
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modulation of calcium channels (142, 180, 249-253, 256-258), production of diacyl
glycerol and inositol triphosphate induced by activation of phospholipase (259),
activation of protein kinase C (260), and stimulation of MAP kinase (261-263). The nongenomic action of la,25-(OH)z-D 3 has been confirmed by studies of analogs of la,25(OH)z-D3. These analogs have been extensively examined for their ability to generate
genomic or non-genomic responses (179, 264). For instance, la,25-dihyroxylumisteroh,
a 6-s-cis-locked analog of la,25-(OH)z-D 3, preferentially exerts a non-genomic action,
including stimulation of Ca2+ influx, via the putative mVDR (265, 266). Another A-ring
diasteromer analog, 1/3,25-dihyroxyvitamin D 3, has been demonstrated to antagonize this
action but has no effects on the nVDR (267,268). Most importantly, recent pursuit of
physical existence of the putative mVDR provides the further evidence to strengthen
these findings. Nemere et al (253) first demonstrated a specific binding protein for la,25(OH)2-D3 in the membrane of chick intestinal epithelium, which mediates the stimulation
of calcium transport. Moreover, Nemere et al (260) subsequently identified a membrane
associated protein with a high binding affinity for la,25-(OH)z-D3, which mediated the
rapid non-genomic regulation of PKC. Further, Baran et al (269) recently found another
plasma membrane-bound protein with a specific and saturable binding for la,25-(OH) 2D3, which was identified as annexin II by sequence analysis and Western Blot. They
further demonstrated that annexin II mediated the rapid effects of la,25-(OH)z-D 3 on
[Ca2+]i- However, it is not known whether these identified binding proteins for la,25(OH)2-D3 are the same protein or different receptors mediating similar non-genomic
functions.
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In addition to the direct stimulation of Ca2+ influx, la,25-(OH)z-D3 also increases the
expression of the CaTl (270), a recently cloned Ca2+calcium channel involved in
capacitative calcium entry (CCE) activated by intracellular Ca2+ release (271,272).

We further extend these observations by demonstrating that la,25-(OH)z-D3 elicits both
genomic and non-genomic action in adipocytes, resulting in modulation of lipid and
energy metabolism (220,222,273). We recently demonstrated that la,25-(OH) 2 -D3
stimulates adipocyte [Ca2+]i, promotes lipogenesis and inhibits lipolysis via a rapid nongenomic action (220, 222). These actions can be mimicked by 1a,25-dihyroxylumisterob,
a specific mVDR agonist, and can be prevented by 1/3,25-dihyroxyvitamin D 3, a specific
mVDR antagonist. We further demonstrated that la,25-(OH) 2 -D 3 exerts an inhibitory
effect on basal, isoproterenol and fatty acid stimulated adipocyte UCP2 expression via a
genomic action (273). m VDR agonist and antagonist fail to exert their actions to either
mimic or prevent la,25-(OH) 2 -D3' inhibitory effect on adipocyte UCP2 expression,
while nVDR knockout by antisense oligodeoxynucleotide (ODN) prevents the inhibitory
effect of la,25-(OH)z-D 3 on adipocyte UCP2 expression (unpublished data).

Regardless of genomic or non-genomic action, la,25-(OH) 2 -D 3 exhibits an important
role in modulation of obesity. Evidence shows that la,25-(OH)z-D 3 is involved in
preadipocytes differentiation. la,25-(OH) 2-D3 up-regulates nVDR expression in 3T3-Ll
preadipocytes (274) and exerts an inhibitory effect on 3T3-Ll preadipocyte
differentiation (275-278). This inhibition is mediated via either competition of nVDR
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with other differentiation transcriptional factors with structural similarity such as RXR
and PPAR-yon DNA response elements (278) or mVDR-mediated Ca 2+ influx. However,
unlike the differentiation of 3T3-Ll preadipocyte which is an embryo-origin cell line, the
differentiation of OB17 preadipocyte, an adult-origin cell line, is stimulated by la,25(OH)2-D3 (279, 280). In addition to differentiation, la,25-(OH)z-D3 also promotes the
expression and secretion of lipoprotein lipase in cultured adipocytes (281 ), indicating that
la,25-(OH)z-D 3 may enhance adipocyte lipid accumulation by increasing fatty acid
uptake.

The role of la,25-(OH)z-D 3 in obesity has been documented in human population-based
studies. n VDR gene polymorphism is associated with the susceptibility to obesity in
humans with early-onset type II diabetes (282). Moreover, Several lines of evidence
demonstrate that circulating la,25-(OH) 2-D 3 level is elevated in obese humans (203-206,
283-285). Since increased circulating la,25-(OH)z-D 3 exerts a negative feedback on the
hepatic synthesis of 25-(OH)-D 3, a negative association between BMI and circulating 25(OH)-D3, as expected, is observed in humans (286, 287). It is noteworthy that la,25(OH)z-D3 induced hyperinsulinemia may be also involved in the development of obesity
in humans. 1,25-(OH) 2-D3 has been shown to stimulate Ca2+ (142) and insulin release
(143, 144) in pancreatic P-cells, indicating that 1,25-(OH)z-D 3, elevated with the
disturbance of calcium homeostasis commonly seen in human obesity, may contribute to
development of hyperinsulinemia via a non-genomic action. Moreover, genetic
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epidemiological studies show that nVDR gene polymorphism influences insulin secretion
and susceptibility to IDDM in Indian Asians (288) and Bangladeshi Asians (289).

Accordingly, antagonism of la,25-(OH) 2 -D 3 and its genomic and/or non-genomic
pathways may represent a promising approaches for development of interventions in
obesity. Since increasing dietary calcium has been demonstrated to suppress la,25(OH)2-D3 levels in several studies (135, 141, 290), we test the hypothesis that dietary
calcium suppression of la,25-(OH)2-D 3 would reduce adipocyte [Ca2+]i and thereby
inhibit triglyceride accumulation by coordinated control over lipogenesis and lipolysis.
Our data demonstrated that suppression of la,25-(OH)2-D 3by increasing dietary calcium
decreased adipocyte intracellular Ca2+, stimulated lipolysis, inhibited lipogenesis,
increased adipocyte uncoupling protein 2 (UCP2) expression and core temperature in
aP2- agouti transgenic mice and that dietary calcium not only attenuated diet-induced
obesity but also accelerated weight loss and fat mass reduction secondary to caloric
restriction (220, 291 ). Consistent with our findings, Metz et al (292) and Bursey et al
(293) previously reported that increased dietary calcium reduced body weight and body
fat composition in spontaneously hypertensive rats, Wistar-Kyoto rats and lean and obese
Zucker rats.

Recent data suggest that this approach may be relevant to humans. Population-based
observation in NHANES III demonstrated a profound reduction in the odds of being in
the highest quartile of adiposity associated with increases in calcium intake (220). This is
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supported by earlier clinical trial demonstrated that increasing daily calcium intake from
400-1000 mg/day for one year resulted in a 4.9 Kg reduction in body fat in obese
African-Americans (220). Consistent with this, a randomized clinical trial demonstrated a
greater weight loss in patients maintained on a milk-based diet with high calcium for 16
weeks, compared with those on conventional hypocaloric diet at same energy intake
(294). Recently, these findings were further confirmed and extended by Davis et al.
(295). They reported that a significant negative association between calcium intake and
body weight was observed in two cross-sectional and two longitudinal studies, and that
the odds ratio of being overweight was 2.25 for women in lower half of calcium intakes
(295). Further, they found a significant weight loss in subjects maintained on a calcium
supplement in a double-blinded, placebo-controlled, randomized clinical trial (295).

58

IV. ROLE OF ADIPOSE TISSUE IN OBESITY
Adipose tissue is the body's largest energy storage organ where energy is stored as
triglyceride (TAG). When total energy intake exceeds the energy expenditure, excessive
energy is deposited in adipose tissue in the form as TAG. The adipocyte TAG is either
derived from chyromicroms (CM) and very-low-density lipoproteins (VLDL) or
synthesized via de novo lipogenesis from carbohydrate precursor such as glucose. TAG
from circulating CM and VLDL is hydrolyzed by lipoprotein lipase (LPL) located on the
capillary walls of adipose tissue to generate free fatty acids (FF As) and
monoacylglycerol. FF As are then transported into adipocytes by specific fatty acid
transport proteins and re-esterified to TAG. On the other hand, excess glucose initiates
the de novo lipogenesis by generating acetyl CoA. Acetyl CoA is used as the substrates to
synthesize the long-chain fatty acids, which are further esterfied to TAG. During
nutritional deprivation, adipocytes undergo lipolysis to release energy. Intracellular TAG
is hydrolyzed to FF As and glycerol by hormone sensitive lipase. These products leave
adipocytes and are transported via the circulation to energy-consuming tissues (296).

Adipose tissue has long been considered as a passive energy-storage depot as described
above. However, data emerging over the past decade have established a new role for
adipose tissue as a functional endocrine/paracrine/autocrine organ. Adipocytes express
and secrete numerous peptide hormones and cytokines, as follows. Leptin plays a key
role in regulating body weight and energy balance. Tumor necrosis factor alpha (TNF-a)
(21 ), resistin (22, 23), and adiponectin (24-26), contribute to insulin resistance/NIDDM.
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Angiotensin II regulates vascular tone, adipocyte lipogenesis and differentiation (297).
Plasminogen-activator inhibitor-I is involved in vascular functions and cardiovascular
heart disease (16). Adipose tissue also secretes active steroid hormones, such as estrogen
and cortisol (298, 299), the immune system-related protein adipsin (300), and
prostaglandins (297). These bioactive molecules link adipocyte biology to the systematic
functions of diverse organ through the body, indicating that local changes of adipocyte
functions or mass may dynamically influence systematic metabolism.

A. ADIPOCYTE HYPERPLASIA
Adipocyte differentiation occurs in both prenatal and postnatal states. It was originally
believed that individuals are born with a fixed complement of adipocytes that developed
prenatally and persisted throughout life without gaining new cells. However, it is now
recognized that adipogenesis occurs throughout the lifespan. Adipogenesis may result
from either normal cell turnover or the requirement for more fat mass upon excessive
energy storage (301, 302). Indeed, although adipocyte size is variable corresponding to
the changes of amount of stored lipid, the physical space for a single adipocyte to store
lipid is ultimately limited. On the other hand, animals always continue to store fat as long
as energy intake exceeds nutritional requirement, suggesting a requirement for de novo
differentiation of adipocytes to accommodate this excessive energy (301).

Increased fat mass can arise from an increase in adipocyte size, number, or both. It was
originally believed that only early-onset obesity was associated with adipocyte
hyperplasia, while maturity-onset obesity was believed to result solely from adipocyte
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hypertrophy (303, 304). This concept was challenged by later studies demonstrating that
the potential to acquire new adipocytes continues through adulthood (305-309). Direct
evidence from studies ofrats fed with a high caloric diet demonstrates that 3H-thymidine
incorporation into new adipocytes occurs throughout life (305). Moreover, expression of
specific early differentiation genes has been reported to express in adipose tissue from
very old mice (306). In addition, fat cell precursors, such as stromal-vascular cells,
isolated from adult human adipose tissue can be fully differentiated into mature
adipocytes in vitro (307, 308). Further, adipocyte development has been shown to depend
on fat precursor cell recruitment in vivo (307). Human population-based study shows that
an increase in fat cell number appears to be well correlated with severity of human
obesity in adult life (309). Although the relative contribution of adipocyte hypertrophy
versus hyperplasia to human adiposity is unknown, the capacity to generate new
adipocytes from cells persists throughout life span and clearly plays a role in regulating
fat tissue mass.

a. Adipocyte Origin
The development of adipocyte origin in vivo is not well defined. However, studies on
pluripotent stem cell lines in vitro demonstrate that the adipocyte lineage derives from the
embryonic stem cell precursors, which possess the potentials to differentiate into
mesodermal cell types, including adipocytes, chondrocytes, osteoblasts, and myocytes
(310). This was confirmed by demonstration that demethylating agents induce murine
embryonic stem cells to differentiate into adipocytes, myocytes, and chondrocytes
simultaneously (310, 311 ). Moreover, there is evidence that the same marrow-derived
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stromal cells give rise to both bone and fat cells (312, 313). This conversion of stromal
cells into specific cell lineages depends on different culture conditions that could
selectively promote the differentiation of one cell type over another. For instance, TGF-/3
superfamily proteins act as potent osteogenic agonist to stimulate bone cell formation,
while these proteins inhibit adipocyte differentiation (310,313,314). By contrast, PPAR-y
agonists function as potent adipogenic factors to stimulate adipocyte differentiation,
while they inhibit bone cell formation (310,313,314).

Although the transcriptional

pathways in the late stages of adipocyte differentiation have been well defined, the early
molecular events that promote the determination of primitive mesenchymal precursor
cells to the adipocyte lineage cells remain unknown. There are no clear molecular
markers identified so far to indicate the determination of the transition from primitive
mesenchymal cells to committed adipocyte lineage cells. However, a recent study shows
that GATA-deficient embryonic stem cells exhibit enhanced capacity to differentiate into
adipocyte (315), indicating that down-regulation of GATA transcriptional factors sets the
stage for the transition of embryonic stem cells to adipocytes. Since the initial steps of
adipogenesis from primitive mesenchymal cells are not clear, pre-determined clonal cell
lines, such as preadipocyte cell lines, and primary-cultured stromal vascular precursor
cells isolated from adipose tissue are used to study adipogenesis. These preadipocyte cell
lines and primary-cultured preadipocytes are already committed to adipocyte lineage,
although they are morphologically fibroblasts and represent different stages of adipocyte
development (310). The most frequently used cell models are 3T3-Ll and 3T3-F442A,
which are clonally derived from 3T3-Swiss cells isolated from disaggregated 17 to 19
day mouse embryo (310, 316-318), and Ob 17 cells, which are adipocyte precursors
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isolated from epididymal fat pads of adult ob/ob mice (319). When these cells are
cultured in appropriate conditions containing fetal bovine serum (FBS),
methylisobutylxanthine (MIX), dexamethasone (not required for 3T3-F442A
differentiation), insulin, and T3 (required for Ob 17 cell differentiation), they are able to
acquire morphological and biochemical characteristics of adipocytes and become fully
differentiated.

Morphological methods such as microscopic investigation have been successfully utilized
to study the early development of adipose tissue in vivo. At early developmental stages of
human fetus, cells with the potential to develop into adipocytes are morphologically
indistinguishable from those with the potentials to develop into other cell types (320).
The human fat organ initially appears between 14th and 16th week of gestation (320,321).
The first indication of adipogenesis is evident as an aggregation of mesenchymal cells
associated with the formation of blood vessels. The first primitive organ structures where
fat cells aggregate are known as fat lobules (320, 322). Although the number of fat
lobules remains constant after 23 th week of gestation, the size of these lobules grows
during the following several weeks of gestation (320, 322). During stages of the early fat
development, adipose tissue predominantly exists as the multilobular forms (320, 322).
Interestingly, the morphological development in vitro resembles that in vivo.
Preadipocyte differentiation from either preadipocyte cell lines or primary-cultured
preadipocytes tends to form adipocyte clusters (320). This not only occurs in adipocyte
differentiation stages but also persists in mature adipocyte culture, such as Matrigelcultured mature adipocytes with a three-dimensional culture model mimicking in vivo
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adipocyte-growing condition (323, 324). At the beginning of the third trimester,
adipocytes exist in the major fat depots but remain rather small. At birth, body fat
accounts for 16% of body weight (320,322).

b. Program of Adipocyte Differentiation
The first stage in the adipocyte differentiation is cell growth arrest, a required event for
further differentiation process (301, 310). At this point, preadipocytes arrest at the Go/G1
cell cycle boundary (325, 326). Although cell-cell contact or cell confluence does cause
preadipocyte growth arrest, cell contact inhibition per se is not a prerequisite for growth
arrest to occur. Preadipocytes plated in at low density or cultured in methylcellulosestabilized suspension are still able to differentiate into mature adipocytes (310, 327).
Following cell growth arrest, preadipocytes must receive mitogenic or adipogenic signals
to proceed further proliferation and adipogenic conversion, which can be initiated by
treating confluent cells with an appropriate combination of hormone agents such as
methylisobutylxanthine (MIX) and dexamethasone. Following exposure to these agents,
preadipocytes undergo at least one round of cell division, so called mitotic expansion.
DNA replication during this mitosis presumably alters the accessibility of gene
promoter/regulatory elements to transcriptional factors that activate or suppress early
regulatory genes responsible for initiating differentiation (325, 326). These mitotic events
are required for cells to enter a unique growth-arrested phase of cell cycle, referred to as
Go (328-330), which is permissive for subsequent differentiation events. Once cells enter
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the Go phase, cells enter a final period of growth arrest and differentiation becomes more
committed and irreversible.

Growth arrest and clonal expansion are accompanied by complex changes in the pattern
of gene expression. Lipoprotein lipase (LPL) is the one of the early genes expressed
during differentiation process. LPL expression appears as early as in the confluent stage
of growth arrest, although biological role of its early expression is not known (325, 326,
331). Two key families of transcriptional factors, CCAAT/enhancer binding protein
(C/EBP) and proliferators-activated receptor-"( (PPAR-y),are expressed in the early stages
of differentiation (301, 310), and play critical roles in terminal differentiation, as
discussed in the following section (Transcriptional Control of Adipocyte Differentiation).
PP AR-y expression increases immediately following the hormonal induction of
differentiation and represents an early marker of adipocyte differentiation. Its expression
can be detectable on the second day of differentiation and remains high in mature
adipocytes (332). Transient induction ofC/EBP/j and C/EBPo precedes that of PPAR-y
(333-335). The subsequent decreases ofC/EBP/j and C/EBPo are concomitant with the
induction of C/EBPa expression, which appears slightly before the induction of
adipocyte-specific genes (333-335). Another important transcriptional factor induced in
the early stage of differentiation is sterol response element binding protein-1/adipocyte
determination and differentiation factor-1 (SREBPl/ADDl), which is also involved in
the induction of adipocyte-specific gene expression (336, 337). Following the expression
of these early transcriptional factors, preadipocytes enter the terminal phase of
differentiation. There are numerous adipocyte-functional genes which characterize the
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adipocyte phenotype induced during this stage. These adipocyte functional genes include
those responsible for lipid metabolism, such as fatty acid synthase (FAS), acetyl CoA
carboxylase (ACC), ATP citate lyase, malic enzyme, and glycerol-3-phosphatedehydrogenase (GPDH) for de novo lipogenesis (310, 338-340) and hormone sensitive
lipase for lipolysis, aP2 for fatty acid transport (339, 341), stearoyl-CoA desaturase-1
(SCDl) for fatty acid desaturation (340), those genes involved in glucose utilization, such
as glucose transport 4 for glucose transport (GLUT4} (342), and phosphoenolpyruvate
carboxykinase for gluconeugenesis (343), and those genes responsible for adipocyte
signaling, such as the insulin receptor and {32 - and {33 - adrenergic receptors (310, 344,
345), and those gene encoding adipocyte secretory hormones/cytokines, such as leptin,
TNFa, resistin, CD36, and Acrp30 (22-25, 310, 346), etc. By contrast, certain

preadipocyte specific genes, such as preadipocyte factor- I (pref-1) which is involved in
maintaining preadipocyte phenotype, are dramatically decreased in the differentiation
process (34 7).

c. Transcriptional Control of Adipocyte Differentiation
1. Proxisome Proliferator-Activated Receptor Gamma (PPARy)
Cloning of PP ARy revealed it to be a member of PP AR subfamily of nuclear hormone
receptor (348-350). PP AR family includes three related but quite distinct proteins,
PPARy, PPARa and PPAR<>,each of which is encoded by a separate gene and shows a
distinct tissue distribution (351 ). PPARy is expressed in an adipose-selective fashion in
both rodents and humans, with 10-30 fold higher levels in fat than in most other tissues
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(350). PPARy exists as two isoforms, PPARyl and PPARy2 which differ in the Nterminus by 30 amino acids, produced by alternative promoter usage (352, 353). PP ARyl
is expressed at low levels in many tissues, but abundantly in fat, while PP ARy2 is
abundantly and selectively expressed in fat (352-354).

The binding of ligands to PP ARy remarkably enhances its transcriptional activity. Two
classes of PP ARy ligands so far have been identified. One is a family of synthetic
compounds, thiazolidinedions (TZDs), which are used to increase insulin sensitivity
clinically (355). These compounds bind to PPARy with high affinity and potently
increase its transcriptional activity (355). Searches for the natural ligands for PP ARy have
revealed that fatty acids and eicosanoid derivatives, such as linoleic acid, linolenic acid,
prostaglandin J2, D2 and other metabolites, are able to bind and activate this receptor
(356-358). The studies of Gal4-reporter gene activation demonstrated that the most potent
natural ligand is 15-deoxy .112• 14 PG J2 (356). Although all of these molecules are
considered as potential ligands in vivo, several ligand-receptor binding assays show that
their binding affinities are low, in the range of 2-50 µM. Indeed, this is inconsistent with
the higher affinities that most nuclear receptors possess for their endogenous ligands (Kd
at low nM level) (348). Recent study of X-ray crystal structure revealed a large binding
pocket in PPARy, which may provide easier access for ligands and explain the diversity
of ligands for PPARy (359).
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PP ARy plays a key role in transcriptional control of adipocyte-specific gene expression,
which include aP2, PEPCK, LPL, GLUT4, and leptin, etc. Ligand-activated PP ARy
heterodimerizes with RXR and this heterodimerization complex acts on a conserved
DNA element DR-1 (direct repeat of the hormone response element separated by one
base) like sequence in these adipocyte-specific genes (352). PPARy-dependent
adipogenic transcription was first characterized on the transactivation of adipocytespecific enhancer of aP2 gene (350, 352). PP ARy also transactivates PEPCK gene
expression during preadipocyte cell line differentiation (343). This PPARy induced
PEPCK expression has recently been extended in vivo, where activation of PEPCK
promoter in adipose tissue depends on PPARy binding site, whereas expression of this
gene in other tissues does not (360).

It is now well recognized that PPARy per se plays a central role in transcriptional control
of adipogenesis. PP ARy was expressed at low but detectable levels in preadipocytes and
its expression was markedly increased early in adipocyte differentiation (350, 352).
Retroviral expression of PPARy in fibroblasts caused an adipocyte phenotype in these
fibroblasts, including morphological changes, lipid accumulation, and adipocyte-specific
gene expression. However, a point mutation in the zinc finger of PPARy required for
DNA binding ablated its capability of differentiation induction (361 ). Moreover,
treatment with selective high-affinity PPARy agonists such as thiazolidinediones (TZDs)
further increased the potency of PPARy on differentiation (362,363). Conversely,
synthetic antagonists for PPARy inhibit adipocyte differentiation (364). Consistent with
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this, a dominant negative mutant of PPARy inhibited PPARy agonist-induced
adipogenesis (365)

The role of PPARy in adipogenesis has also been demonstrated in PPARy knockout mice.
The homozygous null mutation is lethal in gestation, resulting from defective placenta
development (366, 367). Barak et al. created chimeric embryos using a combination of
wild-type tetraploid cells which contribute to the development of extraembryonic tissues
(366). One PP ARy-null homozygous mutant developed to term, but succumbed to a
variety of metabolic disorders by post-natal day 5. This animal lacked adipose tissue,
indicating that PP ARy is required for adipose tissue development in vivo (366).
Moreover, Rosen (368) et al created chimeric mice derived from both wild-type ES cells
and PPARf

1-

ES cells. In these animals, PPARy null ES cells do not contribute to the

formation of fat tissue, but participate in the development of the other tissues. In addition,
PP ARy is also required for the in vitro differentiation of adipocytes from ES cells (368).

2. CCAAT Enhancer Binging Protein (C/EBP) Family
C/EBP proteins were first transcriptional factors demonstrated to play an important role
in adipocyte differentiation. These transcriptional factors contain a basic transactivation
domain and a leucine zipper motif, which are responsible for homo- or
heterodimerization with other transcriptional factor (301, 310, 333). C/EBPs are
expressed not only in adipose tissue, but also in other tissue, such as liver, which actively
metabolize lipid (333).
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The expression of C/EBPs during adipocyte differentiation exhibits a distinct pattern.
C/EBP{j and C/EBPo are transiently expressed early in response to hormonal stimulation,
whereas C/EBPa is expressed just preceding the induction of most adipocyte specific
gene (333-335), suggesting that this protein may be responsible for the expression of
these adipocyte marker genes (330). Several adipocyte-specific genes, such as stearoyl
CoA desaturase-1 (SCD-1), GLUT4, aP2, PEPCK, leptin, and insulin receptor, contain
CEBPa binding site in their promoter regions (310, 333, 369-373).

Ectopic expression of C/EBP/1 is sufficient to induce the differentiation of 3T3-L 1 cells
in the absence of hormone stimulation, while differentiation hormonal agents are required
to induce differentiation in the C/EBPo-overexpressed 3T3-Ll cells, but adipogenesis in
these cells is accelerated (374). Similar result is observed in the NIH-3T3 cells
overexpressing C/EBP/j. C/EBP/1 is also able to determine primitive mesenchymal cells
to the adipocyte lineage and promote adipogenic in these cells (375). By contrast, either
C/EBP{j- or C/EBPo-deficient embryonic fibroblasts exhibited slightly reduced
adipogenic potential, while cells lacking both C/EBPo and C/EBP{j were severely
inhibited from differentiating into adipocytes (376). C/EBPa is also critical to the
adipogenic program. Constitutive expression of C/EBPa is sufficient to induce
differentiation of 3T3-Ll cells without additional hormonal agents, while expression of
antisense C/EBPa mRNA in 3T3-Ll preadipocytes prevents differentiation (377, 378).
Moreover, C/EBPa has been shown to promote adipogenesis in a variety of mouse
fibroblasts which have little or no spontaneous capacity to differentiate into adipocytes
(379).
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Mouse models lacking C/EBPs illustrate the importance of this family of transcriptional
factors in adipogenesis. Mice lacking either C/EBP/3 or C/EBPo usually survive postnatally without significant developmental or physiological defects. These animals
develop normal white adipose tissue, although their brown fat exhibits slight reduction in
lipid accumulation and UCPl expression (376). However, the double-knockout mice
(C/EBPo-1- and C/EBPff 1) have a low survival rate (15%), but the double knockout
survivors exhibit reduced brown and white fat. Interestingly, the reduction in brown fat
results from impaired lipid accumulation, while the reduction in white fat involves
decreased cell number (376). Generation of C/EBPa-deficient mice confirms the
physiological role of C/EBPa in adipose tissue differentiation. A high percentage of these
knockout mice die from hypoglycemia as a result of a failure to activate hepatic
gluconeugenesis postnatally (373,380,381). This is caused by the C/EBPa deficiency in
the liver, where it regulates genes involved in energy metabolism including glucose.
However, phenotype rescue by injection of glucose is able to increase survival rate.
These C/EBPa-null mice do not have subcutaneous inguinal white fat. Although the
interscapular brown fat is still present, lipid accumulation is dramatically reduced in this
tissue (373,380,381).

Moreover, the role of C/EBP family in adipogenesis is further

demonstrated by functional knockout of all members of C/EBP in white adipose tissue.
Transgenic mice expressing a dominant-negative basic leucine zipper protein, termed BZIP protein, under the control of aP2 promoter exhibit lipidystrophy (382). The dominant
negative mutant B-ZIP proteins overexpressed in adipose tissue dimerize with all
member proteins of C/EBP family and abolish their DNA-binging abilities. These mice
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are unable to develop white fat, demonstrating critical roles of C/EBP family proteins in
adipose tissue development.

3. Sterol Response Element Binding Protein-1/Adipocyte Determination and
Differentiation Factor-I {SREBPl/ADDl)
SREBPl/ADDl is a group of basic helix-loop-helix (bHLH) leucine zipper
transcriptional factors (310). SREBP 1/ADD 1 displays a dual DNA binding specificity,
binding to both an E-box motif and non-E-box (SRE-1) motif element. The SREBP
family consists of three members, SREBP-la, le, and 2, which are encoded by 2
independent genes. In human and mouse, SREBP-1 a and le are generated from the same
gene by the usage of alternative transcription start sites (383). ADDI, cloned from a rat
cDNA library, is a homologue of human SREBP-le (384). SREBPl/ADDl has been
shown to regulate expression of numerous genes encoding proteins involved in both
cholesterol and fatty acid metabolism (310, 385-388)). SREBPl/ADDl is an inactive
molecule bound to the membrane of the endoplasmic reticulum. Once cells sense a
cholesterol depletion, SREBPl/ADDl undergoes proteolytic cleavage and translocates to
the nucleus to regulate expression of target genes (389). Although all three SREBPs are
capable of modulating similar gene expression, regulation of fatty acid biosynthesis is
primarily mediated by SREBP-1 a and SREBP-1 c, which is the predominant form in
adipose tissue in vivo (385).

The expression of SREBPl is detectable on the second day of 3T3L-1 cell differentiation
(336). Ectopic expression of a constitutive active form of SREBP-1 c increases expression
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of adipocyte marker genes and enhance the differentiation in the presence of PPAR-y
agonists in NIH-3T3 cells (336). Overexpression of SREBP-lc in preadipocytes increases
the transcriptional activity of PP AR-yon aP2 promoter by increasing the endogenous
ligands (390). Moreover, the ectopic expression of a dominant-negative form of this
transcriptional factor that contains a point mutation in the DNA-binding domain
suppresses the expression of adipocyte marker genes and inhibits differentiation (336).

4. Transcriptional Cascade in Adipogenesis
Addition of specific hormones initiates a cascade of transcriptional events that account
for the expression of adipocyte-functional genes. Transient expression of C/EBP<>and
C/EBP/3precedes that of PPAR-y(375). These C/EBPs have been demonstrated to
mediate the expression of PPAR-ythrough C/EBP binding sites in the PPAR-ypromoter
region (353,391). Moreover, C/EBP<>and C/EBP/3 also induce C/EBPa expression via a
consensus sequence in its promoter (392). Once induced, C/EBPa and PP AR-yappear to
cross-regulate each other to maintain their gene expression levels, although the C/EBPo
and C/EBP/3 levels decrease after early transient expression (393).

SREBPl/ADDl is also induced early during differentiation. This transcriptional factor
appears to up-regulate PPAR-yexpression (391). Moreover, ectopic expression of
SREBP-lc in preadipocytes increases the transcriptional activity of PPAR-yby producing
the endogenous ligands (390). Therefore, SREBPl/ADDl plays an important role in
transcriptional events mediating adipogenesis.
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During the late stages of terminal differentiation, PP ARy and C/EBPa play the major role
in regulating the gene expression of proteins responsible for the development of
functional mature adipocytes. C/EBP5 and C/EBP/3 are able to directly regulate
adipocyte-functional gene expression, as there are a number of these genes that bear
active consensus sequence for either C/EBPa or PP AR-y.It is also possible that C/EBPc>
and C/EBP/3 indirectly regulate expression of other adipocyte-functional genes via the
activation of intermediary transcriptional factors that act on those genes (385).

It is noteworthy that preadipocytes express a number of inhibitory proteins that may

function to maintain the preadipocyte phenotype. Therefore, these inhibitory factors must
be down-regulated or inactivated to allow differentiation process to proceed. Pref- I is an
inhibitor of adipocyte differentiation (347). It is synthesized as a plasma membrane
protein containing 6 EGF repeats. Pref- I is abundantly expressed in preadipocytes, but is
not detectable in mature adipocytes (34 7). Down-regulation of pref- I is required for
adipogenic conversion, while constitutive expression of pref- I inhibits differentiation.
That was confirmed by demonstrating that application of antisense pref- I to
preadipocytes markedly increases adipogenesis (347). However, pref-I expression is not
detectable in stromal-vascular fraction in mouse adipose tissue in vivo (393), suggesting
a different expression pattern of this gene in vivo. Moreover, recent studies demonstrate
novel signaling pathways involved in the inhibition of adipogenesis. Wnt signaling has
been demonstrated to be a molecular switch that controls adipogenesis (394). Wnt
signaling maintains preadipocytes in an undifferentiated state through inhibition of
PPAR-y and C/EBPa expression (394). Conversely, disruption ofWnt signaling increases
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cell adipogenesis. In addition, family of GATA transcriptional factors also plays a role in
modulation of adipogenesis (315). Down-regulation of these transcriptional factors sets
the stage for terminal differentiation. By contrast, constitutive expression of GATA
suppresses adipocyte differentiation and traps cells at the preadipocyte stages. This
inhibitory effect on adipogenesis is mediated by direct inhibition of PP AR -y(315).
Further, several lines of evidence shows that suppression of AP-2a and sp 1 expression
during differentiation is required for PP AR-yand C/EBPa expression (395, 396).

Adipogenic transcriptional factors may also modulate adipogenesis by interacting with
cell cycle proteins to affect preadipocyte cell cycles. Activation of PPAR-ycauses cell
cycle withdraw by inhibiting the DNA-binding and transcriptional activity of the E2F-DP
complex (397). This alteration in E2F/DP DNA binding is secondary to the decreased
expression of protein phosphorylase 2A, which results in increased phosphorylation of
DP-1, thereby preventing E2F DNA binding (397). Moreover, since retinoblastoma
(pRB) is able to bind and sequester E2F, increased pRB expression or activity is expected
to inhibit E2F DNA binding and transcriptional activity. Indeed, knockout of either pRB
activity or expression inhibits adipogenesis (398), whereas either activation or
overexpression of two members of pRb protein, p 107 and p 130, promotes adipogenesis
(399). In addition to sequestering E2F, pRB is also able to directly interact with
adipogenic transcriptional factors, such as C/EBPs and MyoD, to modulate adipocyte
genes involved in terminal differentiation (400). pRB is inactivated via phosphorylation
exerted by a dimmer complex comprising a regulatory subunit cyclin and a catalytic
subunit cyclin-dependent kinase (cdk). This complex is further modulated by cyclin75

dependent kinase inhibitors; phosphorylation of cyclin/cdk complex by cdk inhibitor
inactivates its activity. Recent studies demonstrate that cdk inhibitors, including p 18
(INK4c), p21 (Cipl), and p27 (Kipl), are up-regulated during adipocyte differentiation
(401 ), suggesting that cdk inhibitors may play a role in cell cycle withdraw and
maintaining the irreversible growth arrest which defines the adipocyte terminal
differentiation. This up-regulation of cdk inhibitor is mediated by PP ARy. Either ligand
activation or ectopic expression of PPAR-yincreases the expression of these cdk inhibitor
proteins or even increases the stability of these proteins (401). Further, the p38 MAP
kinase pathway, activated by stress signal for cell growth arrest, is also involved in
adipogenesis. Treatment ofpreadipocytes with p38 MAP kinase inhibitor during the early
differentiation stages blocks adipogenesis (402). Moreover, ectopic expression of a
dominant-negative p38 inhibits adipogenesis. This action is mediated by inhibition of
C/EBP/3, which contains a consensus site for p38 phosphorylation and serves as a
substrate for p38 MAP kinase (402).

d. Hormonal and Cellular Regulation of Adipogenesis
1. Insulin. IGF-1 and Other Growth Factors

Addition of insulin to differentiation media can promote adipogenesis and also increase
lipid accumulation in adipocytes (403). Although preadipocytes do express few insulin
receptors (404), insulin may potentiate adipocyte differentiation via binding to the IGF-1
receptor. This may explain why the pharmacological doses of insulin are required to
achieve the stimulatory effects on adipogenesis.
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IGF-1 is a potent inducer of adipogenesis. It is a critical component of fetal bovine serum
for adipocyte differentiation, as supplementation of this factor enables differentiation to
proceed in serum-free medium (405). Moreover, IGF-1 has been shown to stimulate 3T3Ll preadipocyte differentiation in a dose-dependent manner (406). IGF-1 secreted from
Ob 17 cells could act in an autocrine/paracrine fashion to induce differentiation (407).

Moreover, IGF-1 mediates the adipogenic effect of growth hormone, which is required
for preadipocyte cell line differentiation (310). Growth hormone stimulates expression
and secretion ofIGF-1 in preadipocytes, which in tum act on adipogenesis. Growth
hormone also sensitizes cells to the mitogenic effects of IGF-1 for clonal expansion and
thereby promotes differentiation (310).

IGF-1 and insulin may stimulate adipogenesis by activating downstream signal
transduction. Activation ofras by insulin or IGF-1 has been demonstrated to mediate the
stimulatory effects on adipogenesis. This was confirmed by demonstration that ectopic
expression ofras promotes adipogenesis in the absence of hormonal stimulation (408),
whereas inactivation of ras inhibits adipogenesis (409). However, the timing of ras
activation during differentiation is crucial in determining whether it exerts a stimulatory
or inhibitory effect on differentiation, as this small G protein is a potent mediator of MAP
kinase pathway, whose activation leads to inhibition of differentiation. Moreover,
PKB/ Akt may also function as a down-stream signal for insulin/lGF-1 stimulated
adipogenesis. Ectopic expression of PKB in 3T3-Ll preadipocytes induces spontaneous
differentiation (410).
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Unlike insulin/IGF-1, other growth factors are generally believed to be inhibitors of
adipogenesis, due to their mitogenic effects on cell growth. Epidermal growth factor
(EGF), transforming growth factor-a (TGF-a) and TGF-~ have been consistently shown
to inhibit adipogenesis in a variety of preadipocyte cell lines and primary-cultured
preadipocytes in different species (411, 412). Transgenic mice overexpressing TGF-a
exhibit reduced body fat by 50% (413), while TGF-~ has been shown to inhibit
adipogenesis in vivo (414). However, basic fibroblast growth factor (bFGF) and plateletderived growth factor (PDGF) exhibit either no effects, inhibitory effects, or slightly
stimulatory effects on adipogenesis, depending on the cell origin, developmental stage,
and culture condition ( see review 310). This inhibitory effect on adipogenesis is likely to
be mediated by growth factor activation of MAP kinase pathways, such as erk 1 and 2.
These kinases are able to phosphorylate PPARy at N-terminal serine residues and thereby
inhibit its transcriptional activity (415-417). Moreover, MAP kinases also phosphorylate
RXR, the heterodimerization partner of PPARy, and inhibit its dimerization with PPARy
(418).

2. Tumor Necrosis Factor-a (TNF-a) and Other Cytokines
A number of cytokines, including TNF-a and IL-1, have been shown to inhibit
adipogenesis (301 ). TNF-a is a potent inhibitor of adipocyte differentiation. Moreover, it
also suppresses the expression of some adipocyte-specific gene expression in newly
differentiated adipocytes, serving to dedifferentiate these cells (419-421 ). This inhibitory
effect on adipogenesis is mediated by down-regulation of C/EBPa and PP ARy (421,
422). This may explain the parallel down-regulation of those adipocyte-specific genes,
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such as aP2 and GLUT4, which contain binding sites for PP ARy and C/EBPa in their
promoters.

3. Nuclear Hormone Superfamily
The members of nuclear hormone superfamily that exert effects on adipocyte
differentiation include glucocorticord, 3,3 ',5-triiodothyronine (T3), retinoic acid (RA),
and 1,25-dihroxyvitamine D3 . It is believed that these hormones act on differentiation via
activating nuclear hormone receptors, belonging to a large nuclear receptor superfamily
including PPARy. Dexamethasone (Dex), a synthetic glucocorticoid, has long been used
to induce differentiation in preadipocyte cell lines and primary cultured preadipocytes in
different species (310). Addition of Dex to the differentiation cocktail is either required
for differentiation or at least accelerates the differentiation process, depending on the
origin of the cells (310). Dex has been shown to induce C/EBPs expression, while cells
overexpressing PPARy or C/EBPs still require the addition of Dex to be fully
differentiated (301,310). Recently, Sul et al. demonstrated that Dex promotes
adipogenesis via inhibiting pref-1 expression, while constitutive expression of pref-1
blocks the adipogenic effect of Dex (347).

RA influences adipocyte differentiation in a biphasic manner. Administration of
pharmacologic doses of RA inhibits adipogenesis, while treatment with physiological
doses of RA increases adipogenesis. The inhibitory effect of RA on adipogenesis is
mediated by inhibition of C/EBP/3, C/EBPa and PP ARy expression (310, 423, 424). In
contrast to the inhibitory effect of RA used in pharmacological doses, administration of
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RA in physiological concentration exerts a stimulatory effect on adipogenesis in OB 17
preadipocytes (425, 426). Moreover, RA exhibits a critical role in ES cell-derived
adipogenesis. Application of RA to ES cells markedly promotes adipogenic transition
from ES cells to adipocytes (427).

T 3 is only required for Ob 17 preadipocyte differentiation (428). There is no requirement
of this hormone in the other differentiation system. la,25-(OH)z-D 3 either promotes or
inhibits adipogenesis, depending on cell models. la,25-(OH)z-D 3 up-regulates nVDR
expression in 3T3-Ll preadipocytes (274) and exerts an inhibitory effect on 3T3-Ll
preadipocyte differentiation (275-278). This inhibition is mediated via either competition
of nVDR with other differentiation transcriptional factors with structural similarity such
as RXR and PPAR')'on DNA response elements (278) or mVDR-mediated Ca 2+ influx.
However, unlike the differentiation of 3T3-Ll preadipocyte which is an embryo-origin
cell line, the differentiation ofOBl 7 preadipocyte, an adult-origin cell line, is stimulated
by la,25-(OH)2-D3 (279,280).

4. Prostaglandins
Both mature adipocytes and preadipocytes secrete large amounts of prostaglandins (PG).
Several major PGs that exert effects on adipogenesis and lipid metabolism include PGF 2a,
PGh, PGD2, and PGE 2 (297,310,348, 430-434). PGE2 is a potent anti-lipolytic
compound, suggesting that it may contribute to lipid accumulation in terminal
adipogenesis. PGD 2 and its derivative PGJi are endogenous ligands for PP ARy and
therefore promote adipogenesis via a PPARy-dependent mechanism (348). PGh
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stimulates Obl 771 cell differentiation in an autocrine/paracrine manner (412). This
action may be mediated by stimulation of cAMP (429). Moreover, PGii is also an agonist
for PPARa, PPARo, and PPAR-y(297), suggesting that PGii may exert its adipogenic
effect by activation of PP ARs. In addition, angiotensin II stimulates PGI 2 secretion from
differentiated Ob 1771 cells by binding to AT 2 receptor. The secreted PGI 2 in tum acts on
preadipocytes to promote differentiation in a paracrine manner (430), indicating that PGI2
may play a physiological role in adipogenesis in vivo. By contrast, PGF 2a exerts
inhibitory effect on adipogenesis in various preadipocyte cell lines and primary
preadipocytes (431,432). This was confirmed by demonstration that FP receptor (PGF2a
receptor) agonists potently inhibit 3T3-Ll preadipocyte differentiation (433, 434).

5. Intracellular Secondary Messengers
The role of cAMP in adipogenesis has been well demonstrated in the application of
methylisobutylxanthine (MIX) in adipocyte differentiation. MIX is a component required
in the differentiation medium for most types of preadipocyte differentiation. MIX causes
intracellular cAMP accumulation by simultaneously inhibiting phosphodiesterase and
stimulating adenylyl cyclase via blocking protein Gi (310). MIX has been shown to
induce adipogenesis by increasing C/EBP~. Several studies have demonstrated that MIX
induction of adipogenesis is mediated via increasing cAMP. Synthetic cAMP analogs can
replace MIX for adipocyte differentiation (435) and increasing cAMP through activation
of adenylyl cyclase by forskolin can induce differentiation in the absence of MIX (436).
Recently, the mechanism of cAMP stimulation of adipogenesis was addressed by
demonstration that activated CREB (cAMP response element binding protein) is required
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and sufficient to induce adipogenesis, indicating that CREB, the cAMP-activated
transcriptional factor, mediates the cAMP-stimulated adipocyte differentiation (435).

The G protein family members, including Gas, Gai, and Gaq, are involved in regulation of
adipogenesis. Either suppression of Gas by Gas antisense knockout or ectopic expression
of constitutively active Gai dramatically accelerated adipogenesis. These effects were
exerted at ambient or elevated cAMP levels, suggesting that the effects of G protein on
adipogenesis are independent of G modulation of adenylyl cyclase (437,438). This was
confirmed by further evidence demonstrating that the specific domains of Gas and Gai
responsible for adipogenesis are distinct from those interacting with adenylyl cyclase
(438). Activation of Gaq appears to down-regulate adipocyte differentiation. Gaq activates
phospholipase cp, resulting in production of diacylglycerol and further activation of
PKC, a negatively regulatory signal in adipogenesis (310, 440).

Intracellular Ca 2+ ([Ca 2+]i)is also an important cellular signaling mediating adipogenesis.
Ntambi et al. have reported that increasing [Ca2+]i, by either inhibiting Ca2+-ATPase or
stimulating Ca2+influx, inhibits the early stages of murine adipocyte differentiation
(441 ). [Ca 2+]i exerted this inhibitory effect by blocking the postconfluent mitotic phase
and mediating sustained levels of c-myc expression (441 ). This sustained c-myc
expression precludes cell entry to the Go stage necessary for subsequent differentiation.
Consistent with this, stimulation ofFP receptor by PGF 2 a, an inhibitory prostaglandin in
adipogenesis, causes a transient increase in [Ca2+]i and in turn activates
calcium/calmodulin-dependent kinase (CaM kinase), resulting in an inhibition of
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adipocyte differentiation (431 ). This anti-adipogenic effect of PGF 2 a can be reversed by
KN-62, a CaM kinase inhibitor (431 ). However, other studies demonstrate that activation
of CaM kinase stimulates adipogenesis, while inhibition of CaM Kinase with KN-62 or
KN-93 prevents the adipogenic conversion. A possible explanation to this discrepancy is
that the effect of [Ca2+]ion adipogenesis depends on the timing of [Ca2+]i stimulation
during differentiation process. Our recent data confirm that increasing [Ca2+]i exerts a
biphasic regulatory role in human adipocyte differentiation, serving to inhibit the early
stages of differentiation, while promote the late stages of differentiation and lipid filling
(441). The mechanism whereby [Ca2+]iundergoes the role transition during human
adipocyte differentiation is unknown. However, cAMP also plays a discordant role in
adipocyte differentiation and mature adipocyte metabolism. Increasing cAMP promotes
adipocyte differentiation, while it inhibits expression and activity of fatty acid synthase
(442, 443), a key enzyme in de novo lipogenesis, and stimulates lipolysis in mature
adipocytes. Moreover, there is a significant interaction between the calcium and cAMP
signaling pathways. Structural and functional studies have demonstrated that adenylyl
cyclases are associated with the site of Ca2+ entry into the cell and that Ca2+ entry causes
a marked inhibition of type V and VI adenylyl cyclases, thereby reducing cAMP levels in
several cell types (444). Alternatively, recent data from our laboratory demonstrated that
increasing adipocyte [Ca2+]istimulates phosphodiesterase 3B activity, resulting in
reduced cAMP levels (130). Accordingly, increasing [Ca2+]i in the early stages of
differentiation may suppress pre-adipocyte cAMP levels and thereby inhibit
differentiation. By contrast, a [Ca2+]i-induced decrease in cAMP late in differentiation
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up-regulates lipogenesis and down-regulates lipolysis, thereby promoting adipocyte
maturation and lipid filling.

B. ADIPOCYTE HYPERTROPHY
The adipocyte TAG is either derived from circulating lipoproteins or synthesized via de
novo lipogenesis from carbohydrate. De novo lipogenesis essentially transfers the energy
from carbohydrates to long-chain fatty acids, which are saved as TAG. Meanwhile, TAG
undergoes lipolysis to release fatty acids, which are used as energy. Therefore, adipocyte
hypertrophy characterized as overloaded TAG primarily results from increased de novo
lipogenesis and decreased lipolysis.

a. Regulation of de novo Lipogenesis in Adipocytes
There are several enzymes responsible for de novo lipogenesis. Glucose first undergoes
glycolysis to generate pyruvate, which is catalyzed by glycolytic enzymes. Pyruvate is
then converted to acetyl-CoA which is transported as citrate from mitochondria to
cytosol. ATP-citrate lyase catalyzes citrate into acetyl-CoA, which is then converted to
malonyl-CoA by acetyl-CoA carboxylase (ACC). Fatty acid synthase (FAS) catalyzes the
subsequent synthesis ofpalmitate from acetyl-CoA and malonyl-CoA using NADPH as
reducing equivalent, which is derived from malate conversion catalyzed by malic enzyme
or pentose shunt catalyzed by glucose-6-phosphate dehydrogenase or gluconate-6phosphate dehydrogenase. ACC and FAS are two key enzymes in de novo lipogenesis.
ACC catalyzes the rate-limiting step in fatty acid synthesis. Its enzymatic activity is
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primarily regulated via short-term allosteric modification or covalent phosphorylation,
although long-term regulation of ACC involved in protein amount does exist. FAS
activity, however, is regulated at transcription level, which results in changes of FAS
protein amount (445,446).

Humans exhibit lower FAS activity in both liver and adipose tissue than that of rodents.
This is attributed to the lower metabolic rate and higher fat/lower carbohydrate diets in
human than in rodents (447). However, the physiological significance of de nova
lipogenesis in human adipose tissue has been demonstrated. Indeed, human adipose tissue
expresses substantial levels of FAS, which is subject to nutritional and hormonal
regulation (448-450). In primary cultured human adipose tissue incubated with labeled
glucose, 80% of glucose can be incorporated into lipid (451 ). This was confirmed by in

vivo studies demonstrating that high carbohydrate diets stimulate adipocyte lipogenesis,
resulting in lipid accumulation in human adipose tissue (452, 453). In fact, adipose tissue
may account for up to 40% of whole body lipogenesis in nutritionally-depleted humans
given hypercaloric carbohydrate diets and total fat synthesis in adipose tissue is at least
equal to, if not greater than, that in liver (453). Moreover, adipocyte FAS expression and
activity are elevated in genetic obesity (454). These data suggest that up-regulation of
adipocyte de nova lipogenesis may contribute to obesity in vivo.

Recent studies demonstrated that both ACC and FAS as well as their metabolites may
play novel roles in regulating energy homeostasis involved in energy expenditure and
feeding behavior. Abu-Elheiga et al. (455) generated the mice lacking ACC2, a dominant
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ACC isoform in skeletal and cardiac muscle. These ACC2-deficient mice exhibit reduced
fat storage in liver and adipose tissue by 50%, although they are hyperphagic. This
contributes to the increased fatty acid oxidation in the skeletal muscle. ACC2 deficiency
decreases the levels of malonyl CoA, a potent inhibitor of camitine palmitoyltransferase
(CPT), resulting in increases in fatty acid transport into mitochondria and fatty acid
oxidation. Moreover, these ACC2 knockout mice exhibit increased UCP3 expression in
skeletal muscle, which may also contributes to fatty acid oxidation and thermogenesis.
On the other hand, Loftus et al. reported that treatment of mice with FAS inhibitors
results in inhibition of feeding and dramatic weight loss. These FAS inhibitors suppress
the expression ofneuropeptide Yin hypothalamus and act in a leptin-independent
manner. These actions are attributed to increased malonyl CoA, which acts as a novel
neuronal signal (456).

1. Fatty Acid Synthase (FAS)

The fatty acid synthase in bacterial and plants is a multienzyme complexes consisting of
7 discrete, but tightly associated and well organized monofunctional enzymes (445). By
contrast, the animal FAS is a multifunctional enzyme with a single large polypeptide.
From the N-terminus of FAS to its C-terminus, the amino acid sequence of this large
polypeptide encodes /3-ketoacyl synthase, acetyl-CoA transacylase, malonyl-CoA,
transacylase, dehydratase, enoyl reductase, ketoacyl reductase, acyl carrier protein, and
thioesterase activites, which are organized into discrete domain (445). The functional
FAS consists of two identical 250 KDa subunits which act as a homodimer (445). The
multifunctional organization of animal FAS is believed to result from gene fusion due to
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selection of evolution, as individual domains responsible for specific function can be
coordinately regulated in this way to improve whole functional efficiency (457). For
example, this arrangement facilitates transferring of the product from one reaction to the
active center of subsequent enzymatic step as a substrate. Moreover, regulating product
of one single reaction can modulate all seven catalytic reactions in a concerted manner
(445).

FAS is encoded by a single copy gene that generates a single transcript in mice and
humans, and two transcripts produced by alternative usage of polyadenylation sites in rats
and chickens (445). Using differential display strategy, the mouse FAS cDNA was cloned
by differential hybridization ofliver cDNA library with

32P-labeled

cDNA reverse-

transcribed from mRNA derived from mice fasted or fasted and refed a highcarbohydrate diet (338). A single 8.2 Kb FAS mRNA was identified and exhibited wide
tissue distribution, with the highest levels of expression in liver and adipose tissue. The
human FAS cDNA was also cloned and FAS gene was mapped to 17q25 by fluorescent
in situ hybridization (458,459). Northern blot revealed that human FAS mRNA is 9.3 Kb
in size and that its level varies among human tissues, with liver, adipose tissue, brain
showing prominent expression (460).

2. Nutritional and Hormonal Regulation of Fatty Acid Synthase
Unlike ACC which is subject to allosteric modification and covalent phosphorylation,
FAS, however, is primarily regulated at transcription level in response to nutritional and
hormonal modulation.
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2.1 Nutritional and Hormonal Regulation of FAS in vivo
Starvation followed by re-feeding a high carbohydrate/low fat diet is often used as
paradigm for nutritional regulation of FAS expression (461). Fasting in rats results in a
marked decline of the FAS synthesis, while re-feeding these fasted animals with a high
carbohydrate/low fat diet increases FAS synthesis by 20-25 fold (462). Using the same
starvation-re-feeding approach, similar changes are observed in mouse FAS expression
(442). This starvation-re-feeding manipulation alters the circulating glucose level, which
in tum induces the secretion of hormones responsible for de novo lipogenesis. It is well
recognized that circulating insulin levels are elevated in animals challenged with a highcarbohydrate diet, while circulating glucagon levels are increased during nutritional
deprivation with low circulating glucose levels (445, 463). These two hormones play
major roles in regulating FAS expression in response to changes of nutritional status.
Indeed, streptozotocin-diabetic mice exhibited low FAS expression in both liver and
adipose tissue, while administration of insulin to these animal increased FAS mRNA by
2-fold within 1 hr and 19-fold within 6 hr (442). By contrast, administration of glucagon
or dibutyryl cAMP to the re-feeding animals with previous fasting completely blocked
the elevation of hepatic FAS expression caused by high carbohydrate diets (442). These
data suggest that glucagon, mediated by cAMP, antagonizes insulin stimulation of FAS
expression.

Dietary polyunsaturated fatty acid (PUF A) potently inhibits FAS activity and expression
in both liver and adipose tissue. Supplement of 2% 18:2 (n-6) to a high carbohydrate, fatfree diet results in a marked inhibition of hepatic FAS activity and fatty acid synthesis
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(464). The inhibitory effect of 18:2, n-6 PUFA on FAS expression has been extended to
all PUFAs of both n-3 and n-6 family (465).

The nutritional and hormonal regulation of FAS expression described above was well
demonstrated in the study of transgenic mice carrying the 201-kb 5'-flanking promoter
region of FAS fused to a chloramphenicol acetyltransferase (CAT) reporter gene (443,
463). CAT activity was low in the fasted transgenic mice, while it was significantly upregulated in liver and adipose tissue of fasted animals re-fed with a high carbohydrate
diet. However, administration of dibutyryl cAMP to the re-fed transgenic animals
prevented an increase in CAT activity. Streptozotocin-diabetic transgenic mice exhibited
low CAT activity in both liver and adipose tissue. Moreover, dietary PUF A markedly
suppressed CAT activity as well as endogenous FAS expression in liver and adipose
tissue. Further, administration of glucocorticoid to transgenic mice increased CAT
activity in adipose tissue and liver. This was confirmed by later studies that
dexamethasone increased FAS activity and mRNA by increasing both transcription and
mRNA stability (466, 467).

Other hormones involved in regulation of FAS expression include growth hormone (GH)
and T 3• GH appears to antagonize the effect of insulin on FAS. Administration of GH
decreased FAS mRNA levels in rats and pig (468,469). T 3, however, stimulates FAS
expression. Injection of thyroid hormone into rats increased hepatic FAS activity (470).
In addition, hyperthyroid animals exhibit an elevation in both liver and adipocyte FAS
mRNA, while hypothyroid animals exhibit a decrease in FAS expression (471,472).
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2.2 Molecular Mechanism Mediating FAS Gene Regulation
•

Insulin Response Element and Transcriptional Factors

Insulin stimulates FAS mRNA and activity in both 3T3-Ll adipocytes and primary
cultured human adipocytes (448, 450). This stimulatory effect is mediated by a cis-acting
insulin response element (IRE) in FAS promoter region (463,473,474). Analysis of FAS
5' promoter deletion constructs fused to report genes demonstrated that IRE is located in
the region spanning from -67 to -25. DNAase I footprinting analysis further revealed a
nuclear extract-protected region from -71 to -50. Gel mobility shift assays with the
sequence from -71 to -50 demonstrated a nuclear extract-binding complex in this region.
Further mutation analysis in this region demonstrated that -68/-60 with a functional E box
is required for binding of nuclear extracts (463). Three tandem repeats of the -68/-52
region linked to SV 40 promoter with a luciferase report gene were sufficient to respond
to insulin stimulation. These data demonstrate that the minimal region (-68/-52) that
responds to insulin contains an E box (-65/-60) essential for transcriptional factor
binding, suggesting that those transcriptional factors capable of binding to the E box (65/-60) may mediate insulin stimulation of FAS expression.

Upstream stimulatory factor 1 and 2 (USFl and 2), members of basic helix-loop-helix
leucine zipper family of transcriptional factor, have been shown to bind to E box and
function as heterodimer in the other gene promoters (475, 476). Therefore, the interaction
between USFs and FAS promoter IRE was examined. Indeed, gel shift assay
demonstrated that both USFl and 2 are able to bind to FAS promoter IRE to form a
binding complex which can be disrupted by cold DNA sequence known to bind to USFs
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and can be super-shifted by anti-USFl and anti-USF2 antibodies (477). Moreover,
overexpression of USFl and 2 with FAS promoter luciferase reporter construct increased
insulin stimulation of FAS promoter, while overexpression of dominant negative USF
mutants without DNA binding domains inhibited insulin stimulation of FAS promoter
(463,478). These data demonstrate that insulin stimulation of FAS expression is
dependent on USFs binding to E-box (-65/-60). The role ofUSF in mediating insulin
stimulation of FAS was further confirmed by the in vivo study ofUSF-knockout mice
(479). These animals fed with a high carbohydrate diet exhibit impaired FAS induction,
indicating that USFs mediate glucose/insulin stimulation of FAS in vivo.

Recent studies showed that SREBPl also mediates insulin stimulation of FAS. FAS
promoter contains two tandem SREBPl binding sites which are split by the ----65/-60Ebox. SREBPl binding to these sites was first shown to mediate sterol modulation of FAS
expression (480). However, Kim et al (386) demonstrated that SREBPlc also binds to
this E box region to activate FAS transcription. Moreover, SREBPl levels were reduced
dramatically during fasting and elevated upon re-feeding of a high carbohydrate diet.
These data suggest that SREBP 1 may mediate insulin stimulation of FAS by binding to
the E box (-60/-65).

The cellular signaling pathway mediating insulin regulation of FAS has been explored.
Wortmannin, a PB-kinase inhibitor, has been shown to block insulin stimulation of FAS
promoter (481 ). Moreover, ectopic expression of constitutive active p 110 subunit of PBkinase increased insulin stimulation of FAS promoter, while overexpression of dominant
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negative p85 subunit suppressed insulin stimulation of FAS transcription (481 ). In
addition, overexpression of PKB/Akt, a down-stream signal of PI-3 kinase, stimulated
FAS transcription in the absence of insulin (481 ). These data demonstrate that PB-kinase
and down-stream PKB/Akt signaling pathway mediates insulin stimulation of FAS.

•

Glucose Stimulation of FAS and PUFA Inhibition of FAS

The metabolic relationship between glucose and insulin obscure their effects on FAS
expression. They may exert effects on FAS dependently and independently. Glucose is
definitely required for insulin stimulation of FAS transcription. Both USFs (4 79) and
SREBP 1 (482), which mediate insulin stimulation on FAS, also have been shown to
mediate glucose induced FAS expression by binding to E-box region. These data indicate
that glucose and insulin do share certain common pathways in regulating FAS
expression. However, glucose also exerts the regulatory effect on FAS expression via
distinct pathways. For example, a glucose response element, which is distinct from either
USF or SREBPl binding sites of E-box region, has been identified in the first intron of
FAS gene (483). Moreover, glucose response element binding protein, a distinct
transcriptional factor, has been identified to bind to this response element and mediate
glucose induced FAS expression (483). In addition, glucose is also able to increase
hepatic FAS mRNA stability to increase FAS mRNA levels independent of transcription
(484,485).

Glucose-6-phosphate and its metabolites rather than glucose itself may be the signal that
mediates glucose regulation of FAS. 3-0-methylglucose, a glucose analog that can be
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transported into cells but is unable to be physphorylated, exerts no effects on FAS
expression (486). On the other hand, 2-Deoxyglucose, an unhydrolizable glucose analog
that can be transported into cells and phosphorylated, mimics the effect of glucose on
FAS expression (487).

PUF A has been shown to inhibit hepatic FAS expression by decreasing the mature form
of SREBPl protein. Moreover, PUFA inhibition of FAS expression is also mediated by
decreasing SREBP 1 expression (488). This was confirmed by in vivo study
demonstrating that dietary PUFA suppresses SREBPl expression, decreases SREBPl
mature protein, and inhibits FAS expression (489). Therefore, PUF A may antagonize
insulin stimulation on FAS expression by inhibiting SREBPl.

•

Other Hormone Response Elements in FAS Promoter

Glucagon antagonism of insulin stimulation on FAS expression is mediated by cAMP.
This has been confirmed by in vitro studies. Analysis of promoter deletion constructs
identified a cAMP response element spanning from -149 to +68 in FAS promoter. This
region contains FAS IRE that is required for cAMP inhibition of FAS (489,490). Further
mutation analysis identified an inverted CCAA T box in the -99/-92 region of FAS
promoter, which is also required for cAMP responsiveness, as mutation of this box
blocked cAMP inhibitory effects on FAS expression (489,490).

T3 has been shown to stimulate FAS expression independent of insulin. Thyroid hormone
(T3) activated thyroid hormone receptor {TR), a member of family of nuclear hormone
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receptor, interacts with RXR to form a heterodimer complex. This complex binds to
consensus thyroid hormone response element (TRE), resulting in activation of FAS gene
transcription. Two TREs mediating T3 stimulation of FAS transcription have been
identified in FAS promoter (491).

All also stimulates FAS expression and activity in both 3T3-Ll adipocytes and primary
cultured human adipocytes (451). This action is mediated by activation of SREBPlc and
IRE (492).

Agouti protein has been demonstrated to stimulate adipocyte FAS activity and expression
in a Ca2+-dependent mechanism ( 121). This agouti stimulation of FAS is exerted at
transcription level. The stimulatory effects of agouti and insulin on FAS expression are
independent and additive. Further studies demonstrated an agouti/Ca 2+ response element
mediating agouti stimulation of FAS transcription in FAS promoter (127).

b. Regulation of Lipolysis in Adipocytes
Lipolysis plays a pivotal role in lipid metabolism and overall energy homeostasis as well
as other cellular signaling events. Fatty acids stored in the form of TGs are main source
of energy during nutritional deprivation, during which adipose tissue can release up to 150
g of fatty acids daily through adipocyte lipolysis, contributing to more than half of the
daily caloric supply (493). In addition, lipolysis-derived fatty acids and their derivatives
also participate in various cellular events involved in cell signaling and membrane
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biosynthesis in most cells. For instance, fatty acid derivatives are considered as
endogenous ligands for PPARy, a key regulator of adipogenesis.

1. Hormone-Sensitive Lipase in Adipocyte Lipolysis
Adipocyte lipolysis, a process of mobilization of free fatty acids (FF A) from TG, occurs
through three consecutive reactions which are catalyzed by two enzymes, hormonesensitive lipase (HSL) and monoglyceride lipase (MGL). HSL catalyzes the rate-limiting
step in the hydrolysis of TG to diacylglycerol (DAG), and also the subsequent hydrolysis
of DAG to monoacylglycerol. HSL preferentially acts upon the 1- and 3-ester bond of its
acylglycerol substrates to generate two FFAs and one monoacylglycerol per TG (493,
494). The conversion of monoacylglycrol to FFA and glycerol, the last step in lipolysis,
is carried out by MGL. HSL is under acute hormonal and nutritional control, while there
is no evidence for any regulation ofMGL (493,494). Therefore, HSL is a key enzyme in
lipid metabolism and energy homeostasis.

The HSL cDNA was first cloned from rat adipocytes (495). This cDNA predicts 768
amino acids, with a molecular weight of 84 kDa. Li et al. (496) then cloned the mouse
HSL gene which spans approximately 10.4 kb and comprises 9 exons interrupted by 8
introns. Wang et al. (497) further demonstrated that mouse HSL gene is located on
chromosome 7 and this mouse locus is associated with obesity. Holm et al. used the rat
clone to map the human HSL gene to 19cen-q13.3 by southern analysis of DNA from
human-rodent somatic cell hybrids. This human HSL gene mapping was refined by other
two studies that localize the HSL gene to 19q 13. l-19q 13.2 using fluorescence in situ
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hybridization (498, 499). Like mouse HSL gene, the human HSL gene also comprises 9
exons, encoding 775 amino acids which show 82% and 85% identity with that of rats and
mouse (500), respectively.

Northern blot analysis ofHSL in animals have demonstrated that HSL is expressed in a
variety of tissues, including white and brown adipose tissue, all steroidogenic tissues,
muscle, pancreas, etc (501-505). Several distinct mRNA species exhibiting a tissuespecific distribution have been observed (493). This is attributed to the tissue-specific
expression of exon 1, which is either non-coding in adipose tissue or encodes an Nterminal extension ofHSL in testis and pancreas (507, 508), resulting in a larger mRNA
and protein species in these tissue.

HSL protein consists of two major structure domains: an N-terminal domain and a Cterminal catalytic domain (493, 494). The catalytic domain harbors a catalytic core
composed of Ser-423, Asp-703, His-733 and a regulatory motif with four
phosphorylation sites: Ser-563, Ser-565, Ser-659, Ser-660 (493,494,508,

509). N-

terminal domain is proposed to bind to lipid droplets and interact with other proteins,
such as fatty acid binding protein (FABP) (510).

Adipocyte lipolysis is subject to acute neuronal and hormonal control. Catecholamines
are considered as major stimulators of lipolysis, whereas insulin is believed to be the
most important anti-lipolytic hormone. The increased sympathetic output increases the
release of catecholamines which in turn enhance the cellular cAMP by binding to and
96

activating {3-adrenergic receptors, resulting in activation of PKA. Two main targets for
PKA-mediated phosphorylation in lipolysis are HSL and perilipins, and phosphorylation
of these two proteins markedly increases adipocyte lipolysis (511,512). Insulin, however,
is the most important physiological inhibitor of catecholamine-induced lipolysis. Insulin
binds to its receptor and activates the downstream PB-kinase pathway, leading to
activation of PKB/Akt. Activated PKB/Akt further phosphorylates and activates
phosphodiesterase 3B, which catalyzes the degradation of cAMP, resulting in a decrease
in cAMP level and concomitant decrease of PKA activity, and consequently, inhibition of
lipolysis (513, 514). This was confirmed by demonstration that specific inhibition of
PDE3B completely blocks the anti-lipolytic effect of insulin (515).

HSL is regulated by reversible protein phosphorylation. Phosphopeptide mapping and
amino acid sequencing analysis demonstrated that HSL is phosphorylated at two distinct
serine residues, named regulatory and basal sites (512), respectively. Phosphorylation of
the regulatory site (Ser-563 in rats and Ser-551 in human) by PKA activates HSL activity
(511, 512). However, recent evidence showed that mutation of this regulatory site Ser563 failed to prevent PKA-induced activation of HSL, raising the possibility that
phosphorylation of other regulatory sites might be involved in activation of HSL as well.
Indeed, recent studies have identified two novel PKA-mediated phosphorylation sites,
Ser-659 and Ser-660, whose phosphorylation is responsible for activation ofHSL in
response to isoproterenol stimulation in primary cultured adipocytes ( 516). Further sitedirected mutagenesis study demonstrated the critical roles for these two phosphorylation
sites in regulation of HSL activity.
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In addition to three regulatory sites phophorylated by PKA, HSL is also phosphorylated

at basal site Ser-565 (rat), two residues away to the regulatory site Ser-563, by glycogen
synthase kinase-4, Ca2+/calmodulin-dependent kinase II, and AMP-activated protein
kinase (AMPK) (517,518). The basal site is usually phosphorylated in quiescent cells.
Phosphorylation of the basal site Ser-565 by AMPK prevents the subsequent
phosphorylation ofregulatory site Ser-563 (519), indicating that phosphorylation of the
basal site exerts an anti-lipolytic effect. This was confirmed by evidence that treatment
with AICAR, a stimulator of AMPK, inhibited the catecholamine-stimulated lipolysis in
primary cultured adipocytes (520).

Phosphorylated HSL undergoes regulation of dephosphorylation exerted by several
protein phosphatases, including PP2A, PP2C, and PPl (521, 522). PP2A and PP2C
exhibit higher activity on dephosphorylation of both regulatory sites and basal site than
PPl does. PPl, however, may selectively act on the basal site (521).

Upon lipolytic stimulation, activation ofHSL by PKA-mediated phosphorylation triggers
the translocation ofHSL from cytoplasmic compartment, where HSL resides in quiescent
state, to the surface of the lipid droplets (523-525). Recent evidence demonstrated that
phosphorylation of HSL is required for HSL to translocate and interact with lipid
droplets, as mutation of regulatory phosphorylation sites at Ser-659 and Ser-660 blocks
this translocation (493).
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Ectopic expression of HSL increases lipolysis and reduces TG accumulation in
adipocytes (526). However, HSL-knockout mice exhibit normal body weight, fat mass,
and cold sensitivity (527). The white adipocytes remain 40% lipase activity. The only
significant phenotypic abnormality is that HSL-deficient male mice are sterile. Although
gonadal function is normal in these mice, the neutral cholesterol ester hydrolase (NCEH)
activity is completely lost in the testis.

Perilipins, a family of proteins located on the surface of lipid droplets, preclude HSL
binding to lipid droplets in resting cells (528). Perilipin is a single copy gene that
produces three isoforms by alternative splicing. Perilipin A is the most abundant species
in both adipocytes and steroidogenic cells, while the B and C isoforms reside primarily in
adipocytes and steroidogenic cells, respectively. Perilipin A and B contain a common Nterminal but distinct C terminal region (528). Significant amounts of the perilipin proteins
are found only on the TG-rich droplets in adipocytes and cholesterol ester-rich droplets in
steroidogenic cells (528). It has been proposed that non-phosphorylated perilipins create a
protective barrier to prevent HSL interaction with lipid droplets (493). Upon lipolytic
stimulation, phosphorylation of perilipins by PKA causes redistribution of perilipins in
lipid surface and removes these restraints, which allows HSL to interact with lipid,
leading to initiation of TG hydrolysis (493). Perilipin-deficient mice exhibit hyperphagia,
reduced fat mass and increased muscle mass (529). They also show elevated basal
lipolysis that is resistant to /j-adrenergic agonist stimulation. Moreover, these knockout
mice are resistant to diet-induced obesity. In addition, breeding the perilipin- 1- alleles into
db/db mice reverses the obesity phenotype by increasing the metabolic rate of the mice.
99

Two proteins, ALBP (510, 528) and lipotransin (530), have recently been shown to
interact with HSL at N-terminus. ALBP may function to facilitate rapid evacuation of
lipolytic product such as free fatty acids. Lipotransin is a novel HSL-interacting protein
that appears to translocate HSL to the lipid droplets (530). The interaction between the
two depends on the phosphorylation of HSL. Therefore, lipotransin is an HSL-docking
protein that may direct the hormonally regulated redistribution of HSL (530).

2. Nutritional and Hormonal Regulation ofHSL
2.1 Nutritional Regulation ofHSL
Prolonged fasting in rats increases adipocyte HSL mRNA, proteins, and activity, thereby
resulting in increased basal lipolysis rate (531). Long-chain fatty acid CoA and
intermediary metabolites exert inhibitory effects on HSL activity and lipolysis (532),
while FABP blocks these inhibitory effects by removing these fatty acids away from HSL
(510). The ketone bodies derived from fasting, vigorous exercise, and diabetes
complications, potently inhibit HSL activity and lipolysis (533).

2.2 Hormonal Regulation of HSL
•

Lipolytic Factors

Catecholamines are primary stimulators of adipocyte lipolysis. They exert the stimulatory
effects via four adrenergic receptors:

p1, P2, P3, and a2,

which belong to superfamily of

G-protein-coupled receptors with 7-ransmembrane domain (534). Activation of

p

receptors activates adenylyl cyclase mediated by Gas protein, resulting in increases in
cAMP levels and HSL activity, while activation of a2 receptors inhibits adenylyl cyclase
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via Gai protein, reducing cAMP levels and HSL activity. The physiological significance
of existence of 4 adrenergic receptors in adipocytes is not clear. It has been suggested that
13receptors play major roles in stimulation of lipolysis in stress, while a receptors
predominate in regulation of lipolysis in resting state and provide the opportunity for dual
regulation of adenylyl cyclase (535). Each 13receptor subtype exhibits different
expression pattern in adipocytes. Differentiation of 3T3-F442A cells up-regulates 133
expression, but not 132and 133expression (536). cAMP increases 133expression, but
suppresses 132and 133expression. Insulin and dexamethasone also exerts different effects
on expression of different 13receptor subtype (537). Each 13receptor subtype also serves
as different signaling role in adipocyte lipolysis. 131receptors, which are more sensitive
to catecholamines and desensitize rapidly, may mediate acute stimulation of low doses of
catecholamine, while 133receptor, which are activated by higher doses of catecholamines
and resistant to desensitization, may deliver sustained signal of long-term catecholamine
stimulation (534).

Other lipolytic hormones include growth hormone, glucagon, and glucocorticoids.
Growth hormone and glucagon exert lipolytic effects by stimulating acute HSL
enzymatic activity only, while glucocorticoids increase lipolysis by stimulating both HSL
activity and expression (538).
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TNF-a potently stimulates lipolysis by inhibiting perilipin expression. This was
confirmed by demonstration that over-expression of perilipin blocks TNF-a stimulation
oflipolysis (539).

•

Anti-lipolytic Factors

In addition to insulin which is the most important physiological anti-lipolytic hormone,
adenosine is also a potent physiological inhibitor of lipolysis. Intracellular cAMP is
exported from cytosol to extracellular matrix and then converted to adenosine by
phosphodiesterase and 5'-nucleotidase. Adenosine in tum acts on Al adenosine receptor
in an autocrine/paracrine manner (540). Thus, adenosine exerts the inhibitory effect on
HSL through activation of Al adenosine receptor, which inhibits adenylyl cyclase via
coupling Gm, reducing cAMP levels (534). Al adenosine receptor and coupling
efficiency may influence lipolysis and obesity. The receptors are down-regulated in
adipose tissue of obese humans (541). Moreover, the sensitivity of Al receptor-Gi protein
to GTP is 5- to 10-fold higher in adipocyte membrane from obese Zucker rats compared
to lean animals (542).

Prostaglandins also exert effect on lipolysis. PGE 2 has been demonstrated to inhibit
lipolysis in cultured rat adipose tissue. In contrast, PGh has been shown to stimulate
lipolysis in rat adipocytes (543).
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2.3 Lipolysis in Obesity and Type II Diabetes
Adipocyte lipolysis is altered in obese humans. Although adipocyte lipolytic rate
measured by FF As and glycerol release or turnover in vitro or in vivo is increased in
obese humans compared to lean subjects, this is attributed to the increased adipocyte size
and total fat mass (544, 545). However, obese humans exhibit resistance to the
stimulatory effect of catecholamine on lipolysis (546). This could be attributed to the
decreased number of /3-adrenergic receptors, increased a2-adrenergic receptors, changes
in the functional balance between /3-and a2-adrenergic receptors, or postreceptor
alteration (493, 546, 547). Hellstrom et al (548) reported that impaired lipolytic action of
catecholamines mainly results from reduced HSL activity without changes of HSL
mRNA levels, suggesting an involvement ofposttranscriptional modulation ofHSL or
postreceptor alteration. However, recent studies showed that catecholamine-stimulated
lipolytic capacity in human adipocytes obtained from different individuals is well
correlated with HSL mRNA, protein content, and activity (549), suggesting that both
transcriptional and posttranscriptional mechanisms appear to be involved in determining
the catecholamine stimulation ofHSL activity. This was further demonstrated to be
relevant to obesity, as HSL mRNA, protein, and activity as well as lipolytic rate were
decreased in subcutaneous adipose tissue obtained from obese humans compared to lean
controls (550).

Since elevated circulating FFAs play important role in insulin resistance/type II diabetes,
regulation of HSL may contribute to the development of this metabolic disorder. Adipose
tissue obtained from diabetic subjects exhibits resistance to lipolytic effects of
103

catecholamines, due to a decrease in ,3-adrenergic receptor or an increase in ciladrenergic receptor numbers (551). On the other hand, resistance to anti-lipolytic effects
of insulin may also occur in these patients. Upper-body obesity exhibits greater resistance
to the anti-lipolytic effects of insulin and to the lipolytic effects of catecholamines
compared to lower-body obesity, and the net lipolytic rate and basal FF A release in
upper-body obese subjects are higher than those in lower-body obesity (552, 553). This is
consistent with the observation that upper-body obesity is strongly correlated with insulin
resistance/type II diabetes and other metabolic disorders (554). This insulin resistanceprone obesity can be further extended to those lipolytically active fat depots that have
strong association with insulin resistance. For example, internal visceral fat depots with
potent lipolytic capacity due to abundant expression of ,3-adrenergic receptors are
strongly correlated with insulin resistance (555, 556).

The role of HSL in obesity and diabetes has also been documented in genetic studies in
human population. Klannemark et al. demonstrated that a polymorphic marker in intron 7
of the human HSL gene is associated with abdominal obesity and type II diabetes (557).
Moreover, a similar association was observed on another polymorphism marker of HSL
gene with type II diabetes. In addition, transmission disequilibrium tests suggested
linkage disequilibrium between the HSL gene marker and another allele or gene that
increases susceptibility to abdominal obesity and type II diabetes (558).

104

V. ROLE OF THERMOGENESIS IN OBESITY
A. ADAPTIVE THERMOGENESIS AND RESPIRATORY UNCOUPLING
a. Adaptive Thermogenesis
Obesity is a disorder of energy homeostasis due to a chronic imbalance between energy
intake and energy expenditure. Energy expenditure can be divided into three principle
components: obligatory energy expenditure required for cells and organs to maintain
normal physiological functions, energy expenditure caused by physical activity, and
energy expenditure resulting from adaptive thermogenesis (559). Adaptive thermogenesis
is defined as energy dissipated as a heat instead of being captured in ATP in response to
environment temperature and diet, serving to protect organism from cold exposure or
regulate energy balance after food intake.

Acute cold exposure dramatically increases oxygen consumption and metabolic rate
through muscular shivering involving the synthesis and breakdown of ATP in animals.
However, with the time extended to chronic cold exposure, shivering ceases and the
continued high metabolism still occurs through non-shivering adaptive thermogenesis in
brown adipose tissue in rodents (560). Although the effect is smaller, lowering
temperature by 5 °C also causes a 7% increase in heat production in humans (561). Cold
exposure-induced adaptive thermogenesis is mediated by the sympathetic nervous
system. Administration of the ~-adrenergic agonists to animals causes increases in
thermogenesis comparable to exposure to cold, while treatment with the antagonists of
the sympathetic nervous system makes animals sensitive to cold and unable to maintain
body temperature (562). Moreover, mice lacking adrenaline and noradrenaline, the main
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effectors of the sympathetic nervous system, as a result of dopamine /3-hydroxylase gene
knockout are cold sensitive (563). The central control of adaptive thermogenesis is also
via hypothalamic-pituitary-thyroid axis. Thyroid hormones can either independently
stimulate thermogenesis or interact with sympathetic nervous system to increase energy
expenditure (564). On the other hand, diet also plays an important role in regulation of
adaptive thermogenesis (559). Fasting and caloric restriction decrease metabolic rate and
energy expenditure, while feeding exerts both acute and chronic stimulatory effects on
metabolic rate and energy expenditure (565). As human overeats, a protective
thermogenic adaptation, termed nonexercise activity thermogenesis (NEAT), dissipates
excess energy to preserve leanness (566). Notably, NEAT also bears genetic background
and failure to activate NEAT due to genetic susceptibility may result in obesity (566).

b. Respiratory Uncoupling
Adaptive thermogenesis is mediated by proton leak-induced respiratory uncoupling. In
normal physiology of mitochondrial respiration, the mitochondrial oxidation of substrates
results in reduced NADH and FADH 2 , which donate their electrons to the electron
transport chain in the mitochondrial inner membrane, where oxidative phosphorylation
occurs. The chemiosmotic hypothesis proposes that electron transport along the electron
transport chain is accompanied by pumping of protons into the mitochondrial
intramembrane matrix, generating a proton electrochemical potential gradient (~µH+)
across the mitochondrial inner membrane. This force drives protons back to
mitochondrial matrix via ATP synthase (FoF1-ATPas) in a reaction leading to synthesis of
ATP from ADP (567). The oxidative phosphorylation is tightly regulated by the
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availability of ADP, the by-product of ATP consumption. Once cells become inactive and
reduce the ATP consumption, ADP levels correspondingly decrease. Subsequently,
protons are unable to re-enter the matrix in the absence of ADP through ATP synthase.
Electron transport along the respiratory chain continues to increase proton gradients,
which in tum inhibits further substrate (NADH and FADH 2) oxidation (567). As a result,
substrate oxidation is tightly coupled to energy needs by linking respiration to ADP
availability.

However, even when ADP is not available, isolated mitochondrial still consume oxygen,
a process called state 4 respiration (568). This suggests that protons leak across the inner
membrane of mitochondria in the absence of ADP. Consequently, the coupling of
oxidative phosphorylation is impaired by this proton leaking, leading to respiratory
uncoupling. In fact, proton leaks account for a surprisingly high proportion of cellular
metabolic rate, with 25% and 52% of the resting respiration rate of isolated rat
hepatocytes and perfused rat skeletal muscle preparation (569-571). It has been estimated
that overall proton leak contributes to 20% of standard metabolic rate (SMR), making it
the largest single contributor to mammalian SMR; SMR constitutes 60-70% of total
energy expenditure (572, 573).

A major consequence of the respiratory uncoupling is the activation of substrate
oxidation and dissipation of oxidation energy as heat. This is important in mammalian
energy balance and body weight regulation and represents research targets for obesity.
Uncoupling of respiration and dissipation of energy as heat are commonly observed in
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adaptive thermogenesis in rodents exposed to the cold, which is mediated by uncoupling
protein 1 (UCPl) via catalyzing proton leaking in rodent brown adipose tissue.

B. UNCOUPLING PROTEIN FAMILY

a. Role ofUCPl in Thermogenesis and Energy Expenditure
1. UCPl-Mediated Proton Transport
Nicholls first demonstrated that mitochondria isolated from brown adipose tissue
exhibited increased proton leak (574, 575). This proton leak was stimulated by fatty acid
and inhibited by purine nucleoside di- and tri-phosphate. Using photolabelling with a
radioactive purine nucleotide, a 32-kDa protein with high affinity purine nucleotide
binding sites was identified. This protein, named UCP (changed to UCPl later), was
further purified and sequenced (576, 577). The mouse and rat UCPl gene were also
cloned and the mouse UCPl was further mapped to chromosome 8 (578-580). Bouillaud
et al. cloned human UCPl which spans 13 kb with a 9 kb transcription region containing
6 exons and exhibits 79% and 80% identity with mouse and rat UCPl, respectively (581).
Human UCPl was mapped to 4q31 (582). UCPl is expressed exclusively in mammalian
brown adipose tissue, an important site of thermo genesis in rodents and neonatal humans.

UCPl gene encodes a 306 amino acid protein which contains 6 transmembrane a-helices
(583). Functional assays, immunodetection and purification studies have confirmed that
functional UCPl exists as a dimeric protein in the mitochondrial inner membrane (584).
Over-expressing UCPl in reconstituted liposomes, bacteria, yeasts, adipocytes, and
skeletal myocytes resulted in proton leak and respiratory uncoupling, while brown
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adipose tissue mitochondria from mice lacking UCPl were unable to show proton leak
(585), confirming the proton transport function ofUCPl. UCPl-mediated proton
transport is fully dependent on free fatty acids, which are considered as cofactors for this
action. Proton transport ofUCPl has been shown to be activated by free fatty acids with
10 or more carbons and by saturated as well as unsaturated fatty acids, but not by
esterified carboxy groups, such as acyl CoA (586-588). The mechanism whereby free
fatty acids stimulate UCPl proton transport is still not clear. However, two hypotheses
have been proposed. The first model, termed the UCPI channel model, proposes that
fatty acids function as buffering cofactors, donating H+ to the tanslocation channel
formed by UCPI with a pore-channel domain and a gating domain (567, 583, 589). The
second model, known as fatty acid protonophore cycling (or flip-flop) model, suggests
that UCPI catalyzes the flip-flop transport of the protonated fatty acid head to the inner
mitochondrial membrane, releasing the H+ in the inner mitochondrial matrix, and then
drives the transport of the negatively charged free fatty acid head back to the outside of
mitochondrial membrane. This UCPl action enables fatty acids to behave as cycling
protonophores (567, 583, 590). In addition, coenzyme Q (CoQ) has been recently
identified as a cofactor for the proton transport ofUCPl. On addition of CoQ to
reconstituted UCPI from E. Coli inclusion bodies, fatty acid-dependent proton transport
reached the same rate as with native UCPl (591).

The proton transport activity ofUCPl is inhibited by purine nucleoside di- and triphosphate (GTP, GDP, ATP, ADP), but not by monophosphate (583,584). UCPI bears
specific binding sites for these purine nucleotides, with the highest binding affinity to
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GDP (592). Site-directed mutagenesis of arginine residues at 83, 182, 276 in
transmembrane a-helices abolished the nucleotide binding and inhibition of UCPl proton
transport. Moreover, the binding of nucleotides to UCPl is highly sensitive to pH. When
the pH rises, the affinity of UCPl for nucleotides declines. The glutamate residue at 190
has been demonstrated to be essential for the pH-sensitive nucleotide binding (583, 593).
Further, mutagenesis of histidine residues in UCPl indicated that a pair of histidine (His145 and His-14 7) in the matrix loop is essential for proton transport (594, 595).

2. Regulation ofUCPl Activity and Expression
2.1 Physiological Regulation ofUCPl in vivo
Both acute and chronic cold exposure stimulates UCPl-mediated proton transport and
thermogenesis. Acute cold exposure stimulates UCPl activity in proton transport, while
chronic cold exposure results in increases in UCPl expression, mitochondrial biogenesis,
and brown adipocyte hyperplasia and hypertrophy (596, 597). Sympathetic nerves are
abundantly distributed in brown adipose tissue. Acute cold exposure stimulates
sympathetic output and thereby increases adrenaline and noradrenaline release, resulting
in activation of {3-adrenergicreceptor and cAMP-PKA-dependent pathway (598). The
PKA-stimulated lipolysis causes an increase in the cytosolic free fatty acids, which serve
to directly stimulate UCPl proton transport and supply fuels for mitochondrial
respiration. This is supported by evidence that addition of free fatty acids to brown
adipocytes mimics the stimulatory effects of {3-adrenergenicstimulation ofUCPl proton
transport (599). Moreover, norepinephrine and free fatty acids stimulation of proton leaks
is absent in brown adipocytes from UCPl knockout mice (600). These data indicate that
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free fatty acids secondary to stimulated lipolysis mediate cold stress stimulation ofUCPl
proton transport. On the other hand, chronic cold exposure up-regulates UCPI
transcription by increasing PPAR-ycoactivator-1 (PGCI) expression mediated by
activation of {J-adrenergic receptor and the cAMP-PKA-dependent pathway (601,602).
Cold stress activation of this pathway may also systematically stimulate mitochondrial
biogenesis, and brown adipocyte hyperplasia and hypertrophy, resulting in increases in
overall UCPI protein content. Moreover, free fatty acids secondary to stimulated
lipolysis serve as ligands for PPAR-yto stimulate UCPI expression. Regardless of acute
or chronic clod stress, (,3 -adrenergic receptor plays a key role in mediating the signaling
pathways in thermogenesis. This receptor is expressed abundantly and predominantly in
brown adipocytes and rodent white adipocytes. Appropriate selective agonists for the t,3adrenergic receptor may play a role in modulating thermogenesis and energy balance
(603).

Thyroid hormone T 3 also exerts the effect on cold exposure stimulation ofthermogenesis.
Type II iodothyronine 5' deiodinase, an enzyme which converts T4 to T 3, is activated by
cold-mediated {J-adrenergic stimulation, leading to an increase in most potent thyroid
hormone T3. T3 increases free fatty acids by stimulating lipolysis, and thereby acutely
stimulates activity ofUCPl proton transport. Moreover, T 3 independently stimulate
UCPI transcription or synergize with {J-adrenergenic system to increase UCPI expression
(564, 604, 605).
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Nutritional status also regulates UCPl activity and expression. This effect is at least
partially mediated by leptin. Fasting reduces leptin expression, which in tum inhibits
sympathetic activity and decreases UCPl expression. Moreover, administration ofleptin
stimulates sympathetic outflow and increases expression (606, 607).

2.2 Transcriptional Control ofUCPl Expression
The molecular mechanisms mediating UCPl gene transcription have been extensively
explored. Studies have been conducted to address the mechanisms of specific expression
ofUCPl in brown adipose tissue and identification of cis-acting elements in promoter
regions and transcriptional factors involved in regulation ofUCPl transcription in
response to physiological status. A 221-bp enhancer element, located 2.4 kb upstream of
the mouse and rat UCPl transcription start site, has been identified to be essential for
brown fat-selective expression and full response to {3-adrenergenic stimulation (via
cAMP) (608,609). This complex enhancer element also contains putative binding sites
for the thyroid hormone receptor, retinoic acid receptor (RAR), AP-1, and PPAR-y.The
response elements for these transcriptional factors were identified to be functionally
effective in regulating UCPl transcription. Ligand-activated PPAR-y,thyroid hormone
receptor (TR), and RAR interact with RXR to form heterodimers which further act upon
distinct response elements to stimulate UCPl transcription (559, 605, 610-614). This
underlies the molecular mechanisms by which cold stress, {3-adrenergicagonists, PPAR-y
agonist thiazolidinediones, retinoid acids, and thyroid hormones up-regulate UCPl
expression in vivo and in vitro.
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Although this 221-bp enhancer element is sufficient to induce specific expression of
UCPl in brown adipose tissue (608), the brown-fat selective transcriptional factors that
drive this specific expression have not been identified. The PPAR-ybinding to the
enhancer element is necessary for functional activation of this element and UCPl
transcription. Moreover, PPAR-yis not brown-fat specific transcriptional factor and it also
exerts a crucial effect on white adipocyte adipogenesis, indicating that this transcriptional
factor simultaneously plays a role in energy storage in white adipocytes and energy
dissipation in brown adipocytes. Therefore, other cofactor(s) could interact with PPAR-y
and therefore affect its physiological role in different cell types. The identification of a
PPAR-ycoactivator (PGC-1) provides an explanation to this paradoxical role of PPAR-y.
PGC-1 was cloned using a yeast two-hybrid screening with PP AR-yas bait in a brown
adipose tissue cDNA library (601). PGC-1, a 90 kDa protein, is abundantly expressed in
brown fat and skeletal muscle, two major sites of adaptive thermogenesis, but not in
white adipose tissue (601). Its connection to adaptive thermogenesis was well
demonstrated by its rapid and marked induction in brown fat and skeletal muscle upon
cold exposure of mice (601 602). This cold induction of PGC-1 results from sympathetic
nervous system outflow, as this effect can be mimicked by /3-adrenergic stimulation (601,
602). PGC-1 also interacts with other nuclear hormone receptors, such as RAR and TR,
which along with PP AR-yexert stimulatory effects on UCPl transcription.

The expression of PGC-1 in cell types other than brown adipocytes also initiates multiple
adaptive thermogenic programs that make these cells perform thermogenic function as
brown adipocytes do. Ectopic expression of PGC-1 in white adipocytes increases UCPl
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expression and mitochondrial biogenesis (601), suggesting that PGC-1 may play a role in
determining the phenotypic development of adipocyte lineages to become a brown or
white adipocyte. When over-expressed in skeletal muscle, PGC-1 induces UCP2
expression and mitochondrial biogenesis (602).

In addition to interaction to PPARy, PGC-1 is also involved in regulation of whole
mitochondrial biogenetic system, such as nuclear respiratory factors (NRF) and
mitochondrial transcription factor (mtTF). NRF are key factors that activate the gene
expression of mitochondrial electron transport system, including cytochrome c and
ATPase synthase (559). NRFs also promote the transcription ofmtTF, which is expressed
in nucleus and translocats to mitochondria and promotes mitochondrial gene expression
(559). Cold stress stimulation of PGC-1 expression promotes NRF expression. Moreover,
PGC-1 interacts and co-activates NRFs to stimulate mtTF expression (602). The
increased expression ofNRFs and mtTF may further promote the gene expression of
whole mitochondrial biogenetic system and thereby stimulate adaptive thermogenesis.

Recent studies demonstrated that PGC-1 exerts effects in regulation of energy
metabolism other than thermogenesis. PGC-1 also mediates hepatic gluconeogenesis by
promoting transcription of gluconeugenic enzymes, such as phosphoenopyruvate
carboxykinase and glucose-6-phosphatase (615,616). This effect is mediated by cAMPPKA stimulation of PGC-1 expression, the same signaling pathway as PGC-1 mediated
thermo genesis, indicating a role of PGC-1 in cell type-selective coactivation of gene
expression (616, 617).
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In addition to transcriptional regulation mediated by P-adrenergic stimulation (cAMP),
PGC-1 is also regulated at translational level (617). All nuclear-encoded mRNAs contain
a 5' cap structure that is recognized by the eukaryotic translation initiation factor 4E
(eIF4E) subunit of the eIF4E complex. The eIF4E-binding proteins (4E-BP), however,
reversibly repress cap-dependent translation by binding to eIF4E, thus preventing the
formation of the eIF4E complex. Recent reports demonstrated that disruption of mouse
translational inhibitor 4E-BP1 gene markedly increases PGC-1 protein translation and
UCPl mRNA expression in white adipose tissue, and causes a corresponding increase in
metabolic rate and a reduction in white fat mass (617). These finding demonstrate that
4E-BP1 is a novel thermogenic regulator that is involved in functional switch between
white fat and brown fat. However, it is not known that 4E-BP1 exerts this effect at
adipogenic level or mature adipocyte levels involved in PGC-1 translation and UCP 1
expression.

3. The Role ofUCPl in Energy Expenditure and Obesity
The role ofUCPl in energy balance and obesity was first demonstrated in genetic obese
mouse models, such as leptin-deficient ob/ob and leptin receptor-deficient db/db mouse,
which exhibit reduced sympathetic outflow, decreased UCPl expression and brown fat
thermogenesis, and decreased energy expenditure (618,619), while administration of
leptin to ob/ob mice stimulates sympathetic activity, increases UCPl expression and
energy expenditure (606, 607, 620-621). Transgenic and knockout animal models further
demonstrated the role ofUCPl in energy balance and obesity. Transgenic mice with
ablation of brown fat as a result of over-expression of diphtheria toxin gene under control
115

of the UCP 1 promoter exhibit decreased energy expenditure and the obese phenotype
(622). However, UCP 1 knockout mice exhibit reduced cold sensitivity and thermogenic
response to /3-adrenergic stimulation, but do not develop obesity (623), suggesting either
that UCPl is not essential for the control of body weight or that its absence can be
compensated by other dissipating pathways, such as compensatory up-regulation of
UCP2. In contrast, over-expressing UCP 1 in white adipose tissue under control of aP2
promoter attenuated diet-induced obesity in mice (624). It is noteworthy that overexpression ofUCPl in white adipocytes not only dissipates stored energy but also affects
energy partitioning, as adipocytes from these transgenic animals exhibit not only
decreases in mitochondrial potential but also in lipogenesis (625). Consistent with this,
over-expressing UCPl specifically in skeletal muscle under control of myosin light chain
promoter decreased skeletal muscle mitochondrial potential, increased oxygen
consumption, increased energy expenditure, and prevented diet-induced obesity and
insulin resistance in transgenic mice (626, 627).

Although the role ofUCPl in energy balance and obesity is quite convincing,
unfortunately, the absence ofreadily detectable brown fat depots in adults have led to
precluding this mode of energy expenditure as an applicable target to human obesity. In
fact, brown fat is abundant and active in neonatal humans. It seemingly loses its
importance with age, probably as a consequence of the control of ambient temperature.
Nonetheless, brown adipose tissue does exist in adult humans to a variable extent (605).
It has been reported that normal human white fat depots contain small islands of brown

fat and the ratio of brown to white adipocytes is approximately 1/1000 (301,628,629).
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Indeed, UCPl mRNA is detectable in white-fat depot in adult human using sensitive RTPCR (628, 630). Moreover, it is inducible in certain circumstances. There is a marked
increase in UCPl expression in individuals who have undergo prolonged exposure to
cold stress, such as working in low temperatures and immersion in cold water (631, 632);
this induced UCPl abundance is, in some cases, as high as seen in cold-exposed rodents
(631 ). Moreover, patients with pheochromocytoma, a tumor secreting catecholamines,
develop large and active brown fat depots evidenced by morphological appearance and
UCPl expression (633). These observations support that brown adipocytes do exist in
human adult fat depots and may represent a potentially important target for physiological
and pharmacological intervention. The interest of pharmacological research has focused
on agonists for {33-adrenergic receptors, which are predominantly expressed in rodent
brown and white fat, but at low levels in human white fat. However, these drugs often
prove to have undesirable side-effects in the cardiovascular system and other tissues
associated with agonist activity at {31- and {32- adrenergic receptors, or have a poor
bioavailability (634).

Human genetic studies show that a polymorphic Bel I site resulting from an NG
mutation has been described in the 5'-flanking region of the UCPl gene (635,636). This
polymorphism was reported to correlate significantly with the percentage of body fat gain
over 12 year (635). This is consistent with the notion that marginal increase/decrease in
energy expenditure due to UCPl would influence body weight regulation over time rather
than exert rapid effects as being a determinant of body weight. Moreover, this
polymorphic site is associated with higher weight gain in morbidly obese subjects, and a
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lower weight loss due to caloric restriction (637, 638). In addition, an additive effect of
this UCPl polymorphism and the Trp64 to Tyr mutation of the {13-adrenergic receptor
gene in obese humans has been reported (637).

b. UCP2 and UCP3: Potential Regulators of Energy Metabolism
1. Cloning ofUCPl

Homologues with Sequence Similarity

Since the specific expression ofUCPl in brown fat limits its respiratory uncoupling
system as an applicable target for human obesity, researchers started to pursue the UCPl
homologues. In fact, substantial mitochondrial proton leaks have been observed in tissues
devoid of UCPl. Adult humans who possess little active brown fat exhibit thermo genesis
in skeletal muscle in response to catecholamine administration (639). Moreover, proton
leaks account for 25-52% of the mitochondrial oxygen consumption in isolated rat
hepatocytes and perfused rat skeletal muscle preparation (569-571). These observations
led to the hypothesis that certain components such as UCPl homologues in mitochondrial
inner membrane catalyze the proton leaks in these tissues.

UCP2 and UCP3, two homologues ofUCPl, have been cloned (640-643). UCP2 is 56%
identical to UCPl and is expressed ubiquitously throughout body, with the highest level
in white adipose tissue (640,641). UCP3 is 57 and 73% identical to UCPl and UCP2,
respectively, with its expression confined to brown fat and skeletal muscle (642, 643).
The human UCP3 gene gives rise to two mRNAs, a long form called UCP3L and a short
form called UCP3S, by alternative splicing at a polyadenylation site in intron 6. The
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UCP3S mRNA lacks the last coding exon, presumably generating a truncated form of
UCP3 protein lacking the sixth transmembrane domain (644).

The UCP2 and UCP3 genes have been mapped to mouse chromosome 7, rat chromosome
1, and human chromosome 11. In fact, these two genes are adjacent and located within
100 kb of chromosome region; the UCP2 gene is only 7 kb and 8 kb downstream of the
UCP3 gene in mouse and human, respectively, suggesting a duplication event during
gene evolution. The genomic organization ofUCP2 and UCP3 genes is similar to that of
UCPl gene, with the coding sequence over 6 exons. However, the UCP2 and UCP3
genes differ from the UCPl gene by the presence of two or one untranslated exons
located on the 5' side ofUCP2 and UCP3 gene, respectively (584, 585).

Recently, two additional homologues of uncoupling proteins, UCP4 and BMCP1/UCP5,
were cloned (645, 646). The deduced amino acid sequences are less similar to UCPl,
UCP2, and UCP3, and they are expressed in the brain. Moreover, two plant uncoupling
proteins, termed StUCP in Solanum tuberosum and AtUCP in Arabidopsis thaliana, were
also cloned (647-649).

All these uncoupling protein identified so far belong to a large family of inner
mitochondrial membrane proteins which share a number of features (567). Each protein
monomer contains approximately 300 amino acids which form a tripartite structure with
three 100-amino acid repeats and each repeat possessing a mitochondrial carrier signature
motif. Each functional mitochondrial carrier protein exists as homodimer and each
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monomer consists of six transmembrane domains (567). The uncoupling proteins,
however, exhibit higher sequence similarity to each other than to other members of the
mitochondrial carrier family (567).

2. Proton Transport Activity ofUCP2 and UCP3
The high structural and sequence similarity ofUCP2 and 3 to UCPl suggest that these
two proteins may possess similar proton transport function. Detailed analysis of amino
acid sequences indicates that UCP2 and UCP3 do contain a number of functional
residues, such as Arg83, Arg182, Arg276 (650), Glu190 (593), and His214 (651), which
are crucial for purine nucleotide regulation ofUCPl uncoupling activity, suggesting that
purine nucleotide binding and PH sensitivity are preserved in UCP2 and UCP3. A
histidine pair (His-145 and His-147) in the matrix loop ofUCPl is essential for its proton
transport activity (594, 595). Unlike UCPl, UCP2 lacks both of them and UCP3 lacks
His145 (594), suggesting that UCP2 and 3 may have no or reduced proton transport
function, or that they use a distinct mechanism mediating proton transport. However,
mitochondria from yeast over-expressing UCPl that lacks this histidine pair exhibit
normal function of proton transport (652), demonstrating that absence of this histidine
pair in UCP2 and 3 may not rule out the possibility of being a functional uncoupling
protein.

Functional analysis ofUCP2 and UCP3 uncoupling activity demonstrated that these two
proteins are able to decrease the mitochondrial potential in transformed yeast and
transfected mouse myoblasts (640,641,652,653).
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Expressing UCP2 in yeast causes a

50% increase in state 4 respiration (640), indicating that this protein may act on proton
leak. Similarly, over-expressing UCP3 in yeast increases oxygen consumption
comparable to that observed in UCPl (652,653). This was subsequently confirmed by
demonstrating that UCP2 and UCP3 expressed in Escherichia Coli inclusion body and
then reconstituted into liposomes are able to catalyze electrophoretic proton flux (654).
Like UCPl, UCP2 and UCP3 require fatty acid to mediate this proton transport activity
(654). Consistent with these findings, a recent study demonstrated that UCP2 and UCP3
reconstituted into vesicles is a highly active proton transporter (655). The UCP2 and
UCP3- mediated proton transport activity requires fatty acid and coenzyme Q, an
obligatory cofactor for proton transport by UCPl (656). Moreover, this proton transport
process is highly sensitive to purine nucleotides (655), although the others reported that
UCP2 and UCP3 are not sensitive to purine nucleotide inhibition and exhibit much
greater inhibition constant values compared to UCPl (654). Therefore, all these proton
transport properties for UCP2 and UCP3 resemble those for UCPl.

3. Regulation ofUCP2 and UCP3 Expression
3.1 Physiological Regulation of UCP2 and UCP3 expression
Various physiological states and many nutritional and hormonal factors have been shown
to regulate UCP2 and UCP3 expression. Cold exposure only modestly up-regulates UCP2
in brown fat (657) and UCP3 expression in brown fat and skeletal muscle (658,659).
High fat diet feeding causes increases in UCP2 and UCP3 expression (640,659). Fasting
and total caloric restriction, however, inhibit UCP3, but not UCP2 expression, in brown
fat, and increase UCP2 and UCP3 expression in skeletal muscle (567, 584, 585).
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Increased circulating levels of fatty acids are closely associated with up-regulation of
UCP2 and UCP3 expression (660-663), suggesting that the regulation ofUCP2 and 3
expression may be influenced by the fatty acid utilization. Administration of
thermogenic hormones such as thyroid hormone (T 3) and leptin to rodents increases
UCP2 and UCP3 expression (567,659, 664-671). Moreover, PPARy agonist
(thiazolidinediones) and retinoic acids are potent stimulators ofUCP2 and UCP3
expression (567,584, 585, 668, 672-676). In addition, free fatty acids, potential
endogenous ligands for PP AR-y,and P-adrenergic agonists, are also able to induce UCP2
and UCP3 expression in vitro and in vivo (567, 584, 585, 668, 677-680).

3.2 Transcriptional Control ofUCP2 and UCP3 Expression
Unlike the UCPl gene, the UCP2 gene promoter regions lack TATA and CAAT boxes
(584, 585). Functional characterization ofUCP2 promoter region has demonstrated
several potent cis-acting regulatory elements including 2 PP ARy response elements
(PPRE), 3 cAMP response elements (CREB-1), 2 putative thyroid hormone response
elements (TRE), and MyoD and glucocorticoid receptor binding sites (681-683). These
responsive elements could provide mechanisms of the positive regulation ofUCP2
expression via PP ARy agonists, fatty acids (ligands of PP ARy), thyroid hormones, Padrenergic agonists (isoproterenol). However, little is known regarding negative
regulatory factors ofUCP2 expression. We demonstrated that la,25-(OH)z-D

3

exerts an

inhibitory effect on UCP2 expression. The mechanism of this n VDR mediated inhibition
ofUCP2 is not known. However, the human UCP2 promoter region does contain several
cis-acting negative regulatory elements, which strongly repress promoter activity (681),
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although it is not clear whether nVDR acts on one of these silencers. Alternatively,
n VDR may also compete with other positive transcriptional factors containing similar
DNA binding domains on the responsive element binding or similar protein-protein
interaction domain (such as PPARy) on heterodimerization with the same transcriptional
factor (RXR).

UCP3 gene contains a TATA box in the promoter region (584). Characterization of
UCP3 promoter region has identified several cis-acting response elements, including the
E-box, MyoD, PPAR-y, RAR, and thyroid hormone receptor (TR) binding sites (584,
585). This is consistent with the up-regulation ofUCP3 gene expression by PPAR-y
agonist TZDs, free fatty acids, T3, and retinoid (659, 662, 663, 668, 669, 679, 684).

4. Physiological Functions ofUCP2 and UCP3
Since UCP2 and UCP3 exhibit high sequence similarity and similar uncoupling activity
with UCP 1, it is tempting to speculate that these two homologues may play similar roles
in regulating adaptive thermogenesis and energy expenditure. However, accumulating
evidence indicates that the physiological role ofUCP2 and UCP3 is more complicated
than that ofUCPl. UCP2 and UCP3 in different tissues and physiological states may
exert various functions, even though they assume the same proton transport and
uncoupling activity. However, the true physiological role of these two proteins is still not
clear. The proposed physiological functions ofUCP2 and UCP3 include control of
thermogenesis and energy expenditure, regulation of insulin secretion, regulation of
reactive oxygen species (ROS) and regulation of fatty acid utilization as substrates (567).
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4.1 Regulators of Energy Expenditure and Adiposity
UCP2 is involved in regulating metabolic rate and adiposity in vivo. A high fat diet
increased WAT UCP2 gene expression in obesity-resistant A/J strains but not in obesityprone C57B6 mice, indicating UCP2 also plays a role in preventing obesity (685). A
positive correlation between UCP2 mRNA expression in WAT and resting metabolic rate
(RMR) has been reported in humans (686). In addition, UCP2 expression has also been
shown to decrease by 28% in skeletal muscle of obese subjects (687). Consistent with
this finding, a reduced UCP2 expression in visceral adipose tissue in morbidly obese
subjects has been reported recently (688). A number of genetic linkage studies have also
documented association between genetic markers and variants ofUCP2 gene and human
metabolic rate and/or adiposity (689,690). A genetic study of markers in UCP2/UCP3
locus revealed a highly significant linkage with resting metabolic rate (689). Others
reported that UCP2 gene polymorphisms are associated with sleeping metabolic rate in
Pima Indians (690). Moreover, an association between UCP2 exon 8 variant and BMI
was found in South Indians. A recent study showed that a common G/ A polymorphism in
the UCP2 promoter region is associated with increased white adipocyte UCP2 mRNA
level and reduced adiposity (691). Moreover, this promoter polymorphism results in an
increased transcription of a reporter gene in a human adipocyte cell line (691). However,
two identified frequent polymorphism in human UCP2 gene, one in exon 4 with Ala55Val mutation and the other corresponding to untranslated region of exon 8 with a 45 bp
insertion/deletion, are not associated with obesity (692, 693).
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Several studies have also demonstrated the physiological relevance of UCP 3 in obesity.
In human study, a report showed a negative correlation between UCP 3 mRNA level and
body mass index (BMI) in Pima Indians (694). Consistent with this, a positive correlation
was found between sleeping metabolic rate and UCP 3 mRNA level (694). Moreover, a
mutation in UCP 3 gene resulting in defective function ofUCP 3 has been determined in
African-Americans with severe obesity and type II diabetes (695). A polymorphism in
splicing donor of exon 6 was identified only in African-American. This polymorphism
results in a premature termination of the protein product, which lacks the sixth
transmembrane domain, similar to UCP3S (the short form of UCP3) (696, 697).
Individuals bearing this mutation exhibit reduced fat oxidation by 50%, suggesting a role
for UCP3 in metabolic energy partitioning. Moreover, this mutation frequently exists in
severely obese subjects (696). Recently, mice over-expressing human UCP3 gene in
skeletal muscle were generated (698). These animals exhibit reduced fat mass and body
weight, even though they consume more food than wild-type littermates. Transgenic mice
also exhibit increased resting oxygen consumption in muscle, indicating an increase in
energy expenditure. This was confirmed by observation that the muscle state 4
respiration, an index of proton leaking, is elevated (698).

4.2 Regulators of Insulin Secretion
Abundant expression ofUCP2 in pancreatic-13cells coupled with its uncoupling activity
raises the possibility that UCP2 may be involved in regulating insulin secretion. Indeed,
over-expressing UCP2 in pancreatic 13cells decreases ATP/ ADP ratio and thereby
reduces glucose-stimulated insulin secretion, while UCP2-deficient mice exhibit higher
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ATP levels and increased glucose-stimulated insulin secretion, establishing that UCP2
negatively regulates insulin secretion (699-702). The inhibitory effect ofUCP2 on insulin
secretion is mediated by its proton transport activity, as over-expressing UCP2 in (3cells
decreases the mitochondrial potential, resulting in a decrease in ATP/ADP ratio (699702). The role ofUCP2 in insulin secretion bears physiological significance. UCP2 is
markedly up-regulated in islets of ob/ob mice, a model of obesity-induced diabetes (700).
Moreover, ob/ob mice lacking UCP2 have restored first-phase insulin secretion, increased
serum insulin levels, and decreased levels of glycemia (700). These data demonstrate that
UCP2 functions as a key component of {3-cellglucose sensor, and a critical link between
obesity, /j-cell dysfunction, and type II diabetes. The role ofUCP2 in modulation of /jcell insulin secretion further confirm UCP2 proton transport function and uncoupling
activity, however, in different physiological scenarios.

4.3 Regulators of Fatty Acid Utilization
In contrast to the UCPl expression pattern, skeletal muscle UCP2 and UCP3 mRNA
levels are increased during food deprivation (660, 661), a situation in which whole body
needs to save energy. This suggests that UCP2 and UCP3 in muscle might regulate fatty
acid metabolism rather than thermogenesis. This was confirmed by fasting and re-feeding
studies demonstrating that muscle UCP2 and UCP3 expressions are up-regulated during
food deprivation (when this tissue thermogenesis is decreased, but its lipid utilization is
increased), while down-regulated upon transition to re-feeding (a period of enhanced
efficiency of body fat deposition) (660). The association ofUCP2 and UCP3 expression
with fat metabolism is strong. Starvation and lipid infusion, both of which raise the
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circulating free fatty acid levels, increase UCP2 and UCP3 expression (660, 661, 678,
679). However, the role ofUCP2 and UCP3 in lipid metabolism is not known. It is
proposed that UCP2 and UCP3 may accelerate fatty acid /j-oxidation by facilitating fatty
acid transport.

Recently, Samec et al. reported that the down-regulation of skeletal muscle UCP3
expression during re-feeding is abolished during cold exposure (703). This may suggest
that the necessity to defend body temperature by ensuring utilization of lipid as fuel
overrides the necessity to spare lipid in favor of fat recovery (703). This also suggests
that UCP2 and UCP3 may exert different functions to meet physiological priority
according to different physiological condition.

4.4 Regulators of Reactive Oxygen Species (ROS)
ROS, such as 0 2-, H2O2, •OH, •NO, and •RO, are derived from complex I and complex
III of mitochondrial respiratory chains. The ROS production is markedly increased as the
proton electrochemical gradient increases. Therefore, ROS is positively correlated with
mitochondrial potential. The proton transport activity ofUCP2 and UCP3 raises the
possibility that these two proteins may function to limit ROS production by reducing
mitochondrial potential and thereby decreasing free radical intermediates which can
donate its electron to oxygen to generate ROS (567, 584). This was confirmed by the
studies of UCP2 and UCP3 knockout mice (703, 704). UCP2- and UCP3-deficient mice
do not exhibit an obese phenotype, although UCP3 knockout mice do have increased
mitochondrial uncoupling activity in skeletal muscle (703, 704). However, these
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knockout animals exhibit increased ROS levels in macrophages and are resistant to
deadly parasite infection (703, 704). These results agree with the hypothesis that UCP2
and UCP3 play important roles in modulating ROS production and preventing oxidative
stress.
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I. ABSTRACT
Intracellular calcium ([Ca 2+]i) modulates adipocyte lipid metabolism and inhibits the
early stages of murine adipogenesis. Consequently, we evaluated effects of increasing
[Ca2+]i in early and late stages of human adipocyte differentiation. Increasing [Ca2+]i with
either thapsigargin or A23187 at 0-1 hr of differentiation markedly suppressed
differentiation, with a 40-70% decrease in triglyceride and glycerol-3 phosphate
dehydrogenase (GPDH) (p < 0.005). However, a 1-hr pulse of either agent at 47-48 hr
only modestly inhibited differentiation. Sustained, mild stimulation of Ca2+influx with
either agouti protein or KCl-induced depolarization during 0-48 hr of differentiation
inhibited triglyceride accumulation and GPDH activity by 20-70% (p < 0.05) and
markedly suppressed peroxisome proliferator-activated receptor gamma (PP ARy)
expression. These effects were reversed by Ca 2+ channel antagonism. In contrast, Ca2+
pulses late in differentiation (71-72 h or 48-72 h) markedly increased these markers of
differentiation. Thus, increasing [Ca2+]i appears to exert a biphasic regulatory role in
human adipocyte differentiation, inhibiting the early stages of differentiation while
promoting the late stages of differentiation and lipid filling.
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II. INTRODUCTION
Intracellular calcium [Ca2+]iplays a key role in metabolic derangements associated with
obesity (1-3). Increasing ([Ca 2+]i)via stimulation of either receptor or voltage-mediated
calcium channels has also been shown to stimulate the expression and activity of fatty
acid synthase (FAS), a key enzyme in de novo lipogenesis, and inhibit basal and agoniststimulated lipolysis in both human and murine adipocytes (4, 5). These effects can be
reversed by calcium channel antagonism (4, 5). Therefore, increasing (Ca2+]i appears to
promote triglyceride accumulation in adipocytes by exerting a coordinated control over
lipogenesis and lipolysis, serving to simultaneously stimulate the former and suppress the
latter, resulting in lipid filling and adipocyte hypertrophy.

(Ca2+]i has also been implicated in regulating adipogenesis, which has been thought to
contribute to human and murine obesity (6). Ntambi et al. (7) have reported that
increasing [Ca2+]iby either inhibiting Ca2+-ATPas or stimulating Ca2+ influx, inhibited
the early stages of murine adipocyte differentiation. However, the role of (Ca2+]iin
human adipocyte differentiation is unknown and may not be inferred from the rodent
model, as cells derived from different species and development stages may show distinct
patterns ofresponsiveness to various differentiation-inducing agents. In addition, the
time-course effects of (Ca2+]iin early versus late stages of differentiation is not well
defined. Moreover, further investigation may assist in elucidating the role transition of
(Ca2+]i from preadipocyte, where it exerts a inhibitory effect in murine adipocyte
differentiation, to mature adipocytes, where it acts as a lipogenic and anti-lipolytic
signaling factor in regulating adipocyte metabolism.
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Accordingly, the present study was designed to determine the effect of increasing [Ca2+]i
in both early and late stages of human adipocyte differentiation. We report here that
increasing [Ca2 +]iin early stages of differentiation suppressed human adipocyte
differentiation, similar to previous reports in the murine adipocyte cell line (7). In
contrast, increasing [Ca2+]i in late stages of differentiation promoted human adipocyte
differentiation. Consequently, our data suggest that increasing [Ca2 +]i exerts a biphasic
regulatory role in human adipocyte differentiation, serving to inhibit the early stages of
differentiation, while promote the late stages of differentiation and lipid filling.
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III. MATERIALS AND METHODS
A. CULTURE AND DIFFERENTIATION OF HUMAN PREADIPOCYTES
Human preadipocytes used in this study were supplied by Zen-Bio Inc (Research
Triangle, NC). These preadipocytes originated from normal human subcutaneous adipose
tissue and were isolated using a collagenase digestion and centrifugation method as
previously described (8, 9). Preadipocytes were inoculated in Dulbecco's Modified
Eagle' Medium (DMEM) I Ham' F-10 medium (F-10) (1 :1, v/v) containing 10% fetal
bovine serum (FBS), 15mM Hepes and antibiotics at a density of 30,000 cells/cm 2 •
Confluent monolayers of preadipocytes were induced to differentiate with a standard
differentiation medium consisting ofDMEM/F-10 (1 :1, v/v) medium supplemented with
15 mM Hepes, 3% FAS, 33 µM biotin, 17 µM pantothenate, 1OOnMinsulin, 0.25 µM
methylisobutylxanthine (MIX), 1 µM dexamethasome, 1 µM BRL49653 and antibiotics
with or without calcium agonists (thapsigargin and A23187). Preadipocytes were
maintained in this differentiation medium for 3 days and subsequently cultured in
adipocyte medium in which BRL49653 and MIX were omitted. Cultures were refed
every 2-3 days.

B. INTRACELLULAR Ca 2+ MEASUREMENT
[Ca2+]i in human preadipocytes was measured using a fura-2 dual wavelength
fluorescence imaging system. Preadipocytes were plated in 35 mm dished with glass
coverslips (P35G-0-14-C, MatTek Corporation). Prior to [Ca 2+]i measurement, cells were
preincubated in serum-free medium overnight and rinsed with Hepes Balanced Salt
Solution (HBSS) containing the following components (in mM): NaCl 138, CaCh 1.8,
229

MgSO 4 0.8, NaH 2PO 4 0.9, NaHCO 3 4, glucose 5, glutamine 6, Hepes 20, and bovine
serum albumin 1%. Cells were loaded with fura-2 acetoxymethyl ester (AM) ( 10 µM) in
the same buffer for 2 hr at 37 °c in a dark incubator with 5% CO 2 . To remove
extracellular dye, cells were rinsed with HBSS 3 times and then postincubated at room
temperature for an additional 1 hr for complete hydrolysis of cytoplasmic fura-2 AM. The
dishes with dye-loaded cells were mounted on the stage of Nikon TMS-F fluorescence
inverted microscope with a Cohu 4915 CCD camera. Fluorescent images were captured
alternatively at excitation wavelength of340 and 380nM with an emission wavelength of
520 nM. After establishment of stable image baseline, the response to calcium agonists,
thapsigargin and A23187, was determined. [Ca2+]iwas calculated using a ratio equation
as described previously(! 0). Each analysis evaluated responses of 8-10 representative
whole cells. Images were calibrated using a fura-2 calibrated using a fura-2 calcium
imaging calibration kit (Molecular Probes, Eugene, OR) to create a calibration curve in
solution, and cellular cellular calibration was accomplished using digitonin (25 µM) and
pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal [Ca2+]i levels (10).

C. TRIGLYCERIDE CONTENT ASSAY
Human preadipocytes were incubated with calcium agonists as indicated during
differentiation. Cellular triglyceride content was determined spectrophotometrically using
a triglyceride assay kit (Sigma, St. Louis, MN). Cells were rinsed with Hank' Balanced
Salt solution and scraped in 0.9% saline. Cell suspension was then homogenized with
sonication and subject to measurement.
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D. GLYCEROL-3-PHOSPHATE

DEHYDROGENASE (GPDH) ACTIVITY ASSAY

GPDH activity was measured by a spectrophotometric method (11). Cells were scraped
and sonicated in 250 mM sucrose solution containing 1 mM ethylenediaminetetraacticacid (EDT A), 1 mM dithiothreitol (DTT), and 100 µM phenylmethylsulfonyl
fluoride (PMSF) (pH 7.4). Homogenate was centrifuged at 18,500 X g for 1 hr and the
infranatant was used for measuring oxidation rate ofNADH.

E. PROTEIN ASSAY
Total cellular protein content for correction was measured by a modified Bradford
method using coomassie blue dye (Pierce, Rockford, IL).

F. NORTHERN BLOT ANALYSIS
Northern blot analysis was conducted as previously described (12). Total RNA from
human adipocytes was extracted using CsC}z density centrifugation, run in 1% agarose
gel and transferred to nylon membrane (New England Nuclear, Boston, MA). The
membrane was hybridized with a peroxisome proliferator-activated receptor gamma
(PP ARy) cDNA probe radiolabeled using a random primer method. Unbound probe was
removed by rinsing the membrane with 2X SSC / 0.1 % SDS for 30 min at room
temperature and O.lX SSC/ 0.1% SDS for 45 min at 55 °c.Finally, the membrane was
exposed to X-ray film (New England Nuclear, Boston, MA) at-80 °C. All membranes
were stripped and reprobed with 18s as loading control.
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G. STATISTICAL ANALYSIS
Replicates of 16 independent experiments were conducted for all triglyceride assay, 8
independent studies for GPDH activity, 10 independent experiments for the [Ca2+]i
measurements, and three independent experiments for the PP ARy mRNA measurements.
All data are expressed as mean ± SE and evaluated for statistical significance by one way
Analysis of Variance (ANOVA) using SPSS (SPSS Inc, Chicago, IL).
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IV. RESULTS
To investigate the role of [Ca2+]i in human adipocyte differentiation, we first selected
thapsigargin, a Ca 2+-ATPase inhibitor, and A23187, a calcium ionophore, as calcium
agonists to stimulate [Ca 2+]i-Both agents are widely used to mimic physiological [Ca2+]i
mobilization in many cell types (13-16). In this study, we demonstrate that thapsigargin
and A23187 also stimulated [Ca2+]i in human preadipocytes. A fura-2 dual wavelength
imaging system was used to measure [Ca2+]i stimulation caused by calcium agonists. Fig.

1 (top) shows the cell fluorescence image in pseudocolor, which changed from green in
baseline to yellow upon addition of 30 nM thapsigargin, indicating an increase of [Ca2+]i.
Quantitation of this response demonstrated a 3-fold increase in [Ca 2+]i (baseline of 108 ±
12 nM vs. stimulated value of 456 ± 23 nM, p<0.001). Similar results were observed in
preadipocytes treated with 2 µM A23187 (baseline of 112 ± 14 nM vs. stimulated value
of 412 ± 28 nM, p<0.001), as shown in Fig.1 (middle). Similarly, using KCl as a
depolarizing agent caused a slow, sustained increase in [Ca 2+]i (baseline of 117 ± 15nM
vs. stimulated value of 280 ± 26 nM, p<0.001; Fig. 1, bottom).

To evaluate the effect of increasing [Ca2+]i in early stages of differentiation, we treated
human preadipocytes with calcium agonists during the first 48 h of differentiation, using
triglyceride content and GPDH activity as late differentiation markers. Fig. 2 illustrates
that a 1-h pulse with 30 nM thapsigargin or 2 µM A23187 between the 23 rd and 24 th hour
of differentiation suppressed subsequent triglyceride accumulation by 60 and 40%
(p<0.005), respectively. Similarly, a 1-hr treatment with 30 nM thapsigargin or 2 µM
A23187 at 23-24 hr inhibited GPDH activity by 70 and 65% (p<0.005, Fig. 3),
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Fig 1. The effects ofthapsigargin, A23187, and KCl on human preadipocyte [Ca 2+]i. A
fura-2 dual wavelength fluorescence imaging system was used to measure [Ca2+]i as
described in Materials and Methods. Ten independent experiments were conducted for
each experiment. Left: cell fluorescence images in pseudocolor, which changes from
green in baseline (right) to yellow (left) upon addition of each agonist, indicating
increased [Ca 2+]i. Quantitation of this response is shown in the graph on the right. The
arrow indicates the time of addition of each agonist, as follows. Top: a 3-fold increase in
[Ca2+]i in response to 30 nM thapsigargin (456 ± 23 vs. 108 ± 12 nM [Ca2+]i, p<0.001).
Middle: Similar results with 2µMA23187

(412 ± 28 vs. 112 ± 14 nM [Ca2+]i, p<0.001).

Bottom: addition of20 mM KCl caused a slow, sustained increase in [Ca 2+]i (280 ± 26 vs.
117 ± 15 nM [Ca2 +]i, p<0.001).
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Fig. 2. The effects of the thapsigargin and A23187 treatment at 23-24 hr of
differentiation on human adipocyte triglyceride accumulation. Confluent monolayers
of human preadipocytes were induced to differentiation with a standard adipocyte
medium supplemented with or without thapsigargin or A23187 as indicated. 1-hr
pulse treatment of human preadipocytes with 30 nM thapsigargin or 2 µM A23187
was conducted at 23-24 hr of differentiation. Total cellular triglyceride content was
measured at the end of day 8 of differentiation as described in Material and Methods.
Data are normalized to percent of control (0.988 ± 0.079 µg!µg protein). *p<0.005 vs
control; n=16.
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Fig. 3. The effects of the thapsigargin and A23187 treatment at 23-24 hr of
differentiation on human adipocyte glycerol-3-phosphate dehydrogenase (GPDH)
activity. Confluent monolayers of human preadipocytes were induced to
differentiation with a standard adipocyte medium in the presence or absence of
thapsigargin or A23187 as indicated. A 1-hr pulse treatment of human preadipocytes
with 30 nM thapsigargin or 2 µM A23187 was conducted at 23-24 hr of
differentiation. GPDH activity was measured at the end of day 8 of differentiation as
described in Material and Methods. Data are normalized to percent of control
oxidation ofNADH (23.2 ± 0.9 nmol.min-1.mg protein-I). *p<0.005 vs control; n=8.
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respectively. However, a later 1-hr pulse ofthapsigargin or A23187 at 47-48 hr of
differentiation caused an inhibition in triglyceride content by only 20% (p<0.05, Fig. 4),
indicating an attenuation of their inhibitory effects on differentiation.

We next utilized more physiological [Caz+]iagonists, such as KCl, a cell membrane
depolarization agent, and agouti protein, which is expressed in human adipose tissue and
increases [Caz+]iin several cell types (17, 18), to stimulate Caz+ influx during
differentiation. Agouti protein was obtained as previously described (5). Fig. 5 shows
that treatment with 10 mM KCl or 100 nM agouti protein during 0-48 hr of
differentiation suppressed triglyceride content by 70 and 20% (p<0.01), respectively.
Similarly, a long-term treatment with 10 mM KCl or 100 nM agouti during 0-48 hr of
differentiation caused an inhibition in GPDH activity by 40 and 20% (p<0.05, Fig. 6),
respectively. This inhibition was completely prevented by 30 nM nitrendipine, an L-type

..

Caz+ channel antagonist. Moreover, using PPARy expression as a differentiation marker,
we demonstrated that long-term treatment with 10 mM KCl or 100 nM agouti during 048 hr of differentiation greatly inhibited PP ARy expression, which was totally recovered
by nitrendipine (Fig. 7).

We next assessed the effect of increasing [Caz+]iin late stages of differentiation. In
contrast to early stage of treatment, a 1-hr pulse treatment with 30 nM thapsigargin or 2
µM A23187 at 71-72 hr of differentiation increased triglyceride content by 90 and 65%
(p<0.001, Fig. 8), respectively. Similarly, Fig. 9 illustrates that a sustained treatment with
10 mM KCl or 100 nM agouti during 48-72 hr of differentiation enhanced triglyceride
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Fig 4. The effects of the thapsigargin and A23187 treatment at 4 7-48 hr of
differentiation on human adipocyte triglyceride accumulation. Confluent monolayers
of human preadipocytes were induced to differentiation with a standard adipocyte
medium supplemented with or without thapsigargin or A23187 as indicated. A I-hr
pulse treatment of human preadipocytes with 30 nM thapsigargin or 2 µM A23187
was conducted at 47-48 hr of differentiation. Total cellular triglyceride content was
measured at the end of day 8 of differentiation as described in Material and Methods.
Data are normalized to percent of control (1.04 ± 0.05 µg/µg protein). *p<0.005 vs
control; n=16.
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Fig. 6. The effects of KCl and agouti protein treatment during 0-48 hr of
differentiation on human glycerol-3-phosphate dehydrogenase activity. Confluent
monolayers of human preadipocytes were induced to differentiation with a standard
adipocyte medium in the presence or absence ofKCl or agouti alone, KCl or agouti
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day 8 of differentiation as described in Material and Methods. Data are normalized to
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human preadipocytes were induced to differentiation with a standard adipocyte
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Northern blot analysis was performed as described in Materials and Methods. Blot
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accumulation by 2 to 3 fold (p<0.001). Further, Fig. 10 shows that a long-term treatment
with either KCl or agouti late in differentiation caused a marked increase in PP ARy
expression.
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V. DISCUSSION
Intracellular Ca 2+ ([Ca 2+]i)appears to play a key role in metabolic disorders associated
with obesity, and sustained high levels of [Ca2+]imay contribute to this derangement (13). In this study, we demonstrate that [Ca2+]iplays a regulatory role in adipogenesis, an
important contributor to increased fat tissue mass. Our data suggest that increasing [Ca2+]i
in the early stages of differentiation inhibits human adipocyte differentiation, whereas
increasing [Ca2+]i in late stage promotes human adipocyte differentiation. This delineates
a role transition in [Ca2+]i, which serves to inhibit differentiation in early stages but
promote differentiation in late stages.

[Ca2+]i appears to promote and accelerate preadipocyte differentiation program(s),
thereby inducing adipocyte phenotype in the late stage of differentiation. To achieve this,
increasing [Ca2+]i causes a marked increase in the expression of PPARy (Fig. 10), a
nuclear hormone receptor that acts as a critical transcriptional factor in adipocyte
differentiation programs (19). Increased expression of PPARy may subsequently
accelerate adipocyte differentiation by directly acting upon and eliciting late
differentiation gene expression, such as aP2, steroyl-CoA desaturase (SCD-1 ),
phosphoenolpyruvate carboxykinase (PEPCK) and fatty acid synthase (FAS) (20-25). On
the other hand, in late differentiation, preadipocytes become more committed to terminal
differentiation after the expression of several critical differentiation transcriptional
factors, such as CCAAT/enhancer binding protein beta and delta (C/EBPJ3 and 8), PPARy
and sterol regulatory element binding protein-1/adipocyte determination and
differentiation factor-I (SREBP-1/ADD-1) (19, 20, 26, 27). [Ca2+]i may synergize with
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these transcriptional factors to promote differentiation program by stimulating late
differentiation gene expression. Consistent with this, (Ca 2+]i acts as a lipogenic and antilipolytic signaling factor in regulating adipocyte metabolism in both rodent and human
adipocytes (4, 5). Previous reports from our laboratory demonstrated that increasing
[Ca2+]i stimulates the expression and activity of fatty acid synthase (FAS), a key enzyme
in de nova lipogenesis and thereby increases triglyceride storage (4). In addition, we have
also shown that increasing [Ca2+]i inhibits basal and agonist-stimulated lipolysis in
primary cultured human adipocytes (5). These effects can be completely blocked by
calcium channel antagonism (4, 5). Therefore, increasing (Ca2+]i appears to promote
triglyceride accumulation in adipocytes by exerting a coordinated control over
lipogenesis and lipolysis, serving to simultaneously stimulate the former and suppress the
latter, thereby resulting in lipid filling and adipocyte hypertrophy. Accordingly, the
lipogenic and anti-lipolytic effects of [Ca2+]i, coupled with increased expression of
differentiation transcriptional factor such as PP ARy, may contribute to the stimulatory
effect of [Ca 2+]i in the late stages of differentiation.

However, data from Ntambi et al (7) did not show the stimulatory effect of increasing
(Ca2+]i in late stages of differentiation in 3T3-Ll cells. The reason for this discrepancy is
not clear. A possible explanation is that these two studies used two different cell models,
3T3-Ll derived from mouse embryo and human preadipocyte originating from human
stromal-vascular cells in subcutaneous fat depot (20). Therefore, cell models derived
from different species and development stage may exhibit distinct differentiation
properties.
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In contrast to the stimulatory effect of increasing [Ca2+]i in late stages of differentiation,
increasing [Ca2+]iin the early stage suppresses human adipocyte differentiation. In
agreement with our findings, increasing [Ca2+]ihas been shown to exhibit an inhibitory
effect in early stages of murine adipocyte differentiation (7). [Ca2+]i exerted this
inhibitory effect by blocking the postconfluent mitotic phase and mediating sustained
levels of c-myc expression (7). This sustained c-myc expression precludes cell entry to
the Go stage necessary for subsequent differentiation (28-30) and instead forces cells to
re-enter the normal cell cycle (31). In this study, increasing [Ca2+]i in early stage of
differentiation caused a substantial inhibition in PP ARy expression (Fig. 7), which would
be expected to subsequently reduce late differentiation gene expression and thereby
inhibit further differentiation.

The mechanism whereby [Ca2+]iundergoes this role transition during human adipocyte
differentiation is unknown. However, cAMP also plays a discordant role in adipocyte
differentiation and mature adipocyte metabolism. Increasing cAMP promotes adipocyte
differentiation (20), while it inhibits expression and activity of fatty acid synthase (32,
33), a key enzyme in de novo lipogenesis, and stimulates lipolysis in mature adipocytes.
Moreover, there is a significant interaction between the calcium and cAMP signaling
pathways. Structural and functional studies have demonstrated adenylyl cyclases are
associated with the site of Ca2+ entry into the cell and that Ca2+ entry causes a marked
inhibition of type V and VI adenylyl cyclases, thereby reducing cAMP levels in several
cell types (34). Alternatively, we have recently demonstrated that increasing human
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adipocyte [Ca2+]i stimulates phosphodiesterase 3B activity, resulting in reduced cAMP
levels and thereby inhibit differentiation (35). Conversely, a [Ca2+]i-induced decrease in
cAMP late in differentiation up-regulates lipogenesis and suppresses lipolysis, thereby
promoting adipocyte maturation and lipid filling.

It was originally believed that only early-onset obesity was associated with adipocyte

hyperplasia, while maturity-onset obesity was believed to result solely from adipocyte
hypertrophy (36, 3 7). This concept was challenged by later studies demonstrating that the
potential to acquire new adipocytes persists even at adult stage. Several lines of evidence
demonstrate that an increase in fat cell number appears to be well correlated with severity
of human obesity in adult life (8). Moreover, specific early differentiation genes have
been reported to express in adipose tissue from very old mice (38). In addition, fat cell
precursors, such as stromal-vascular cells, isolated from adult human adipose tissue can
be fully differentiated into mature adipocytes in vitro (8, 39). Further, adipocyte
development has been shown to depend on fat precursor cell recruitment in vivo (40).
Although the relative contribution of adipocyte hypertrophy versus hyperplasia to human
adiposity is unknown, the capacity to generate new adipocytes from cells persists
throughout life span and clearly plays a role in regulating fat tissue mass. Our data in the
present study implicate a role of [Ca2+]iin modulating adipocyte hyperplasia and further
affecting adipose tissue mass in vivo. The significance of [Ca2+]iin regulating
adipogenesis bears physiological basis, as there are many nutritional, hormonal and
pharmaceutical factors that can modulate [Ca2+]i signaling in both adipocytes and
preadipocytes. In addition to the [Ca2+]imobilization agents used in this study (cell
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membrane depolarization and agouti protein, an obesity gene product expressed in human
adipose tissue), other endocrine and/or paracrine factors, including 1,25-dihydroxyvitamin D, parathyroid hormone (41), angiotensin II, and arginine vasopressin
(unpublished data), have also been demonstrated to mobilize adipocyte [Ca2+]i- Further,
we recently reported that sulfonylureas, a family of insulin secretgogues widely used to
stimulate insulin release in the treatment of type II diabetes, stimulates

[Ca2+]i and

thereby modulates lipid metabolism in human adipocytes (12). Thus, [Ca2 +]i appears to
exhibit a physiological role in regulating adipogenesis and fat tissue mass formation.

In summary, our data suggest that increasing [Ca2+]i exerts a biphasic regulatory role in
human adipocyte differentiation, serving to inhibit the early stages of differentiation
while promoting the late stages of differentiation and lipid filling. We conclude that the
role of [Ca 2+]i in adipocyte differentiation may not only provide insight into the
mechanism of human adipogenesis and energy homeostasis, but also represent an
important target for further development of therapeutic intervention in obesity.
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PART4
ROLE OF THE SULFONYLUREA RECEPTOR (SUR) IN
REGULATING HUMAN ADIPOCYTE METABOLISM

This manuscript has been published in the similar form with co-authors MoustaidMoussa, N., Wilkison, W. 0., and Zemel, M. B. in FASEB. J. 13, 1833-1838, 1999.

257

I. ABSTRACT

A regulatory role for intracellular Ca2+ ([Ca2+]i) in adipocyte lipogenesis, lipolysis and
triglyceride accumulation has been demonstrated. Compounds acting on the pancreatic
sulfonylurea receptor (SUR) to increase (e.g. glibenclamide) or decrease (e.g.diazoxide)
[Ca2+]i cause corresponding increases and decreases in weight gain. However, these
weight gain and loss effects have been attributed to insulin release rather than primary
effects of these compounds on the adipocyte SUR and its associated

KATP

channel.

Accordingly, we have now evaluated the direct role of the human adipocyte SUR in
regulating adipocyte metabolism. We used RT-PCR with primers for a highly conserved
region of SURI to demonstrate that human adipocytes express SURI.The PCR product
was confirmed by sequence analysis and used as a probe to demonstrate adipocyte SURI
expression by northern blot analysis. Adipocytes exhibited corresponding glibenclamide
dose-responsive (0-20 µM) increases in [Ca2+]i (p<0.05). Similarly, glibenclamide (10
µM) caused a 67% increase in adipocyte fatty acid synthase (FAS) activity {p<0.001), a
48% increase in glycerol-3-phosphate dehydrogenase (GPDH) activity (p<0.01) and a
68% inhibition in lipolysis (p<0.01), while diazoxide (10 µM) completely prevented each
of these effects. These data demonstrate that human adipocyte express a SUR which
regulates [Ca2+]i and, consequently, exerts coordinate control over lipogenesis and
lipolysis. Accordingly, the adipocyte SURl may represent an important target for the
development of therapeutic interventions in obesity.
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II. INTRODUCTION
Intracellular Ca 2+ ([Ca 2+]i) plays a key role in the metabolic disorders associated with
obesity and insulin resistance (1-3). Recombinant agouti protein, an obesity gene product,
causes a dose-responsive increase in [Ca2+]i in a variety of cells (4,5), including both
murine and human adipocyte. Moreover, agouti protein promotes the expression and
activity of fatty acid synthase (FAS), a key enzyme in de nova lipogenesis, and thereby
increases triglyceride storage in a Ca2+- dependent manner (6). In addition, we have also
shown that agouti inhibits basal and agonist-stimulated lipolysis in primary cultured
human adipocytes via a Ca2+- dependent mechanism (7). Therefore, increasing [Ca2+]i
appears to promote triglyceride accumulation in adipocytes by exerting a coordinated
control over lipogenesis and lipolysis.

Sulfonylureas, such as glibenclamide, are insulin secretagogues widely used to stimulate
insulin secretion in the treatment of non-insulin-dependent diabetes mellitus.
Sulfonylureas depolarize pancreatic 13cells by blocking

KATP

channels, thereby resulting

in depolarization and secondary Ca2+ influx via L-type Ca2+ channels, which in tum
triggers insulin release (8,9). The 13cell receptor for sulfonylureas, sulfonylurea receptor!
(SURI), has been cloned (10).

Recently, Alemzadeh et al. (11, 12) reported that diazoxide, a drug that activates the 13
cell KATP channel and subsequently exerts an anti-obesity effect in obese Zucker rats.
Further, they recently reported that diazoxide exerted a significant anti-obesity effect in
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hyperinsulinemic obese adults (13). However, this action was attributed to direct actions
of diazoxide on

p cells, rather than direct effects of diazoxide

on adipocyte metabolism.

Accordingly, the present study was conducted to assess the direct role of the human
adipocyte SUR in adipocyte metabolism. We report here that human adipocytes express
SUR and exhibit corresponding glibenclamide dose-responsive increase in [Ca2+]i.
Moreover, glibenclamide exerts lipogenic and antilipolytic effects in human adipocytes,
while diazoxide completely blunts each of these effects. These data demonstrate that
SUR in human adipocyte regulates [Ca2+]i and thereby exerts coordinate control over
lipogenesis and lipolysis.
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III. MATERIALS AND METHODS
A. ISOLATION AND CULTURE OF HUMAN ADIPOCYTES
Human subcutaneous adipose tissue was obtained from patients undergoing abdominal
plastic surgery with no known history of metabolic disorders. This protocol was approved
by the Institutional Review Board for Human Subjects and the Committee for Research
Participation of the University of Tennessee. Adipocytes were isolated as previously
described (14). Briefly, adipose tissue was first washed several times with Hank's
Balanced Salt Solution, minced into small pieces and digested with 0.8 mg/ml type 1
collagenase in a shaking water bath at 37 °c for 30 min. Adipocytes were then filtered
through a sterile 500 µm nylon mesh and cultured in Dulbecco's Modified Eagle's
Medium (DMEM) supplemented with 1% fetal bovine serum (FBS), 100 UI/ml
penicillin, 100 µg/ml streptomycin and 50 µg/ml gentamicin. Cells were cultured in
suspension and maintained in a thin layer at the top of culture media, which were
changed every day. Cells were maintained viable and metabolically responsive under this
culture condition for 7 days.

B. REVERSE TRANSCRIPTION-POLYMERASE

CHAIN REACTION (RT-PCR)

Total RNA from human adipocytes was extracted using CsCii density centrifugation.
mRNA from human adipocyte was isolated according to manufacture's instruction (micro
poly(A) pure kit, Ambion Inc, Austin, TX). RT-PCR was performed essentially as
previously described (7). Briefly, 400 ng of human adipocyte mRNA was reversetranscribed to first strand cDNA using random-hexamer and reverse transcriptase (Perkin
Elmer, Norwalk, CT} and amplified by PCR (Perkin Elmer, Norwalk, CT}. The PCR
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conditions were as follows: initial denaturation at 94 °c for 5min, followed by 34 cycles
of denaturation at 94 °c for 45s, annealing at 55 °c for lmin, and extension at 72 °c for 2
min, with a final extension step at 72 °c for 8 min with 0.5 µM 5' primer (5'CATCATTGATGGCATTGACATCCGC) and 3' primer (5'CTCTGGCTT ATCGAACTCAAGGATGG) which correspond to nucleotide positions
4206-4230 and 4664-4689 in HSU63421 respectively. The amplified PCR products were
then visualized by 1.2% agarose gel electrophoresis, purified (Geneclean kit, bio 101,
Inc) and subjected to sequence analysis using ABI PRISM system (model version 2. 1.
1).

C. NORTHERN BLOT ANALYSIS
Northern blot analysis was conducted as previous described (15). Human adipocyte
mRNA (4 µg/well) was run in 1% agarose gel and transferred to nylon membrane, which
was hybridized with human SURI cDNA probes eluted from PCR products and
radiolabeled using a random primer method. Unbound probe was removed by rinsing the
membrane with 2X SSC for 30 min at room temperature and O.IX SSC/ 0.1% SDS for 45
min at 60 °C.Finally, membrane was exposed to X-ray film at -80 °c.

D. INTRACELLULAR Ca2+ MEASUREMENT
[Ca2+]i in isolated human adipocytes was determined fluorometrically as previously
described (2, 16). Briefly, the human adipocytes isolated as described above were
incubated in DMEM medium overnight for cell recovery. Prior to [Ca2+]i measurement,
adipocytes were pre-incubated in serum-free medium for 2 hrs, rinsed with HBSS
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solution containing the following components in mM: NaCl 138, CaCh 1.8, MgSO4 0.8,
NaH 2 PO 4 0.9, NaHCO3 4, glucose 20, glutamine 6, HEPES 20 and BSA 1%. Cells were
then loaded with fura-2 acetoxymethyl ester (10 µM) in the same buffer for 45 min at 37
0

c in dark with

continuous shaking. To remove extracellular dye, cells were rinsed with

HBSS for 3 times and resuspended in this solution at a concentration of 2X 105 cells/ml.
[Ca 2+]i was measured using dual excitation (340 and 380 nm) and single emission (510
nm) fluorometry. Following the establishment of stable baseline, the response to
glibenclamide (10 and 20 µM) was determined. Digitonin (25 µM) and Tris/EGTA (100
mM) were used to measure maximal and minimal fluorescence to calibrate the signals,
and final [Ca 2+]i was then calculated by the equation of Grynkiewicz et al ( 17).

E. FATTY ACID SYNTHASE (FAS) AND GL YCEROL-3-PHOSPHA TE
DEHYDROGENASE (GPDH) ACTIVITY ASSAY
Human adipocytes were incubated in 24-well plates with the treatments indicated for 48
hr. FAS and GPDH activities were determined spectrophotometrically in crude cytosolic
extracts of human adipocytes by measuring the oxidation rate ofNADPH or NADH
respectively, as previously described (18). The protein correction was measured by a
modified Bradford method using Coomassie Blue dye (Pierce, Rockford, IL).

F. LIPOLYSIS ASSAY
Human adipocytes were treated as described above, and glycerol release into the culture
medium was determined as an indicator for lipolysis using a one step enzymatic
fluorometric method (19). After treatment medium was obtained, HC1O4 was added for
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deproteinization. The sample was next centrifuged to precipitate protein and the
supernatant was neutralized with NaOH before glycerol assay.

G. STATISTICAL ANALYSIS
All data are expressed as mean±SE. Data were evaluated for statistical significance by
analysis of variance or t-test.
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IV. RESULTS

Human SURI is expressed in adipocytes. Using RT-PCR, we detect a 490 hp SURI
fragment, which represents a highly conserved region in SUR gene (Fig. 11). Sequence
analysis confirmed the identity of this PCR product, which was 100% identical to human
SURI. Interestingly, no SURI transcript was detectable in mRNA isolated from human
preadipocytes (Fig. 11). The PCR product was purified and used as a probe to detect
adipocyte SURI expression by northern blot analysis, which showed an approximately 5
Kb transcript of SURI mRNA in adipose tissue (Fig. 12).

To determine the functional significance of this adipocyte SUR, the [Ca2+]i response to
glibenclamide was evaluated. 5 and 10 µM glibenclamide induced sustained increases of
[Ca2+]i in human adipocytes in a dose-dependent manner, while pre-treatment of human
adipocytes with diazoxide, the KATPchannel opener, completely prevented
glibenclamide-induced increases in [Ca2+]i (Fig. 13 and 14). However, human
preadipocytes did not exhibit any [Ca2+]iresponse to glibenclamide. This is consistent
with the absence of SURI in human preadipocytes noted above.

To study the role of adipocyte SURI in regulating lipogenesis, we treated human
adipocyte with SURI agonist and antagonist using FAS and GPDH activities as lipogenic
markers. 10 µM glibenclamide caused a 67% increase in adipocyte FAS activity
(0.692±0.052 NADPH nM/min/mg protein vs. 1.154±0.010 NADPH nM/min/mg protein,
p<0.001, Fig. 15), which was completely blocked by 10 µM diazoxide, a KATPchannel
activator, and partially inhibited by nitrendipine, an L-type Ca2+ channel antagonist.
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Fig 11. Detection of the expression of SURI gene in human adipocyte by RT-PCR. The
PCR product, a 490 hp SURI fragment (designated by arrow), was visualized by 1.2%
agarose gel electrophoresis. Lane 1: human pancreatic

~

cells as positive control; lane 2:

human preadipocytes without reverse transcriptase; lane 3: human preadipocyte with
reverse transcriptase; lane 4: human adipocytes without reverse transcriptase; lane 5:
human adipocytes with reverse transcriptase; lane 6: 18s fragment amplified as RT-PCR
system positive control; lane 7: DNA marker. RT-PCR was performed as described in
Materials and Methods.
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5Kb
2

Fig 12. Detection of the expression of SURI mRNA in human adipocyte by northern
blot analysis. A 5 Kb transcript of SURI mRNA was detected in human adipocyte. Lane
1: human pancreas mRNA as positive control~ lane 2: human adipocyte mRNA. Northern
blot analysis was conducted as described in Materials and Methods.
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Glibenclamidef

Fig 13. Effects of glibenclamide (IO µM) on stimulation of [Ca2+]i in human adipocytes.
[Ca 2+]imeasurement was conducted as described in Materials and Methods.
Glibenclamide was added at time designated by the arrow. The upper panel shows the
cell fluorescence image in pseudocolor, which changed from green in baseline to yellow
upon the addition of IO µM glibenclamide, indicating an increase in [Ca2+]i. Quantitation
of this response by Ca 2+ tracing demonstrated a 2.5 fold increase in [Ca2+]i (lower panel).
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Figure 14. The dose-responsive effect of glibenclamide ( 5 µM and IO µM) on [Ca2+]iin
human adipocytes. [Ca2+]imeasurement was conducted as described in Materials and
Methods. Glibenclamide was added at time designated by the arrow. Upper panel:
glibenclamide stimulates a dose-responsive increase in human adipocyte [Ca2+]i__
Lower
panel: pre-treatment of human adipocyte with diazoxide prevented glibenclamideinduced increases in [Ca2+]i.

269

-e

.5

1.4

Q.

1.2

* p < 0.001 vs. control

~

*

~

E

.5

t=
1:1,.

1
0.8
0.6

~--0.4
;,,.,

·"'=
.i:::

-

V
0.2
<
r'1
<
0
~

Control

Glybenclamide Glybenclamide Glybenclamide
+diazoxide
+nitrendipine

Fig 15. The effect of glibenclamide on FAS activity in human adipocytes. Human
adipocytes were treated with 10 µM glibenclamide alone, 10 µM glibenclamide plus 10
µM diazoxide or 10 µM glibenclamide plus 30 nM nitrendipine for 48 hr. FAS activity

was measured as described in Materials and Methods. * p < 0.001 vs. Control; n=8.
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Similarly, 10 µM glibenclamide stimulated a 48% increase in GPDH activity (554.0±33.0
NADH nM/min/mg protein vs. 821.0±73.4 NADH nM/min/mg protein, p<0.01, Fig. 16),
which was totally blocked by 10 µM diazoxide.

We next investigated the role of adipocyte SURI on lipolysis. 48 hr-treatment with 10
µM glibenclamide caused a 68% inhibition in lipolysis (0.193±0.050 NADH µM/mg
protein vs. 0.061±0.009 NADH µM/mg protein, p<0.05, Fig. 17), which was recovered
to 75% and 50% by diazoxide and nitrendipine, respectively.
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Fig 16. The effect of glibenclamide on GPDH activity in human adipocytes. Human
adipocytcs were treated with 10 µM glibenclamide or 10 µM glibenclamide plus 10 µM
diazoxide for 48 hr. GPDH activity was measured as described in Materials and Methods.
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Fig 17. The effect of glibenclamide on lipolysis in human adipocytes. Human adipocytes
were treated with 10 µM glibenclamide alone, 10 µM glibenclamide plus 10 µM
diazoxide or 10 µM glibenclamide plus 30 µM nitrendipine for 48 hr. Glycerol release
was determined as described in materials and methods.* p < 0.01 vs. Control; n=8.
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V. DISCUSSION
We have demonstrated that the sulfonylurea receptor is expressed in human adipose
tissue. We have found that this receptor responds similarly to the pancreatic form of the
receptor to a typical agonist, glibenclamide. Importantly, this receptor mediates
physiological response such as lipogenesis and lipolysis in the adipocytes. These results
implicate the SUR in mediating energy homeostasis in an extrapancreatic tissue and
suggest that the adipocyte SUR may be a suitable system for the identification of novel
anti-obesity agents.
Intracellular Ca 2+ ([Ca 2+]i) appears to play a key role in the metabolic disorders
associated with obesity and insulin resistance and sustained high levels of [Ca2+]imay
contribute to these derangement (1-3). Several reports from our laboratory demonstrated
that [Ca2+]imodulates de nova lipogenesis and lipolysis in both rodent and human
adipocytes (4-7). Sulfonylureas are a family of oral drugs used to promote insulin release
in the treatment of type II diabetes. These insulin secretagogues bind to the sulfonylurea
receptor (SUR) of pancreatic

p cells and then block the conductance

of an ATP-

dependent potassium channel (KATPchannel) (8). The attenuation of potassium current by
blocking this channel depolarizes the

p cells and thereby induces Ca2+ entry via L-type

calcium channels (20), leading to increased insulin secretion (21 ). The SUR is a member
of the ATP- binding cassette proteins, with multiple membrane-spanning domains and
two nucleotide- binding folds (10). The SUR itself does not form the ion-conducting part
of the KATPchannel. However, SUR combines and interacts with an inward-rectifier K+
channel (Kir6.2) to generate KATPchannel(22). Thomas et al (23) reported that familial
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persistent hyperinsulinemic hypoglycemia of infancy (PHHI), an autosomal recessive
disorder characterized by unregulated insulin secretion, was associated with two separate
SUR gene splice site mutations.

Patients treated with glibenclamide frequently experience weight gain as a side effect.
Conversely, reports by Alemzadeh et al. (11-13) showed that diazoxide, which inhibits
SUR by activating

KATP

channels, exerts an anti-obesity effect in obese Zucker rats and

hyperinsulinemic obese humans. These effects of glibenclamide and diazoxide on body
weight have been attributed to their effect on circulating insulin rather than to any direct
effect on adipocytes (11-13). However, our data indicate that these effects may also be
attributable in part to direct effects on the adipocyte SUR and KArP channel.

SUR agonists have previously been demonstrated to exert direct effects on adipocytes.
Draznin et al. (2, 16) reported that glibenclamide increased [Ca2+]i in isolated rat
adipocytes in a dose dependent manner by promoting Ca2+influx through voltagedependent Ca2+ channels, while this effect was blocked by nitrendipine. Moreover,
glibenclamide has been reported to potentiate peripheral insulin effect in isolated
adipocytes (24, 27). These data support our observation of a direct effect of
glibenclamide on adipocyte metabolism. In contrast, Rajan et al. (26) were unable to
identify high affinity SUR in either isolated rat adipocytes or 3T3-Ll adipocytes.
Moreover, they were unable to inhibit

86Rb+ efflux

(a surrogate for KATP channel activity)

or increase [Ca2+]iwith glibenclamide. The reason for this discrepancy is not clear.
However, several other investigators have reported both specific binding of sulfonylurea
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and specific post-receptor effects in murine and rat adipocytes. For example, rat
adipocytes exhibit specific, saturable glibenclamide binding (Ko of 1-3 µM), which is
displaced by other sulfonylureas, and sulfonylurea treatment of isolated rat adipocytes
potentiates insulin receptor of glucose transport (24, 25, 27). Further, Muller et al (28, 29)
reported that glimepiride exhibits specific binding to 3T3-Ll and rat adipocytes, resulting
in an insulin-mediated stimulation of glucose transport and non-oxidative glucose
disposal. These effects were attributed to sulfonylurea-induced inhibition of cAMP level
and protein kinase A activity. Thus, rodent adipocytes appear to exhibit SUR binding and
functional response to this binding.

Similarly, data presented here demonstrate that SUR appears to play an important role in
adipocyte metabolism. We have demonstrated that human adipocytes express SURI by
both RT-PCR and northern blot analysis, while human preadipocytes do not. This
provides a mechanism for SUR agonists and antagonists to modulate [Ca2+]i levels.
Indeed, glibenclamide elicited sustained increases in human adipocyte [Ca2+]i, while
human preadipocytes were not responsive to glibenclamide. Similarly, glibenclamide (10
µM) caused a 67% increase in FAS activity, a 48% increase in GPDH activity and a 68%
inhibition in lipolysis, while diazoxide ( 10 µM) completely prevented each of these
effects. These observations are consistent with our previous reports that modulation of
[Ca2+]i in adipocytes may exert the coordinated regulation oflipogenesis and lipolysis (6,
7). Thus, these data suggest that previous observations of diazoxide-induced weight loss
may be attributed to the effects of this compound on the adipocyte SUR rather than
primarily to effects on insulin release.
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Interestingly, the human chromosome region encoding both the SUR and the associated
inward rectifying K+ channel, 1lp15.l (30) also contains the human homolog of Tubby, a
locus responsible for severe obesity in mice (31 ). Moreover, a significant association was
recently reported between an exon 22 allelic variant of the SUR gene and obesity in
French Caucasians (32). In addition, linkage between the SUR region and a subgroup of
morbidly obese families was also noted (32). Thus, the SUR locus may contribute to
genetic susceptibility to obese (32). Whether this contribution is based on alteration in
insulin secretion or an extrapancreatic role of the SUR is unknown. However, our data
suggest a potential role for the human adipocyte SUR in modulating energy storage and
thereby potentially contribute to obesity.

We conclude that modulation of the human adipocyte SUR results in corresponding
significant modulation of adipocyte energy storage. This provides a potential mechanism
for previous observations of each sulfonylurea induced weight gain and diazoxideinduced weight loss. Our data suggest that diazoxide-induced antagonism of adipocyte
lipogenesis and promotion of lipolysis, possibly coupled with suppression of insulin
release, provide a likely mechanism for the anti-obesity effect of diazoxide. Accordingly,
the human adipocyte SURI appears to represent an important target for further
development of therapeutic intervention in obesity.
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DIETARY CALCIUM ATTENUATES DIET-INDUCED OBESITY IN
aP2-AGOUTI TRANSGENIC MICE
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I.ABSTRACT
Recent data from this laboratory demonstrate that increasing adipocyte intracellular Ca2+
results in a coordinated stimulation of lipogenesis and inhibition of lipolysis. We have
also noted that increasing dietary calcium of obese patients for one-year resulted in a 4.9
kg loss of body fat (p<0.01). Accordingly, we tested the possibility that calcitrophic
hormones may act on adipocytes to increase Ca2+ and lipid metabolism by measuring the
effects of 1,25-(OH)i-D in primary cultures of human adipocytes, and found significant,
sustained increases in intracellular Ca2 + and a corresponding marked inhibition of
lipolysis (EC 50 ~50 pM; p<0.001), suggesting that dietary calcium could reduce
adipocyte mass by suppressing 1,25-(OH)i-D. To test this hypothesis, we placed
transgenic mice expressing the agouti gene specifically in adipocytes on a low (0.4%)
Ca/high fat/high sucrose diet either unsupplemented or with 25 or 50% of the protein
replaced by non-fat dry milk or supplemented to 1.2% Ca with CaCO 3 for six weeks.
Weight gain and fat pad mass were reduced by 26-39% by the three high calcium diets
(p<0.001 ). The high calcium diets exerted a corresponding 51 % inhibition of adipocyte
fatty acid synthase expression and activity (p<0.002) and stimulation oflipolysis by 3.45.2-fold (p<0.015). Thus, increasing dietary calcium suppresses adipocyte intracellular
Ca2+and thereby modulates energy metabolism and attenuates obesity risk.
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II. INTRODUCTION
Intracellular Caz+ plays a key role in the metabolic disorders associated with obesity and
insulin resistance (1-3). Recombinant agouti protein, an obesity gene product, stimulates
Caz+ influx in a variety of cells (4, 5). Agouti also stimulates the expression and activity
of fatty acid synthase, a key enzyme in de nova lipogenesis, and inhibits basal and
agonist-stimulated lipolysis in human and murine adipocytes via a Caz+_dependent
mechanism (6, 7). These effects can be mimicked in the absence of agouti by either
receptor or voltage-mediated Caz+channel activation and inhibited by Caz+ channel
antagonism (6-8), and agouti-induced obesity in transgenic mice was markedly attenuated
by four-weeks of Caz+ channel antagonism (9). Thus, increasing adipocyte intracellular
Caz+ appears to promote triglyceride storage in human adipocytes by exerting a
coordinated control of lipogenesis and lipolysis, serving to simultaneously stimulate the
former and inhibit the latter.

During the course of a previous, unrelated clinical trial investigating the antihypertensive
effect of calcium in obese African Americans, we noted that increasing daily calcium
intake from approximately 400 to 1,000 mg/day for one-year resulted in a 4.9 kg
reduction in body fat. Although these data were inexplicable at the time, our recent data
demonstrating regulation of adipocyte energy storage by intracellular Caz+ leads to the
proposal that increases in circulating calcitrophic hormones (1,25-(OH)z-D and/or
parathyroid hormone) secondary to low calcium diets stimulate adipocyte Caz+ influx and
thereby increase lipid storage. If this is correct, then increasing dietary calcium should
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suppress calcitrophic hormones and thereby reduce adipocyte intracellular Ca2+ and lipid
storage. The present study was conducted to address this concept.
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III. MATERIALS AND METHODS
A. ISOLATION AND CULTURE OF HUMAN ADIPOCYTES
Human subcutaneous adipose tissue was obtained from patients with no known history of
metabolic disorders undergoing abdominal plastic surgery. Adipocytes were isolated by
washing, mincing, collagenase digestion and filtration as previously described (12, 17)
and cultured in Dulbecco's Modified Eagle's Medium supplemented with 1% fetal
bovine serum, penicillin (100 IU/mL), streptomycin (100 µg/mL) and gentamicin (50
µg/mL). Approval for this procedure was obtained from the Institutional Review Board
for Human Subjects of the University of Tennessee. Cells were cultured in suspension
and maintained in a thin layer at the top of the culture media, which was changed every
day. Cells were studied ~ 72 hours following isolation, and were serum-starved prior to
study.

B. ANIMALS AND DIETS
To evaluate the role of dietary calcium in regulating adiposity in vivo, transgenic mice
expressing agouti specifically in adipocytes under the control of the aP2 promoter were
studied. We have previously reported a characterization of these animals. Briefly, they
exhibit a normal pattern ofleptin expression and activity, similar to that found in humans,
and exhibit a human pattern (adipocyte-specific) of agouti expression (10). We have
found these mice to be useful models for diet-induced obesity in that they are not obese
on a standard AIN-93G diet, but become obese in response to hyperinsulinemia induced
by either insulin administration (10) or high sucrose diets (11). Male aP2-agouti
transgenic animals from our colony were placed at six weeks of age on a modified AIN
286

93-G diet with suboptimal calcium (0.4%), sucrose as the sole carbohydrate source and
fat increased to 25% of energy with lard. They were randomized to four groups, as
follows: The basal group continued this diet with no modifications; a high calcium group
received the basal diet supplemented with CaCO 3 to increase dietary calcium three-fold,
to 1.2%; a medium dairy diet, in which 25% of the protein was replaced by non-fat dry
milk, and dietary calcium increased to 1.2%; and a high dairy group, in which 50% of the
protein was replaced by non-fat dry milk, increasing calcium to 2.4%. Food intake and
spillage was measured daily, and animals were weighed weekly. At the conclusion of the
six-week feeding period, animals were euthanized by exsanguination under isofluorane
anaesthesia, and blood was collected via cardiac puncture for glucose and insulin
measurements. Fat pads (epididymal, perirenal, abdominal and subscapular) were
dissected, immediately weighed, frozen in liquid nitrogen, and stored at -80°C. Fatty
acid synthase activity and mRNA levels were measured in abdominal fat as described
below.

C. CORE TEMPERATURE
Core temperature was used as an indirect metabolic index to determine if any reduction in
efficiency of conversion of food energy to body weight was accompanied by increased
thermogenesis (9). Temperature was measured via a thermocouple (Columbus
Instruments, Columbus, Ohio). The probe was inserted a constant distance ( 1.8 cm) into
the rectum of each animal. After stabilization (10 seconds), the temperature was recorded
every 5 seconds for 30 seconds (9). All temperature measurements were made between
8:00 and 9:00 A.M.
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D. INTRACELLULAR CALCIUM (HUMAN ADIPOCYTES)
Intracellular Ca 2 + was determined flourometrically as previously described (17). Cells
were washed with HEPES buffered salt solution, loaded with fura-2-acetoxymethyl ester
(10 µM) for 45 minutes at 37° in the dark with continuous shaking. Cells were then
rinsed three times, resuspended and intracellular Ca 2+ measured using dual excitation
(340 and 380 nm)/single emission (510 nm) fluorometry. Following the establishment of
a stable baseline, the response to 1,25-(OH)z-D or parathyroid hormone (10 pM - 100
nM) or their respective vehicles was determined. Digitonin (25 µM) and Tris/EGT A

(100 mM, pH 8.7) were used to for calibration to calculate the final intracellular Ca 2+.
(18).

E. LIPOL YSIS
Adipocytes were incubated for four hours in the presence or absence of forskolin (1 µM),
and glycerol release into the culture medium was measured (18) to assess lipolysis.
Glycerol release data was normalized for cellular protein.

F. FATTY ACID SYNTHASE ACTIVITY AND mRNA LEVELS
Immediately following sacrifice, adipose tissue was isolated and fatty acid synthase
activity was measured in cytosolic extracts by measuring the oxidation rate of NADPH,
as previously described (6, 9, 17). Enzyme activity was protein corrected using
Coomassie Blue dye.
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Total RNA was extracted by guanidine thiocyanate (GTC) lysis, cesium chloride density
gradient, electrophoresed, subjected to northern blot analysis and hybridized with a
radiolabelled rat cDNA probe for fatty acid synthase using standard methods (6, 12, 17).
Autoradiographs were quantitated densitometrically, and all blots were stripped and reprobed with 13-actinas a loading control.

G. STATISTICAL ANALYSIS
All data are expressed as mean± SD. Data were evaluated for statistical significance by
one-way analysis of variance or t-test, depending upon the number of comparisons made.
All data sets with multiple comparisons were analyzed via ANOV A followed by
separation of significantly different group means via test the least significant difference
using SPSS-PC (v. 8.0).
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IV. RESULTS
Fig. 18 demonstrates that both 1,25-(OH) 2-D and parathyroid hormone (PTH) stimulate
significant, sustained increases in intracellular Ca 2+ in primary cultures of human
adipocytes (p<0.001; EC 5o ~ 50 pM for 1,25-(OHh-D and~ 10 nM for PTH). l,25(OH)2-D treatment also resulted in marked (83%) inhibition of forskolin-stimulated
lipolysis (p<0.001) in human adipocytes (Fig. 19). PTH treatment exerted little effect on
lipolysis (data not shown) despite its stimulation of an intracellular Ca 2+ response, most
likely as a result of an accompanying activation of adenylate cyclase.

Treatment of aP-2-transgenic-agouti mice with the high fat/high sucrose basal diet
resulted in a weight gain of 24%, which was reduced by 26 and 29% by the high calcium
and medium dairy diets, respectively (p<0.04) and further reduced by 39% by the high
dairy diet (p<0.04; Fig. 20). These differences occurred despite the lack of any
difference in food intake. Measurement of core temperature, an indirect metabolic index,
reflected these observations, with ~0.5° C increases in core temperature in response to all
three high calcium diets (p<0.03; Fig. 21). This increase, coupled with the lack of
difference in food intake, is indicative of a shift in efficiency of energy metabolism from
energy storage to thermogenesis.

This shift in energy metabolism was evident in studies of fatty acid synthase, a key
enzyme in de nova lipogenesis which is highly sensitive to regulation by nutrients and
hormones (12). The basal diet caused a 2.6-fold increase in fatty acid synthase activity,
and this effect was markedly attenuated by all three high calcium diets (p<0.002; Fig 22
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Fig 18. Effects of 1,25-(0H)i-D (left panel) and parathyroid hormone (right panel) on
intracellular calcium in human adipocytes.
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Fig 22. Effects of calcium and dairy products on adipocyte fatty acid synthase activity
(upper panel), fatty acid synthase mRNA (middle panel; data are expressed as fatty acid
synthase (FAS):actin ratio.) and lipolysis in transgenic mice expressing agouti in adipose
tissue ynder the control of the aP2 promoter. Data are expressed as mean± standard
deviation (n = 10/group). Statistical significance is as indicated in each panel.
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upper). The diets caused corresponding decreases in adipocyte fatty acid synthase
mRNA, with a 27% reduction on the high calcium diet and a 51 % reduction on the
medium and high dairy diets (p<0.01; Fig. 22 middle). Adipocyte lipolysis responded to
dietary manipulations in an inverse fashion to the fatty acid synthase responses. The
basal diet caused a marked (67%) suppression oflipolysis (p<0.0001); however, lipolysis
was stimulated 3.4-fold to 5.2-fold by the high calcium diets (p<0.015; Fig. 22 bottom),
with greater effects from the high dairy diets than from the high calcium diet.
Assessment of fat pad mass following six weeks of dietary treatment provide further
support for these findings. Table 1 demonstrates that all three high calcium diets caused
a 36% reduction the mass of the epididymal, abdominal, perirenal and subscapular
adipose tissue compartments (p<0.001). Epidymal and subscapular fat pad mass was
reduced by ~50% by all three diets, while the abdominal fat pads exhibited greater
decreases on the medium and high dairy diets than on the high calcium diet (p<0.001;
Table 1).

Serial measurements of plasma glucose and insulin demonstrate a diabetogenic effect of
the basal high fat/high sucrose/low calcium diet, with an increase in fasting glucose from
98±10 to 130±11 mg/dL (p<0.02) and a corresponding degree of compensatory
hyperinsulinemia. These increases were attenuated by the high calcium and medium
dairy diets and prevented by the high dairy diet (Fig. 23).

298

Table 1.

Effects of Calcium and Dairy Products on Fat Pad Mass in Transgenic
Mice Expressing Agouti in Adipose Tissue Under Control of the aP2
Promoter

Basal

High Calcium

Medium Dairy

High Dairy

Abdominal

(g)

2.239±0.109

1.807±0,082*

1.661±0.127**

1.680±0.113**

Perirenal

(g)

1.675±0.124

1.271±0,098*

1.172±0.123*

1.052±0.094*

Epididymal (g)

0.198±0.036

0.110±0.017*

0.110±0.014*

0.097±0.015*

Subscapular(g)

1.592±0.318

0.680±0.069*

0.663±0.068*

0.639±0.087*

Sum 2

5.703±0.548

3.649±0.238*

3.705±0.276*

3.787±0.251 *

(g)

Data expressed as mean ±.standard deviation
of Abdominal, perirenal, epididymal and subscapular fat pads
*p<0.001 vs. basal
**p<0.001 versus high calcium

2 Sum
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Fig 23. Effects of calcium and dairy products on fasting plasma glucose and insulin levels
in transgenic mice expressing agouti in adipose tissue under the control of the aP2
promoter. Top panel depicts insulin and the bottom panel depicts glucose.
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V. DISCUSSION
We have previously shown that agouti, an obesity gene expressed in human adipocytes,
stimulates Ca 2 +influx (4, 5) and promotes energy storage in human adipocytes by
coordinately stimulating the expression and activity of fatty acid synthase, a key enzyme
in de nova lipogenesis, and inhibiting lipolysis in a Ca 2+-dependent fashion (6, 7).
Interestingly, the C-terminus of agouti protein, which retains functional activity in an in

vitro assay system (20), bears a striking spatial homology in number and spacing of
cysteine residues to spider and snail venoms (co-conotoxins, plectoxins), which target
Ca2+channels (21 ). Moreover, this agouti modulation of adipocyte lipid metabolism is
fully mimicked by Ca 2+ channel agonists and inhibited by Ca2+channel antagonists (6-8).
In addition, treating transgenic mice overexpressing agouti with a Ca 2+ channel
antagonist (nifedipine) for four weeks resulted in significant decreases in adipocyte
lipogenesis and an 18% reduction in adipose tissue mass (9). Thus adipocyte Ca 2+
modulates energy storage, suggesting that adipocyte Ca 2+ is a logical target for
pharmacological and/or nutritional regulation of adiposity.

Dietary calcium modulation of intracellular calcium, mediated by suppression of
calcitrophic hormones, has previously been demonstrated to attenuate the risk of
hypertension, and possibly type II diabetes as well (23, 24). Intracellular calcium plays a
key role in multiple related metabolic disorders, including hypertension, cardiac
hypertrophy, insulin resistance and hyperinsulinemia, all of which are commonly
associated with obesity. It is now well recognized that these are not merely co-morbid
factors which occur secondary to obesity, but rather are part of an integrated metabolic
302

syndrome referred to as "Syndrome X " (25), "plurimetabolic syndrome", the "deadly
quartet" (obesity, hypertriglcyeridemia, hypertension and insulin
resistance/hyperinsulinemia), or "generalized cardiovascular and metabolic disease"
(23,24). Regardless of terminology, a growing body of evidence suggests that these
conditions are all characterized by an underlying impairment in intracellular Ca 2+ (1-3,
23, 24, 26-28). Indeed, Resnick (23) has proposed a unifying "ionic hypothesis", in
which the varying metabolic abnormalities associated with "Synrome X" represent
different tissue-specific manifestations of a cellular lesion which is characterized, in part,
by elevations in steady-state intracellular Ca2+levels. Consistent with this concept,
correcting elevations in intracellular Ca2+ results in clinical improvements in blood
pressure, insulin resistance, platelet aggregation, and left ventricular hypertrophy (23).
Our previous studies of the mechanisms of agouti-induced obesity indicate that obesity
may also be, in part, a manifestation of a "lesion" in intracellular Ca2+ regulation (4-7, 9),
and data from the present study lend further support for this hypothesis.

In order for adipocyte Ca 2+ to serve as a logical target for nutritional regulation, human
adipocytes would need to exhibit responsiveness to calcitrophic hormones. Our
observation in the present study that human adipocytes respond to both parathyroid
hormone and 1,25-(OH)i-D with dose-responsive increases in intracellular Ca 2+ suggests
that low Ca 2+ diets, by virtue of stimulating a calcitrophic hormone response, will
increase adipocyte intracellular

ca2+,while higher calcium diets will suppress this

response. Accordingly, a coordinated down-regulation of lipogenesis and up-regulation
of lipolysis would be predicted to result from increasing dietary calcium. Data from the
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present study of transgenic mice over-expressing agouti in adipose tissue to mimic the
human pattern of expression support this prediction, as the obesity promoting effects of
the lard/sucrose-based diet were significantly attenuated on the high calcium and high
dairy diets. These data are further supported by the measurements of fatty acid synthase
mRNA and activity, as well as the lipolysis data. Thus, these data demonstrate that
increasing dietary calcium attenuates diet-induced adiposity by modulating adipocyte
intracellular Ca 2+ and thereby coordinately regulating lipogenesis and lipolysis (6-9).

Dairy and elemental sources calcium exerted qualitatively comparable effects; however,
calcium in the form of dairy exerted a greater effect on attenuating fat deposition than a
comparable quantity of elemental calcium. Consistent with this, a recent randomized
clinical trial demonstrated a markedly greater weight loss (7 .0 vs 1.7 kg) in patients
maintained on a milk-based diet for 16 weeks versus those maintained on conventional
hypocaloric diet at the same level of energy intake (16). Although this difference was
attributed to the novelty of the milk-based diet possibly contributing to a greater level of
compliance, data presented herein suggest that this effect may also be attributable to
suppression of 1,25-(OH)2-D and adipocyte

ca2+,
with a consequent

reduction in the

efficiency of energy utilization. Accordingly, dietary calcium appears to modulate the
efficiency of energy utilization, with low calcium diets favoring increased efficiency of
energy storage and higher calcium diets reducing energy efficiency and instead favoring
increased thermogenesis. This concept is further supported by our observation of
reduced energy efficiency and increased core-temperature in the transgenic mice fed the
higher calcium diets.
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PART6

DIETARY CALCIUM ACCELERATES BODY WEIGHT LOSS IN
ENERGY-RESTRICTED AP2-AGOUTI TRANSGENIC MICE

This manuscript has been published in a similar form with co-authors DiRienzo, D and
Zemel, M. Z. in FASEB. J. express article, online Dec.8, 2000.
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I. ABSTRACT

We have previously demonstrated a regulatory role for intracellular Ca2+ ([Ca 2+]i) in
adipocyte lipogenesis and lipolysis, and recently reported that 1,25-(OH)i-D increases
adipocyte [Ca2+]i, causing increased lipogenesis and decreased lipolysis. We have now
tested the hypothesis that suppressing 1,25-(OH)i-D by increasing dietary Calcium will
suppress adipocyte [Ca2+]i, thereby facilitating weight loss by stimulating lipolysis and
inhibiting lipogenesis in calorically (Kcal)-restricted (70% of ad lib) aP2-agouti
transgenic (aP2-a) mice. Mice (aP2-a) exhibiting a pattern of obesity gene expression
similar to humans were fed a low (0.4%) Ca/high fat/high sucrose diet for 6-weeks,
resulting in a 27% and 2 fold increase in body weight and total fat pad mass, respectively,
with a 2-fold increase in adipocyte [Ca2+]i (p<0.001). Mice were then either maintained
on the same low Ca basal diet ad lib or Kcal-restricted (70% of ad lib) on this diet either
unsupplemented (basal) or with 25 or 50% of the protein replaced by non-fat dry milk
(medium or high) dairy or supplemented with CaCO 3 to 1.2% Ca for 6 weeks. Adipocyte
[Ca2+]i was unaffected by Kcal restriction but was markedly reduced by all three high Ca
diets (290 vs. 130 nM, p<0.001). Body weight was reduced by 11, 19, 25, and 29% by
the restricted basal, high Ca, medium dairy and high dairy diets, with corresponding
decreases in fat pad mass of 8, 42, 60, and 69% vs. ad lib basal (p<0.001), respectively.
The high Ca diets caused similar decreases in fatty acid synthase activity 35-63%,
p<0.001), increases in lipolysis (2-3 fold, p<0.001). All three high Ca diets increased
adipocyte uncoupling protein 2 expression ~2 fold (p<0.02), with a corresponding
increase in core temperature (0.48-0.67

°c,p<0.05).
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Thus, high Ca diets suppress

adipocyte [Ca2+]i and thereby reduce energy storage and increase thermogenesis during
Kcal restriction.
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II. INTRODUCTION
Intracellular Ca 2+ ([Ca 2+]i) plays a key role in the metabolic disorders associated with
obesity and insulin resistance (1-3). Recombinant agouti protein, an obesity gene product,
causes a dose responsive increase in [Ca2+]i in a variety of cells, including both human
and murine adipocytes (4, 5). Agouti protein has also been shown to stimulate the
expression and activity of fatty acid synthase (FAS), a key enzyme in de novo
lipogenesis, and inhibit basal and agonist-simulated lipolysis in a Ca2+ dependent manner
(6, 7). These effects of agouti in promoting lipogenesis and suppressing lipolysis can be
mimicked by Ca 2+ channel activation and reversed by Ca2+ channel antagonism (6, 7).
Therefore, increasing adipocyte [Ca2+]i appears to promote triglyceride accumulation in
adipocytes by exerting a coordinated control over stimulation of lipogenesis and
inhibition of lipolysis, thereby resulting in an obese phenotype.

Recent data from our laboratory demonstrate that 1,25-dihydroxyvitamin D (1,25-(OH) 2D) causes a significant, sustained increase in [Ca2+]i in primary cultured human
adipocytes and a corresponding inhibition of lipolysis (8). We also reported that
inhibition of 1,25-(OH)z-D by increasing dietary calcium suppresses [Ca2+]i and
subsequently attenuates diet-induced adiposity by simultaneously stimulating lipolysis
and inhibiting lipogenesis (8). Consistent with this, increasing dietary calcium from 400
to 1000 mg/day in humans for 1-year results in a 4.9 kg body fat reduction (8), suggesting
that dietary calcium may not only attenuate the diet-induced development of adiposity but
also promote weight loss in established obesity.
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Accordingly, the present study was conducted to test the hypothesis that suppressing
1,25-(0H)z-D by increasing dietary calcium inhibits adipocyte [Ca 2+]i, and thereby
accelerates weight loss secondary to caloric restriction in aP2-agouti transgenic mice
exhibiting a pattern of obesity gene expression similar to humans.
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III. MATERIALS AND METHODS
A. ANIMALS AND DIETS
aP2-agouti transgenic (aP2-a) mice from our breeding colony were used as an animal
model in this study. This study was approved from an ethical standpoint by the
University of Tennessee Institutional Animal Care and Use Committee. The
characterization of these animals has been described previously (9). These transgenic
mice express normal agouti protein specifically in adipose tissue under the control of the
aP2 promoter (9), similar to the adipocyte-specific human pattern of agouti expression.
These mice are useful animal model for the study of diet-induced obesity study, as they
are not obese on a standard AIN 93-G diet, but become obese in response to
hyperinsulinemia induced by either exogenous insulin administration (9) or high sucrose
diet (10).

This study was divided into two 6-week stages. In the first stage, 60 6-week-old male aP2
mice were placed on a modified AIN 93-G diet with suboptimal calcium (0.4%), sucrose
as the sole carbohydrate source and lard added to increase fat to 25% of energy. To
evaluate this low calcium/high fat/high sucrose diet-induced obesity in these animals, we
monitored the body weight every 5 days and euthanized 8 representative mice for
measurement of fat pad mass and adipocyte [Ca2+]i at the end of first 6 week-basal diet
feeding. In the second 6-week stage, the rest of these diet-induced obese transgenic mice,
weighing from 45.44 ± 0.81 g, were randomly assigned to five groups. One group was
continued ad lib on the same low calcium (0.4%) diet with no modification, while the
other four groups were maintained with energy restriction (70% of ad lib) as follows. The
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mice in basal restriction group were placed on the basal low calcium (0.4%) diet with
energy-restriction. A high calcium energy restricted group received the basal diet
supplemented with calcium increased to 1.2%. Two additional groups, termed medium
dairy and high dairy, were fed modified basal diet in which either 25 or 50% of protein
was replaced by non-fat dry milk, with total dietary calcium increased to 1.2 or 2.4%,
respectively. Diet was administrated daily and body weight was monitored every five
days. At the end of second stage, all mice were euthanized with beuthanasia
(concentrated pentobarbital with phenytoin) and blood was obtained via cardiac puncture
for insulin and glucose measurement. Fat pads (epididymal, perirenal, abdominal and
subscapular) were dissected, immediately weighed, frozen in liquid nitrogen, and stored
at -80

°c.Fatty

acid synthase activity and mRNA levels were measured in abdominal fat

as described below.

B. CORE TEMPERATURE
Core temperature was used as an indirect metabolic index to determine if dietary calcium
regulates energy metabolism associated with increased thermogenesis, an important
contribution to energy expenditure. Temperature was measured via a thermocouple
(Columbus Instruments, Columbus, Ohio) weekly (11). The probe was inserted a constant
distantance (1.8 cm) into the rectum of each mouse. After stabilization (10 seconds), the
temperature was recorded every 5 seconds for 30 seconds. All core temperature
measurements were performed between 8:00 and 9:00 A.M.
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C. MOUSE ADIPOCYTE INTRACELLULAR Ca 2 + MEASUREMENT
Isolated mouse adipocytes were prepared from mouse abdominal fat depots as previously
described (12) with slight modification. Briefly, adipose tissue was first washed several
times with Hank's Balanced Salt Solution, minced into small pieces and digested with 0.8
mg/ml type I collagenase in a shaking water bath at 37 °c for 30 min. Adipocytes were
then filtered through a sterile 500 µm nylon mesh and cultured in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 1% fetal bovine serum (FBS). Cells were
cultured in suspension and maintained in a thin layer at the top of culture media for two
hours for cell recovery.

[Ca2+]iin isolated mouse adipocytes was measured using a fura-2 dual wavelength
fluorescence imaging system (13). Prior to [Ca2+]i measurement, adipocytes were preincubated in serum-free medium for 2 hrs and rinsed with Hepes Balanced Salt Solution
(HBSS) containing the following components (in mmol/L): NaCl 138, CaCii 1.8, MgSO 4
0.8, NaH 2PO 4 0.9, NaHCO 3 4, glucose 5, glutamine 6, Hepes 20, and bovine serum
albumin 1%. Adipocytes were loaded with fura-2 acetoxymethyl ester (AM) (10 µmol/L)
in the same buffer for 1 hr at 37 °c in a dark incubator with 5% CO 2 • To remove
extracellular dye, adipocytes were rinsed with HBSS 3 times and then post-incubated at
room temperature for an additional 30 min for complete hydrolysis of cytoplasmic fura-2
AM. A thin layer of adipocytes was plated in 35 mm dished with glass coverslips (P35G0-14-C, MatTek Corporation). The dishes with dye-loaded cells were mounted on the
stage of Nikon TMS-F fluorescence inverted microscope with a Cohu 4915 CCD camera.
Fluorescent images were captured alternatively at excitation wavelength of 340 and
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380nM with an emission wavelength of 520 nM. [Ca 2+]i was calculated using a ratio
equation as described previously(14).

D. FATTY ACID SYNTHASE ACTIVITY ASSAY
FAS activity was determined spectrophotometrically in crude cytosolic extracts of mouse
adipose tissue as previously described (15). Mouse abdominal fat pads were
homogenized in 250 mmoVL sucrose solution containing 1 mmoVL ethylenediaminetetraacticacid (EDT A), 1 mmoVL dithiothreitol (DTT), and 100 µmoVL
phenylmethylsulfonyl fluoride (PMSF) (pH 7.4). Homogenate was centrifuged at 18,500
X g for 1 hr and the infranatant was used for measuring oxidation rate ofNADPH.

E. LIPOL YSIS ASSAY
Following the sacrifice, mouse perirenal adipose tissue was immediately dissected and
incubated for four hours. Glycerol released into the culture medium was determined as an
indicator of lipolysis (7), using a one-step enzymatic fluorometric method as previously
described (16).

F. NORTHERN BLOT ANALYSIS
Northern blot analysis was conducted as described (13). Total RNA from mouse
abdominal adipose tissue was extracted using CsClz density centrifugation, run in 1%
agarose gel and transferred to nylon membrane (New England Nuclear, Boston, MA).
The membrane was hybridized with uncoupling protein 2 (UCP2) or FAS cDNA probes
that were radiolabeled using a random primer method. Unbound probe was removed by
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rinsing the membrane with 2X SSC/ 0.1% SDS for 30 min at room temperature and 0. IX
SSC IO. I% SDS for 45 min at 55 °c.Finally, the membrane was exposed to X-ray film
(New England Nuclear, Boston, MA) at -80

°c.All membranes

were stripped and

reprobed with 13-actinas loading control.

G. STATISTICAL ANALYSIS
All data are expressed as mean ± SE. Data are evaluated for statistical significance by one
way Analysis of Variance (ANOVA), and significantly different group means were then
separated by the least Significant Difference (LSD) test using SPSS (SPSS Inc, Chicago,
IL). A p value< 0.05 is considered significant.
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IV. RESULTS
Administration of the low calcium (0.4%), high-fat, high sucrose diet to aP2-a mice for 6
weeks resulted in a ~100% increase in adipocyte [Ca 2 +]i (128 ± 18 vs. 267 ± 15 nM, p <
0.001, lower panel, Fig 24), with a corresponding body weight gain of29% (p < 0.001,
upper panel, Fig 24) and two fold increase in total fat pad mass (p < 0.001, middle panel,

Fig 24), demonstrating that diet-induced dysregulation of adipocyte [Ca 2+]i is associated
with increased adiposity in aP2-a mice.

All three calcium diets, including high calcium diet (1.2% Ca derived from CaCO 3),
medium dairy diet (1.2% Ca derived from non-fat dry milk replacing 25% of protein) and
high dairy diet (2.4% Ca derived from non-fat dry milk replacing 50% of protein), caused
a 50% decrease in adipocyte [Ca2+]i (p < 0.001, Fig 25, lower panel), while [Ca 2+]i in
adipocytes from mice maintained on the Kcal-restricted basal low calcium diet remained
at the same elevated level as that of ad lib animals

Energy restriction resulted in a body weight loss by 11% (p < 0.001, Fig 25, upper
panel), compared to ad lib group. However, markedly greater weight reductions of 19,
25, 29% were observed in the high calcium, medium and high dairy groups, respectively
(p < 0.01 vs. basal energy-restricted group, Fig 25). Consistent with this, energy

restriction caused an only 8% decrease in fat pad mass (not significant), compared to
basal diet ad lib group, while the high calcium diet caused a 42% decrease (p < 0.001,

Fig 25, middle panel), which was further reduced by 60 and 69% by the medium and
high dairy diets (p < 0.001 vs. basal energy-restricted group), respectively.
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Fig 24. Effects of 6-week administration of basal low Calcium (0.4%)/high fat/ high
sucrose diet on body weight (top panel), total fat pad mass (middle panel) and basal
adipocyte [Ca2+]i ( lower panel) in aP2-agouti transgenic mice. Diet and animal
administration was conducted as described in Materials and Methods. Data are expressed
as mean± SE (n = 8/group). * p < 0.001 vs. before administration.
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Fig 25. Effects of 6-week administration of high calcium diets on weight reduction (upper
panel), fat pad mass (middle panel) and basal adipocyte [Ca 2+]i (lower panel) in energyrestricted (70% of ad lib) aP2-agouti trangenic mice. Diet and animal administration was
conducted as described in Materials and Methods. Data are expressed as mean± SE (n =
8).
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Dairy

Fig 26 (upper panel) demonstrates that the high calcium diet caused a 35% decrease in

fatty acid synthase (FAS) activity (p < 0.05 vs. basal energy-restricted group), which was
further reduced by 63 and 62% by the medium and high dairy diets (p < 0.05),
respectively. Similarly, the three high calcium diets caused corresponding decreases in
adipocyte FAS mRNA, with 61 %, 72% and 81% reductions on high calcium, medium
dairy and high dairy diets, respectively (p < 0.05 vs. basal energy-restricted group, Fig
26, middle panel). Increasing dietary calcium caused a corresponding increase in

lipolysis. Although the basal energy restricted diet did not affect adipocyte lipolysis, the
high calcium diet caused 77% stimulation in lipolysis (p < 0.05. Fig 26, lower panel),
which was further increased in the medium and high dairy diet groups (p < 0.05 vs. basal
energy-restricted group). Increased lipolysis, coupled with decreased lipogenesis, may
represent a metabolic state in which the efficiency of energy metabolism is shifted from
energy storage to energy expenditure.

This shift in energy metabolism was further confirmed by dietary calcium-induced
increase in core temperature. All three high calcium diets exerted stimulatory effects on
core temperature, with 0.48 °c,0.57 °c and 0.67 °c increases on the high calcium,
medium dairy and high dairy diets, respectively (p < 0.05, table 2), while the basal
energy restricted diet did not affect core temperature. A possibly physiological basis
underlying the increased core temperature is that the expression of uncoupling protein 2
(UCP2), which has been implicated in thermogenesis (17, 18), was up-regulated in white
adipose tissue, with 80% increase on all three high calcium diets (p < 0.05, Fig 27).
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Fig 26. Effects of 6-week administration of high calcium diets on fatty acid synthase
activity (upper panel), fatty acid synthase mRNA (middle panel) and lipolysis (lower
panel) in energy-restricted (70% of ad lib) aP2-agouti trangenic mice. Diet and animal
administration was conducted as described in Materials and Methods. Glycerol release is
used to measure lipolysis, as described in Materials and Methods. Data are expressed as
mean± SE (n = 8).
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Table 2. Effects of 6-week administration of high calcium diets on core temperature
in energy-restricted (70% of ad lib) aP2-agouti transgenic mice.

Core temperature (°C)
Groups (n=8)

Before

After

Control (ad lib)

37.26 ± 0.24

36.56 ± 0.24

Control (restriction)

37.43 ± 0.19

37.30 ± 0.12

High Ca

37.11 ±0.24

37.59 ± 0.13*

Medium dairy

37.28 ± 0.14

37.85 ± 0.11 * +

High dairy

37.27 ± 0.14

37.94 ± 0.15*

+

Diet and animal administration was conducted as described in Materials and Methods.
Data are expressed as mean± SE (n=8/group ). * p<0.05 vs. before treatment; + p<0.05
vs. basal diet.
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Fig 27. Effects of 6-week administration of high calcium diets on abdominal adipose
tissue uncoupling protein 2 (UCP2) expression in energy-restricted (70% of ad lib) aP2agouti trangenic mice. Diet and animal administration was conducted as described in
Materials and Methods. Upper panel: a representative northern blot from 8 replicates;
lower panel: quantitative analysis of UCP2/actin mRNA density units. Data are
expressed as mean± SE (n = 8/group).

* p < 0.05 vs. basal diet.
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The basal low calcium diet exerted a hyperinsulinemic effect, with a doubling of plasma
insulin levels (p <0.001, Figure 5). The mice maintained on this basal diet ad lib
exhibited sustained levels of hyperinsulinemia, while energy restriction per se reduced
plasma insulin by approximately 50%. The high calcium diets did not further
significantly affect insulin levels, although there was a non-significant trend towards
further reductions (p=0. l, Fig 28).
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Fig 28. Effect of dietary calcium on plasma insulin levels. Diet and animal administration
was conducted as described in Materials and Methods. Data are expressed as mean ± SE
(n = 8/group).
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vs. before basal diet treatment;+ p < 0.001 vs. ad lib.
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V. DISCUSSION
Obesity is closely related to other metabolic disorders, including insulin
resistance/hyperinsulinemia, hypertension and cardiac hypertrophy. These diseases are
integrated into a metabolic syndrome referred to as "Syndrome X" (19). To explain these
tightly interacting abnormalities, Resnick (20) proposed a unifying "ionic hypothesis", in
which a common cell lesion underlying these disorders in different tissues was
characterized, in part, by elevations in steady-state [Ca2+]ilevels. Consistent with this,
sustained elevations of [Ca2+]ihave been observed in vascular smooth muscle cells,
platelets and erythrocytes in patients with hypertension (20-24), skeletal muscle cells and
adipocytes in patients with insulin resistance (1, 2), and cardiomyocytes in patients with
left ventricular hypertrophy (20). Moreover, antagonism of Ca 2+ influx results in
improvements in blood pressure, platelet aggregation, insulin resistance, and left
ventricular hypertrophy (20).

Draznin et al (2) first reported that obese patients exhibited a elevation in basal adipocyte
[Ca2+]i. The physiological consequence of this elevation in adipocyte [Ca2+]i was
addressed by our later studies demonstrating that increasing [Ca2+]i via activation of
either receptor or voltage-mediated calcium channels stimulates expression and activity
of fatty acid synthase (FAS), a key enzyme in de nova lipogenesis, and inhibits basal and
agonist-stimulated lipolysis in both human and murine adipocytes (6, 7). These effects
can be reversed by calcium channel antagonism (6, 7). In addition, modulation of [Ca2+]i
play a role in mediating both lipolytic and antilypolytic actions of hormones in
adipocytes (25-28). Therefore, increasing [Ca 2+]i appears to promote triglyceride storage
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in adipocytes by exerting coordinated control over lipogenesis and lipolysis, serving to
simultaneously stimulate the former and suppress the latter, and thereby cause lipid
filling.

Other endocrine and/or paracrine hormones that modulate human adipocyte [Ca2+]ialso
modulate adipocyte lipid metabolism. Agouti protein, an obesity gene product that is
expressed in human adipose tissue and stimulates Ca 2+ influx (4, 5), simultaneously
stimulates the expression and activity of fatty acid synthase (FAS) and inhibits basal and
agonist-stimulated lipolysis via a Ca2 + dependent mechanism (6, 7). Moreover, we
recently demonstrated that agouti expression is highly correlated with in vivo FAS
expression and activity in human adipose tissue (29), suggesting that agouti protein, a
physiological Ca 2+ agonist, may play a role in human obesity. In addition, we have
recently reported that the calcitrophic hormone 1,25-(0H)i-D, which has been previously
shown to stimulate [Ca2+]iin both vascular smooth muscle cells and pancreatic 13cells
and play a role in development of hypertension and hyperinsulinemia, respectively (30,

31), also acts on human adipocytes to cause a sustained increase in [Ca 2+]iand a
corresponding marked inhibition oflipolysis (8). Further, several lines of evidence
demonstrated that circulating 1,25-(0H) 2 -D level is increased in obese humans (32-35),
further suggesting that increased 1,25-(0H)i-D may exert effects in human obesity in
VIVO.

Accordingly, antagonism of [Ca2+]iby either blocking Ca2+ channels or inhibiting Ca2+
agonists is an attractive and logical approach for development of therapeutic intervention
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in obesity. Indeed, calcium channel blockade has been proven to reduce body weight and
fat pad mass effectively in several animal models. We previously reported that treating
transgenic mice overexpressing agouti with a Ca2+ channel antagonist (nifedipine)
resulted in significant decreases in adipocyte lipogenesis and reduction in adipose tissue
mass (11). Similarly, Ca2+ channel antagonists, such as nifendipine, verapamil and
felodipine, caused decreases in body weight and fat pad mass in obese SHHF/Mcc-facp
rats (36, 37).

In present study, antagonism of [Ca2+]iwas achieved through a dietary intervention,
increasing dietary calcium. This approach has previously been demonstrated to suppress
1,25-(OH)i-D levels in multiple studies (20, 38). Accordingly, we proposed that dietary
calcium suppression of 1,25-(OH)i-D would reduce adipocyte [Ca2+]i and thereby inhibit
triglyceride accumulation.

Although Metz et al. (39) and Bursey et al. (40) previously reported that increased dietary
calcium reduced body weight and body fat composition in spontaneously hypertensive
rats, Wistar-Kyoto rats and lean and obese Zucker rats, they were unable to demonstrate
the mechanism involved in this adiposity modulation. Although some investigators have
attributed the effect of dietary calcium on lipid metabolism to potential inhibition of
dietary fatty acid absorption, significant feed caloric losses do not result from moderate
increases in dietary calcium. Indeed, data presented in this study demonstrate that
increasing dietary calcium inhibits adipocyte [Ca2+]i, thereby facilitating weight loss by
simultaneously stimulating lipolysis and inhibiting lipogenesis in energy restricted aP2-a
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transgenic mice. Consistent with this, we previously found that increasing dietary
attenuated the development of diet-induced obesity in aP2-agouti transgenic mice (8).
Increasing dietary calcium resulted in increased adipocyte lipolysis and suppression of
lipogenesis (8), similar to our observations in the present study. Accordingly, these data
extend our previous observations by demonstrating that dietary calcium not only
attenuates diet-induced obesity but also accelerates weight loss and fat mass reduction
secondary to caloric restriction in established obesity. It is noteworthy that dairy and
elemental calcium exerted qualitatively comparable effects; however, quantitatively, the
effects were significantly different. Calcium in the form of dairy exerted a markedly
greater effect on lipid metabolism and corresponding body weight/adipose tissue mass
reduction compared to a comparable quantity of elemental calcium. The reason for this
difference is not yet apparent, although it is consistent with our previous observations (8).

Interestingly, dietary calcium not only modulates lipid metabolism involved in
lipogenesis and lipolysis, but also causes an increased expression of white adipose tissue
uncoupling protein 2 (UCP2), which has been implicated in thermogenesis (17, 18), and a
corresponding higher core temperature, an indirect metabolic index associated with
thermogenesis. The contribution ofthermogenesis to anti-obesity action of Ca 2+ channel
blockade has been addressed in previous studies (41, 42). However, this mechanism
remains controversial in that some investigators have attributed the thermogenic effect of
Ca2+ channel blockade to the increased function of brown adipose (41, 42). In fact, we
have also previously observed an increased core temperature in agouti-overexpressing
Avymice treated with L-type Ca2+ channel antagonist nifendipine (11). Although this
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action was inexplicable at the time, our present data in this study suggest that upregulation ofUCP2 expression may be responsible. However, further study is required to
address the precise mechanism whereby dietary calcium regulates UCP2 expression.
Although this up-regulation ofUCP2 expression may result directly from inhibition of
[Ca2+]i, it is also possible that it is merely a result of increased substrate (fatty acid) flux
secondary to increased lipolysis.

Ad lib feeding of the basal low calcium diet caused sustained hyperinsulinemia in the
aP2-agouti transgenic mice. We previously found that increasing the level of calcium
intake resulted in reductions in circulating insulin in both obese humans and aP2
transgenic mice (8), suggesting that suppression of insulin might contribute to the antiobesity effect of dietary calcium. However, data from the present study demonstrate that
energy restriction per se reduced the plasma insulin levels and that increasing dietary
calcium did not further reduce insulin levels but nonetheless exerted potent effects on
body weight loss and fat pad mass reduction. Thus, the effects of dietary calcium on
accelerating weight lost are not due to insulin suppression and instead are likely to result
from the observed suppression of adipocyte [Ca 2+]i and modulation of adipocyte lipid
metabolism.

Limited data suggest that these findings are relevant to humans. Data from our earlier
clinical trial investigating the anti-hypertensive effect of calcium in obese African
Americans demonstrated that increasing daily calcium intake from approximately 4001,000 mg/day for one-year resulted in a 4.9 Kg reduction in body fat (8). Consistent with
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this, a recent randomized clinical trial demonstrated a greater weight loss in patients
maintained on a milk-based diet for 16 weeks, compared to those on conventional
hypocaloric diet at the same energy intake (43). These studies are further supported by
our population-based observation in NHANES III, which demonstrate a profound
reduction in the odds of being in the highest quartile of adiposity associated with
increases in calcium and dairy product intake (8).

In summary, high calcium diets exert potent effects in enhancing reduction of body
weight and fat pad mass in energy-restricted aP2-agouti transgenic mice. High calcium
diets suppressed adipocyte [Ca2+]i,stimulated lipolysis, inhibited lipogenesis, and caused
an increased white adipose tissue uncoupling protein 2 (UCP2) expression and a
corresponding increase in core temperature. Consequently, dietary calcium facilitates
reduction of fat tissue mass and body weight in Kcal restriction by modulating energy
metabolism, serving to reduce energy storage and increase thermogenesis. These data
may provide a useful framework for further development of effective dietary intervention
in obesity.
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I. ABSTRACT
We recently reported that suppression of the renal la,25-dihyroxyvitamin

D3 (la,25-

(OH)i-D3) production in aP2-agouti transgenic mice by increasing dietary calcium
decreases adipocyte intracellular Ca2+ ([Ca2+]i), stimulates lipolysis, inhibits lipogenesis,
and reduces adiposity. However, it was not clear whether this modulation of adipocyte
metabolism by dietary calcium is a direct effect of inhibition of 1a,25-(OH) 2-D3 induced
[Ca2+]i. Accordingly, we have now evaluated the direct role of la,25-(OH) 2-D3. Human
adipocytes exhibited a la,25-(OH}i-D 3 dose-responsive (1-50 nM) increase in [Ca2+]i
{p<0.01). This action was mimicked by la,25-dihyroxylumisteroh

(la,25-(OH)

2-

lumisteroh) (p<0.001), a specific agonist for a putative membrane vitamin D receptor
(mVDR), and completely prevented by 1J3,25-dihydroxyvitamin D 3 (1J3,25-(OH)2-D3), a
specific antagonist for the mVDR. Similarly, la,25-(OH}i-D 3 (5 nM) caused 50-100%
increases in adipocyte fatty acid synthase (FAS) expression and activity (p<0.02), a 61 %
increase in glycerol-3-phosphate dehydrogenase (GPDH) activity (p<0.01), an 80%
inhibition

of isoproterenol-stimulated

lipolysis

(p<0.001),

while

1J3,25-(OH)2 -D3

completely blocked all these effects. Notably, la,25-(OH) 2 -lumisteroh exerted more
potent effects in modulating adipocyte lipid metabolism, with 2.5-3.0 fold increases in
FAS expression and activity (p<0.001), a 3 fold increase in GPDH activity (p<0.001),
and was approximately twice as potent in inhibiting basal lipolysis (p<0.025), whereas
1J3,25-(OH)2-D3 completely blocked all these effects. These data suggest that la,25(OH}i-D3 modulates adipocyte Ca2+ signaling and, consequently, exerts a coordinated
control over lipogenesis and lipolysis. Thus, a direct inhibition of la,25-(OH)i-D 3
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induced [Ca 2+]i may contribute to an anti-obesity effect of dietary calcium, and the
m VDR may represent an important target for obesity.
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II. INTRODUCTION

Intracellular Ca 2+ ([Ca 2+]i) plays a key role in metabolic disorders associated with obesity
and insulin resistance (1-3). We previously reported that increasing [Ca 2+]i via
stimulation of either receptor or voltage-mediated calcium channels stimulates the
expression and activity of fatty acid synthase (FAS), a key enzyme in de nova
lipogenesis, and inhibits basal and agonist-stimulated lipolysis in both human and murine
adipocytes (4-9). Therefore, increasing [Ca2+]i appears to promote triglyceride
accumulation in adipocytes by exerting a coordinated control over lipogenesis and
lipolysis, serving to simultaneously stimulate the former and inhibit the latter.

la,25-dihyroxyvitamin

D3 (la,25-(0H)z-D 3) was originally believed to solely function

via a nuclear vitamin D receptor (nVDR) to generate genomic action (10). However, this
concept was challenged by recent studies revealing that it also generates rapid,
nongenomic signal transductions including stimulation of [Ca 2+]i via a putative
membrane vitamin D receptor (mVDR) in a wide variety of cells (11-15).

la,25-(0H)z-D 3 is a highly conformationally flexible molecule and is able to rotate
around its 6, 7 carbon-carbon bond of Bring. This rotation allows generation of a
continuum of potential ligand shapes ranging from the steroid like 6-s-cis conformation
to the extended 6-s-trans conformation (16, 17). Thus, this conformational flexibility of
la,25-(0H) 2-D 3 in a structure and function context underlies the mechanism whereby
la,25-(0H) 2-D 3 generates both genomic and non-genomic cellular responses. It is also
suggested that analogs of la,25-(0H)2-D3 with different conformations differ in their
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abilities to mediate biological responses (16, 17). Indeed, analogs of la.,25-(OH)i-D 3
have been extensively examined for their ability to generate genomic or non genomic
biological responses (16, 17). la.,25-dihydroxylumisteroh, a 6-s-cis-locked analog of
la.,25-(OH)z-D 3, preferentially exerts a non-genomic action, including stimulation of
Ca 2+ influx, via the putative mVDR (18, 19). Another A-ring diastereomer analog, 113,25dihyroxyvitamin D 3, has been demonstrated to antagonize this action but has no effects
on the nVDR (20, 21). Therefore, la.,25-dihydroxylumisteroh is a specific agonist of
non-genomic action, while lj3,25-dihyroxyvitamin D 3 is a specific antagonist of nongenomic action.

We recently demonstrated that increasing dietary calcium decreases adipocyte
intracellular Ca 2+, stimulates lipolysis, inhibits lipogenesis, and thereby reduces adiposity
in aP2-agouti transgenic mice (22, 23). However, although high calcium diets are
associated with suppression of circulating la.,25-(OH)2-D3, it is not clear whether this
modulation of adipocyte metabolism by dietary calcium is a direct effect of inhibition of
la.,25-(OH)i-D 3 induced [Ca2+]i- Accordingly, the present study was designed to
determine the direct role of la.,25-(OH) 2-D 3 in modulating adipocyte Ca2+ signaling and
lipid metabolism.
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III. MATERIALS AND METHODS
A. CULTURE OF HUMAN ADIPOCYTES

A human adipocyte cell line and primary-cultured human adipocytes were both used as
cell models in this study. The human adipocyte cell line was differentiated from human
preadipocytes obtained from Zen-Bio Inc (Research Triangle Park, NC). Human
preadipocytes were inoculated in Dulbecco's Modified Eagle' Medium (DMEM) / Ham'
F-10 medium (F-10) (1:1, v/v) containing 10% fetal bovine serum (FBS), 15mM Hepes
and antibiotics at a density of 30,000 cells/cm 2 • Confluent monolayers of preadipocytes
were induced to differentiate with a standard differentiation medium consisting of
DMEM/F-10 (1:1, v/v) medium supplemented with 15 mM Hepes, 3% FBS, 33 µM
biotin, 17 µM pantothenate, 100 nM insulin, 0.25 mM methylisobutylxanthine (MIX), 1
µM dexamethasome, 1 µM BRIA9653 and antibiotics. Preadipocytes were maintained in
this differentiation medium for 3 days and subsequently cultured in adipocyte medium in
which BRL49653 and MIX were withdrawn. Cultures were refed every 2-3 days (24).

Primary-cultured human adipocytes were derived from human subcutaneous adipose
tissue obtained from patients undergoing abdominal plastic surgery with no known
history of metabolic disorders. This protocol was approved by the Institutional Review
Board for Human Subjects and the Committee for Research Participation of the
University of Tennessee. Adipocytes were isolated as previously described (25). Briefly,
adipose tissue was first washed several times with Hank's Balanced Salt Solution,
minced into small pieces and digested with 1 mg/ml typel collagenase in a shaking water
bath at 37 °c for 30 min. Adipocytes were then filtered through a sterile 500 µm nylon
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mesh and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with
1% fetal bovine serum (FBS), 100 UI/ml penicillin, 100 µg/ml streptomycin and 50
µg/ml gentamicin. Cells were cultured in suspension and maintained in a thin layer at the
top of culture media, which were changed every day. Cells were maintained viable and
metabolically responsive under this culture condition for 7 days.

B. HUMAN ADIPOCYTE INTRACELLULAR Ca2+ MEASUREMENT
[Ca2+]i in human preadipocytes was measured using a fura-2 dual wavelength
fluorescence imaging system (24). Preadipocytes were plated and differentiated in 35 mm
dishes with glass coverslips (P35G-0-14-C, MatTek Corporation). Prior to [Ca2+]i
measurement, cells were preincubated in serum-free medium overnight and rinsed with
Hepes Balanced Salt Solution (HBSS) containing the following components (in mM):
NaCl 138, CaCh 1.8, MgSO4 0.8, NaH2PO4 0.9, NaHCO3 4, glucose 5, glutamine 6,
Hepes 20, and bovine serum albumin 1%. Cells were loaded with fura-2 acetoxymethyl
ester (AM) (10 µM) in the same buffer for 2 hr at 37 °c in a dark incubator with 5% CO2.
To remove extracellular dye, cells were rinsed with HBSS 3 times and then postincubated
at room temperature for an additional 1 hr for complete hydrolysis of cytoplasmic fura-2
AM. The dishes with dye-loaded cells were mounted on the stage of Nikon TMS-F
fluorescence inverted microscope with a Cohu 4915 CCD camera. Fluorescent images
were captured alternatively at excitation wavelength of 340 and 380nM with an emission
wavelength of 520 nM. After establishment of stable image baseline, the response to
la,25-(OH)2-D3 and its membrane receptor (mVDR) agonist la,25dihydroxylumisteroh (la,25-(OH) 2-lumisteroh), was determined. [Ca2+]i was calculated
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using a ratio equation (26). Each analysis evaluated responses of 8-10 representative
whole cells. Images were analyzed with InCytlm2 version 4.62 imaging software
(Intracellular Imaging, Cincinnati, OH). Images were calibrated using a fura-2 calcium
imaging calibration kit (Molecular Probes, Eugene, OR) to create a calibration curve in
solution, and cellular calibration was accomplished using digitonin (25 µM) and pH 8.7
Tris-EGTA (100 mM) to measure maximal and minimal [Ca2+]i levels.

C. FATTY ACID SYNTHASE AND GLYCEROL-3-PHOSPHATE
DEHYDROGENASE ACTIVITY ASSAY
FAS and GPDH activity was determined spectrophotometrically in crude cytosolic
extracts of human adipocytes as previously described (25). Human adipocytes were
homogenized in 250 mmol/L sucrose solution containing 1 mmol/L ethylenediaminetetraacticacid (EDT A), 1 mmol/L dithiothreitol {DTT), and 100 µmol/L
phenylmethylsulfonyl fluoride (PMSF) (pH 7.4). The homogenate was centrifuged at
18,500 X g for 1 hr and the infranatant was used for measuring oxidation rate ofNADPH
or NADH, respectively.

D. LIPOLYSIS ASSAY
Glycerol released into the culture medium was determined as an indicator of lipolysis,
using a one-step enzymatic fluorometric method as previously described (8, 27).
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E. NORTHERN BLOT ANALYSIS
Northern blot analysis was conducted as previously described (25). Total RNA from
human adipose tissue was extracted using CsCh density centrifugation, run in 1%
agarose gel and transferred to nylon membranes (New England Nuclear, Boston, MA).
The membrane was hybridized with FAS cDNA probes that were radio labeled using a
random primer method. Unbound probe was removed by rinsing the membrane with 2X
SSC/ 0.1 % SDS for 30 min at room temperature and O.lX SSC/ 0.1 % SDS for 45 min at
55 °c.Finally, the membrane was exposed to X-ray film (New England Nuclear, Boston,
MA) at -80

°c.All membranes were stripped and reprobed with 13-actinas loading

control. The blot image was captured using DigiPix 1260™ imager system with a CCD
camera and a electronic transilluminator (ULTRA-LUM, Inc. Paramount, CA). A ZERODscan software (Scanalytics, Inc, Fairfax, VA) was used to quantitatively analyze these
images.

F. STATISTICAL ANALYSIS
All data are expressed as mean ± SE. Data are evaluated for statistical significance by one
way Analysis of Variance (ANOVA), and significantly different group means were then
separated by the least Significant Difference (LSD) test using SPSS (SPSS Inc, Chicago,
IL). A p value< 0.05 is considered significant.
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IV. RESULTS

To determine the direct effect of la,25-(OH)z-D 3 on adipocyte Ca2+ signaling, the [Ca2+]i
response to la,25-(OH) 2-D 3 was evaluated. la,25-(OH) 2-D 3 induced a significant
increase of [Ca2+]i in human adipocyte in a dose-dependent manner, with 13.33±1.22 nM
vs. 23.33±2.81 nM increases over baseline (5 nM vs.IO nM la,25-(OH)z-D 3 treatment,
p<0.02), respectively (Fig. 29 upper left). This action was mimicked by la,25dihydroxylumisteroh (la,25-(OH)z-lumisteroh), a specific agonist for membrane vitamin
D receptor (mVDR). la,25-(OH) 2 -lumisteroh caused a marked dose-responsive increases
in human adipocyte [Ca2+]i, with 27.75±7.82 nM and 131.00±11.00 nM increases over
baseline (p<0.001), respectively (Fig. 29 upper right), while these effects were
completely prevented by pre-treatment of human adipocytes with 1P,25dihydroxyvitamin D 3 (lp,25- (OH)2-D 3), a specific antagonist for mVDR (Fig. 29 lower
panel).

To investigate the role of la,25-(OH)z-D3 in regulating lipid metabolism, we treated
human adipocytes with la,25-(OH)z-D 3 and its mVDR agonist and antagonist, using
FAS and GPDH as lipogenic markers and glycerol release as a lipolytic indicator. 1a,25(OH)z-D3 (5 nM) caused a 40% increase in adipocyte FAS activity over 48 hrs (p<0.05,
Fig. 30 lower panel), while la,25-(OH)i-lumisteroh exerted a more potent effect, with a

2.5 fold increase in FAS activity (p<0.001, Fig. 30 lower panel). However, pretreatment
of human adipocytes with IP,25- (OH)i-D 3 completely prevented this stimulation of FAS
(Fig. 30 lower panel). A similar stimulation was observed on FAS mRNA expression,
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Fig 29. The effects of la,25-(OH) 2-D3 and la,25-(OH)z-lumisteroh on stimulation of
human adipocyte [Ca2+]i. A fura-2 dual wavelength fluorescent imaging system was used
to measure [Ca 2+]i as described in Materials and Methods. 4~6 independent experiments
were conducted for each treatment. The arrows under each [Ca2+]i tracing figure indicate
the time of addition of either 1a,25-(OH) 2-D 3 or 1a,25-(OH) 2-lumisteroi). Upper left:
la,25-(OH) 2-D 3 stimulated a dose-responsive increase in human adipocyte [Ca2+]i, with
13.33 ± 1.22 nM and 23.33 ± 2.81 nM increases over baseline (p<0.05), respectively.
Upper right: la,25-(OH)2-lumisterob caused a similar but more sustained doseresponsive increase in human adipocyte [Ca2+]i, with 27.75 ± 7.82 nM and 131.0 ± 11.0
nM increases over baseline (p<0.05). Lower panel: Pre-treatment of human adipocytes

with 1B,25- (OH) 2-D 3 completely prevented either 1a,25-(OH)z-D3 (right) or 1a,25(OH)2-lumisterob-induced (left) increases in human adipocyte [Ca2+]i.
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Fig 30. The effects of la,25-(OH) 2-D3 and la,25-(OH)i-lumisteroh

on FAS activity and

expression in human adipocytes. Human adipocytes were treated with la,25-(OH)i-D3 (5
nM) alone or la,25-(OH) 2-lumisteroh (5 nM) alone, la,25-(OH) 2-D 3 (5 nM) plus lP,25-

(OH)i-D3 or la,25-(OH)i-lumisteroh

(5 nM) plus lp,25- (OH)i-D3 for 48 hours. FAS

activity measurement and expression analysis were conducted as described in Materials
and Methods. Lower panel: The effects of la,25-(OH) 2 -D 3 and la,25-(OH) 2 -lumisteroh
on stimulation of human adipocyte FAS activity. Bars with non-matching letters are
significantly different (*p<0.05); n=8. Upper panel: The effects of la,25-(OH) 2-D3 and
la,25-(OH)i-lumisteroh

on stimulation of human adipocyte FAS expression. Blot shown

is representative of 3 similar experiments. *p<0.01 vs. control.
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with 2 and 2.5 fold increases on la,25-(OH) 2-D3 and la,25-(OH)i-lumisteroh

treatment

(p<0.001, Fig. 30 upper), respectively, while this stimulation was completely blocked by
lP,25- (OH) 2-D3. Consistent with this, la,25-(OH)i-D 3 (5 nM) stimulated a 50% increase
in human adipocyte GPDH activity (p<0.05, Fig 31), while a markedly greater
stimulation of 2.8 fold was found with la,25-(OH)i-lumisteroh treatment (p<0.001, Fig
31). Although lP,25- (OH)i-D 3 exerted little effect on la,25-(OH)i-D 3 stimulated GPDH

activity, it markedly inhibited la,25-(OH) 2-lumisteroh stimulated GPDH activity (Fig
31).

Adipocyte lipolysis responded to la,25-(OH)i-D 3 and its agonist in an inverse manner to
the lipogenesis. Fig. 32 (upper) illustrates that la,25-(OH)i-D 3 exerted a inhibitory effect
on adipocyte basal lipolysis, with a 35% reduction (p<0.05). A greater inhibition of 50%
was found with la,25-(OH) 2-lumisteroh treatment (p<0.01, Fig. 32 upper). Conversely,
this inhibition was completely prevented by pretreatment with lP,25- (OH)2-D3.
Similarly, treatment of human adipocytes with isoproterenol resulted in a 3.2 fold
increase in lipolysis (p<0.001, Fig. 32 lower panel), while la,25-(OH)i-D 3 and la,25(OH)i-lumisteroh inhibited isoproterenol-stimulated lipolysis by 56% and 53% (p<0.001,
Fig. 32 lower panel), respectively. Pretreatment with lP,25- (OH)i-D 3 prevented this

inhibitory effect of la,25-(OH)2-D3 and la,25-(OH)i-lumisteroh on isoproterenolstimulated lipolysis (Fig. 32 lower panel).
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Fig 31. The effects of la,25-(OH) 2 -D3 and la,25-(OH)z-lumisteroh on GPDH activity in

human adipocytes. Human adipocytes were treated with la,25-(OH) 2 -D3 (5 nM) alone or
la,25-(OH) 2 -lumisteroh (5 nM) alone, la,25-(OH)z-D 3 (5 nM) plus lP,25- (OH)z-D3 or
la,25-(OH) 2 -lumisteroh (5 nM) plus lP,25- (OH)z-D3 for 48 hours. GPDH activity
measurement was performed as described in Materials and Methods. *p<0.05 vs. control;
**p<0.001 vs. control; n=8.
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Fig 32. The effects of la,25-(OH)z-D 3 and la,25-(OH)z-lumisteroh on human adipocyte

lipolysis. In basal lipolysis study, human adipocytes were treated with la,25-(OH)i-D 3 (5
nM) alone or la,25-(OH)2-lumisteroh (5 nM) alone for 2 hours, or pretreated with lP,25-

(OH)z-D3 for half hour and then treated with la,25-(OH)z-D 3 (5 nM) plus lP,25- (OH)iD3 or la,25-(OH)2-lumisteroh (5 nM) plus lP,25- (OH)2-D3 for 2 hours. In
isoproterenol-stimulated lipolysis study, human adipocytes were first pre-treated with or
without lP,25- (OH)2-D3 for half hour, and then treated with or without la,25-(OH)z-D 3
(5 nM) alone or la,25-(OH)2-lumisteroh (5 nM) alone for half hour, or la,25-(OH)z-D 3
(5 nM) plus lp,25- (OH)z-D3 or la,25-(OH)z-lumisteroh (5 nM) plus lP,25- (OH)i-D 3
for half hour, and finally treated with isoproterenol alone, or isoproterenol plus previous
combinations. Glycerol release was determined as described in Materials and Methods.
Upper panel: la,25-(OH) 2-D3 and la,25-(OH)z-lumisteroh (5 nM) inhibited adipocyte
basal lipolysis, with a 35% or 50% reduction, respectively. *p<0.05 vs. control; **<0.01
vs. control; n=8. Lower panel: la,25-(OH)z-D 3 and la,25-(OH)z-lumisteroh (5 nM)
inhibited isoproterenol-stimulated lipolysis. *p<0.001 vs. control; **p<0.001 vs.
isoproterenol; n=8.
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V. DISCUSSION
We previously reported that agouti, an obesity gene expressed in human adipose tissue,
stimulates Ca 2+ influx (4, 5) and promotes triglyceride accumulation in adipocytes by
simultaneously stimulating the expression and activity of FAS and inhibiting basal and
agonist-stimulated lipolysis via a Ca 2+ dependent mechanism (6, 7). Moreover, we
recently demonstrated that agouti expression is highly correlated with in vivo FAS
expression and activity in human adipose tissue (28), further suggesting that agouti
protein, a physiological Ca 2+ agonist, may play a role in obesity. Therefore, identifying
and characterizing hormones that modulate [Ca2+]i is a logical approach for elucidating
novel mechanisms involved in modulating adiposity.

Data presented here show that the calcitrophic hormone la,25-(0H)2-D

3

exhibits a

similar role in modulating adipocyte Caz+ signaling, resulting in a coordinated control
over lipogenesis and lipolysis. These data indicate that la,25-(0H)z-D

3

plays a novel role

in mediating energy homeostasis in adipose tissue and suggest that the la,25-(0H)z-D

3

mediated signaling pathways in regulating adipocyte energy metabolism may represent a
suitable target for the development of pharmacological and/or nutritional interventions in
obesity. Although it is possible that la,25-(0H)2-D

3

may also exert its effects on

adipocyte lipid metabolism via other signal transduction pathways, this is unlikely, as we
have previously demonstrated similar effects which result from direct activation of
adipocyte Caz+ channels (6, 8, 9, 25) and can be reversed by Ca 2+ channel inhibition (7,
25). Moreover, we recently demonstrated that protein kinase C does not mediate [Caz+]i
inhibition of lipolysis (9).
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la,25-(OH)z-D 3, the biologically active form of the vitamin D, was originally believed to
solely function via a nuclear receptor in a manner similar to the other members of steroid
hormone superfamily, resulting in a biological response (10). Briefly, la,25-(OH)2-D3
binds to and activates a specific nuclear hormone receptor, nVDR. The activated nVDR
then interacts with another nuclear receptor RXR and forms a heterodimer complex. This
complex functions as a transcriptional factor to act on the direct repeat response element
named DR-3 in the promoter region of target genes, thereby stimulating or suppressing
transcription of those genes encoding for proteins that carry out a variety of functions
(10). Indeed, recent studies ofnVDR knockout mouse showed that mice lacking nVDR
exhibit a vitamin D deficient phenotype, such as impaired bone formation and growth
retardation 29, 30), demonstrating that nVDR mediated genomic action exhibits an
important biological function. However, a high calcium/phosphorus/lactose diet fed at 16
days of age in nVDR knockout mice allows normal mineral ion homeostasis and thereby
rescues the vitamin D deficient phenotype (31), suggesting that an alternative pathway
may compensate to preserve intestinal calcium absorption and bone development and
modeling in the absence of a functional n VDR. Moreover, several studies demonstrated
that la,25-(OH) 2-D 3 is able to induce rapid non-genomic effects in nVDR-null cells or
cells from nVDR knockout mice (32, 33), indicating that the genomic model of la,25(OH)z-D3 action is not complete. la,25-(OH)z-D3 also generates rapid, nongenomic
signal transduction including modulation of calcium channels ( 12-15) via a putative
membrane vitamin D receptor (mVDR) in a wide variety of cells (11 ). Nemere et al (34,
35) identified a membrane associated protein with a high binding affinity for la,25(OH)z-D3, which mediated the rapid non-genomic regulation of PKC. Baran et al (36)
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recently found another plasma membrane-bound protein with a specific and saturable
binding for la,25-(OH) 2-D3, which regulates the rapid effects of la,25-(OH)2-D3 on
[Ca2+]i. This protein was identified as annexin II by sequence analysis and Western Blot.
However, it is not known whether these identified binding proteins for la,25-(OH)2-D3
are the same protein or different receptors mediating similar non-genomic functions.

Our data further extend these observations by demonstrating that la,25-(OH) 2-D3 elicits
a non-genomic action in adipocytes, resulting in a stimulation of [Caz+]iand
corresponding modulation oflipid metabolism. Although la,25-(OH) 2-D3 does regulate
FAS expression, this is attributed to la,25-(OH) 2-D3 induced increases in [Ca2+]irather
than a direct effect on FAS expression, as this effect can be mimicked by the mVDR
agonist and blocked by the mVDR antagonist. Further, we have previously demonstrated
modulation of [Ca 2+]i to correspondingly regulate FAS expression (4-7).

The analogs of la,25-(OH)z-D 3 have been extensively examined in term of their ability
to generate genomic or non genomic biological response (16, 17). Several reports (18, 19)
demonstrated that 6-s-cis-locked analogs of la,25-(OH)2-D3, such as la,25dihydroxylumisteroh, are specific for non-genomic action, including stimulation of Ca2+
influx, via binding to mVDR. In contrast, this analog exhibits low binding affinity to
nVDR and fails to activate the genomic pathway. Further, 1~,25-dihyroxyvitamin D 3,
blocks rapid physiological response elicited by la,25-(OH) 2-D 3 or la,25dihydroxylumisteroh but has no effects on nVDR (20, 21). Therefore, la,25363

dihydroxylumisteroh is a specific agonist of non-genomic action, while 113,25dihyroxyvitamin D 3 is a specific antagonist of non-genomic action. It is noteworthy that
la,25-dihydroxylumisterob

exerted more potent effects in modulating adipocyte [Ca2+]i

and corresponding lipid metabolism, and that 113,25-dihyroxyvitamin D 3 completely
blocked these effects. This suggests that la,25-dihydroxylumisterob

acts on the mVDR

solely to generate non-genomic action in adipocytes, while la,25-(OH)i-D

3

may target

both mVDR and nVDR to mediate non-genomic and genomic actions which may interact
with each other in signal response, thereby compromising the modulation of lipid
metabolism. These data further demonstrate that la,25-(OH)i-D

3

mediated non-genomic

action via mVDR may play a major role in regulating adipocyte lipogenesis and lipolysis.

Regulation of adipocyte metabolism via la,25-(OH) 2-D 3 signaling pathways may play an
important role in the development of obesity in vivo. Several lines of evidence
demonstrate that circulating la,25-(OH)i-D
Accordingly, la,25-(OH)i-D

3

3

level is elevated in obese humans (37-40).

mediated signaling pathway in regulating adipocyte energy

homeostasis may represent a suitable target for the development of pharmacological
and/or nutritional interventions in obesity. Previous studies showed that increasing
dietary calcium suppressed la,25-(OH) 2-D 3 levels (41, 42). Accordingly, we tested the
hypothesis that dietary calcium suppression of la,25-(OH)2-D 3 would reduce adipocyte
[Ca2+]i and thereby inhibit triglyceride accumulation by coordinated control over
lipogenesis and lipolysis. Our data demonstrated that suppression of la,25-(OH) 2-D3 by
increasing dietary calcium decreased adipocyte intracellular
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ca2+,
stimulated lipolysis,

inhibited lipogenesis, increased adipocyte uncoupling protein 2 (UCP2) expression and
core temperature in aP2-agouti transgenic mice and that dietary calcium not only
attenuated diet-induced obesity but also accelerated weight loss and fat mass reduction
secondary to caloric restriction (22, 23). Moreover, these results were supported by recent
clinical observations (22, 43)

In summary, these data suggest that la,25-(0H)i-D

3

modulates adipocyte Ca2+ signaling

and, consequently, exerts a coordinated control over lipogenesis and lipolysis. Thus, a
direct inhibition of la,25-(0H) 2 -D3 induced [Ca2+]i may contribute to an anti-obesity
effect of dietary calcium, and the mVDR mediated non-genomic pathway may represent
an important target for development of therapeutic interventions in obesity.
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PARTS
la,25-DIHYDROXYVITAMIN D3 INHIBITS UNCOUPLING
PROTEIN 2 EXPRESSION IN HUMAN ADIPOCYTES
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I. ABSTRACT
We have previously demonstrated a regulatory role for intracellular Ca 2+ ([Ca 2+]i) in
regulating adipocyte lipogenesis and lipolysis. Recent data from this laboratory
demonstrates that 1a,25-dihydroxyvitamin D 3 (1 a,25-(OH)z-D 3) stimulates human and
murine adipocyte Ca 2 + influx, and that suppressing la,25-(OH)z-D 3 by increasing dietary
calcium decreases adipocyte [Ca2+]i, stimulates lipolysis and inhibits lipogenesis.
Notably, these high calcium diets also increase core temperature and white adipose tissue
uncoupling protein 2 (UCP2) expression in aP2-agouti transgenic mice. However, it is
not clear that whether this up-regulation ofUCP2 is a direct effect of inhibition of la,25(OH)z-D/ genomic action, inhibition of non-genomic action induced [Ca 2+]i, or a result
of increased fatty acid secondary to increased lipolysis. Accordingly, we have evaluated
the role of 1,25-(OH)z-D in regulating human adipocyte UCP2 mRNA and protein levels.
48 hr treatment of human adipocytes with 1 nM la,25-(OH)z-D3 caused a 20-50%
decrease in basal UCP2 expression and protein levels, while direct stimulation of Ca2+
influx did not. Further, la,25-(OH) 2-D 3 completely prevented the isoproterenolstimulated 2-3 fold increases in UCP2 expression and protein levels, whereas direct
stimulation of Ca 2+ influx exerted only minimal effects. Moreover, 1a,25-(OH)z-D 3
blocked free fatty acid-stimulated UCP2 expression by 40%, while direct stimulation of
Ca 2+ influx was without effect. In contrast, la,25-dihydroxylumisteroh

(la,25-(OH)

2-

lumisteroh), a specific agonist for a putative membrane vitamin D receptor (m VDR), was
unable to inhibit either basal or isoproterenol-stimulated or fatty acid-stimulated UCP2
expression. Consistent with this, 1J3,25-dihydroxyvitamin D 3 (1J3,25-(OH)i-D 3), a
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specific antagonist for the mVDR, was unable to prevent the la,25-(0H)

2 -D 3'

inhibition

on either basal or isoproterenol-stimulated or fatty acid-stimulated UCP2 expression.
Further, n VDR knockout via antisense oligodeoxynucleotide (ODN) prevented the
inhibitory effect of 1a,25-(0H)i-D 3 on adipocyte UCP2 expression. These data indicate
that 1a,25-(0H)i-D 3 exerts an inhibitory effect on white adipocyte UCP2 expression and
that this effect is mediated via a genomic (nVDR) action. Thus, suppression of la,25(0H)i-D3 and consequent up-regulation of UCP2 may contribute to our previous
observation of increased thermogenesis in mice fed with high calcium diet. This effect,
coupled with decreased lipogenesis and increased lipolysis secondary to decreased [Ca2+]i
mediated by nongenomic action may contribute to an anti-obesity effect of dietary
calcium.
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II. INTRODUCTION
Intracellular Ca 2+ ([Ca 2+]i)plays a key role in metabolic disorders associated with obesity
and insulin resistance (1-3). We previously reported that increasing [Ca2 +]ivia
stimulation of either receptor-mediated or voltage-dependent calcium channels stimulates
the expression and activity of fatty acid synthase (FAS), a key enzyme in de nova
lipogenesis, and inhibits basal and agonist-stimulated lipolysis in both human and murine
adipocytes (4-7). Therefore, increasing [Ca2+]i appears to promote lipid accumulation in
adipocytes by exerting a coordinated control over lipogenesis and lipolysis, serving to
simultaneously stimulate the former and inhibit the latter.

la,25-dihyroxyvitamin

D3 (la,25-(0H)

2-D 3)

was originally believed to solely function

via a nuclear vitamin D receptor (nVDR) to generate genomic action (8). However, this
concept was challenged by studies demonstrating rapid nongenomic signal transduction,
including stimulation of [Ca2+]ivia a putative membrane vitamin D receptor (mVDR), in
a wide variety of cells (9-13). We recently demonstrated that 1a,25-(0H) 2 -D 3 stimulates
adipocyte [Ca2+]i, promotes lipogenesis and inhibits lipolysis via a rapid non-genomic
action (14). We further demonstrated that suppressing la,25-(0H)z-D3 by dietary
calcium decreases adipocyte [Ca2+]i, stimulates lipolysis, inhibits lipogenesis and thereby
reduces adiposity in aP2-agouti transgenic mice (15, 16). Notably, it also increases core
temperature and white adipocyte uncoupling protein 2 (UCP2) expression (15, 16).
UCP2, a homolog ofUCPl, is ubiquitously expressed, with the highest level in white
adipose tissue (17, 18). UCP2 has been shown to decrease the mitochondrial potential in
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transformed yeast (17), indicating that this protein stimulates mitochondrial proton leak.
Several lines of evidence show that UCP2 is involved in regulating metabolic rate and
adiposity in vivo. However, it is not clear whether this up-regulation ofUCP2 in our
animal studies is a direct effect of inhibition of la,25-(0H)i-D

3'

genomic action, or

inhibition of non-genomic action induced [Ca2+]i, or a result of increased fatty acid flux
secondary to increased lipolysis. Accordingly, this study was designed to determine the
role of la,25-(0H)i-D

3

in regulating human adipocyte UCP2 mRNA and protein levels.
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III. MATERIALS AND METHODS
A. CULTURE OF HUMAN ADIPOCYTES
A human adipocyte cell line and primary-cultured human adipocytes were both used as
cell models in this study. The human adipocyte cell line was differentiated from human
preadipocytes obtained from Zen-Bio Inc (Research Triangle Park, NC). Human
preadipocytes were inoculated in Dulbecco's Modified Eagle' Medium (DMEM) / Ham'
F-10 medium (F-10) (1:1, v/v) containing 10% fetal bovine serum (FBS), 15mM Hepes
and antibiotics at a density of 30,000 cells/cm 2 • Confluent monolayers ofpreadipocytes
were induced to differentiate with a standard differentiation medium consisting of
DMEM/F-10 (1:1, v/v) medium supplemented with 15 mM Hepes, 3% FBS, 33 µM
biotin, 17 µM pantothenate, 100 nM insulin, 0.25 mM methylisobutylxanthine (MIX), 1
µM dexamethasome, 1 µM BRL49653 and antibiotics (100 UVml penicillin, 100 µg/ml
streptomycin and 50 µg/ml Fungizone ). Preadipocytes were maintained in this
differentiation medium for 3 days and subsequently cultured in adipocyte medium in
which BRL49653 and MIX were withdrawn. Cultures were refed every 2-3 days (19).
Primary-cultured human adipocytes were derived from human subcutaneous adipose
tissue obtained from patients undergoing abdominal plastic surgery with no known
history of metabolic disorders. This protocol was approved by the Institutional Review
Board for Human Subjects and the Committee for Research Participation of the
University of Tennessee. Adipocytes were isolated as previously described (20). Briefly,
adipose tissue was first washed several times with Hank's Balanced Salt Solution,
minced into small pieces and digested with 1 mg/ml typel collagenase in a shaking water
bath at 37 °c for 30 min. Adipocytes were then filtered through a sterile 500 µm nylon
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mesh and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with
1% fetal bovine serum (FBS), 100 UI/ml penicillin, 100 µg/ml streptomycin and 50
µg/ml gentamicin. Cells were cultured in suspension and maintained in a thin layer at the
top of culture media, which were changed every day. Cells were maintained viable and
metabolically responsive under this culture condition for 7 days.

B. NORTHERN BLOT ANALYSIS
Northern blot analysis was conducted as previously described (20). Total RNA from
human adipose tissue was extracted using CsC}z density centrifugation, run in 1%
agarose gel and transferred to nylon membranes (New England Nuclear, Boston, MA).
The membrane was hybridized with UCP2 cDNA probes that were radiolabeled using a
random primer method. Unbound probe was removed by rinsing the membrane with 2X
SSC I 0.1 % SDS for 30 min at room temperature and O.lX SSC / 0.1 % SDS for 45 min at
55 °c.Finally, the membrane was exposed to X-ray film (New England Nuclear, Boston,
MA) at -80

°c.All membranes

were stripped and reprobed with ~-actin as loading

control. The blot image was captured using DigiPix 1260™ imaging system with a CCD
camera and a electronic transilluminator (ULTRA-LUM, Inc. Paramount, CA). ZERODscan software (Scanalytics, Inc, Fairfax, VA) was used to quantitatively analyze these
images.

C. WESTERN BLOT ANALYSIS
Adipocytes were harvested and sonicated in a homogenization buffer containing 50 mM
Tris-HCl (PH 7.4), 250 mM sucrose, 1 mM EDTA, 1 mM dithiothreitol, 1% (v/v) Triton

379

X, 10% protease cocktail (Sigma, St. Louis, MO). Cell homogenate was incubated on ice
for 1 hr to solubilize all proteins and insoluble portion was removed by centrifugation at
12,500 x g at 4 °C for 15 minute. Homogenate intrafranatant protein from equal numbers
of cells (determined via DNA quantitation) was boiled in Laemmli sample buffer and
subject to 10 % SDS-PAGE (21). Proteins on the gels were transferred to Hyond ECL
nitrocellulose membrane (Amersham Pharmacia Biotech, Piscataway, NJ). The
transferred membranes with proteins were blocked, washed, incubated with UCP2
monoclonal antibody and followed by horseradish peroxidase-conjugated secondary
antibody (Amersham Pharmacia Biotech, Piscataway, NJ). Visualization was detected
with chemiluminescence reagent using the ECL Western Blotting Analysis System
(Amersham Pharmacia Biotech, Piscataway, NJ).

D. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA from human adipocytes was extracted using CsCh density centrifugation. RTPCR was performed as previously described (20). Briefly, 1 µg of human adipocyte total
RNA was reverse-transcribed to first strand cDNA using random-hexamer and reverse
transcriptase (Perkin Elmer, Norwalk, CT) and amplified by PCR (Perkin Elmer,
Norwalk, CT). The PCR conditions were as follows: initial denaturation at 94 °c for
5min, followed by 34 cycles of denaturation at 94

°c for 45s, annealing

at 58 °c for

lmin, and extension at 72 °c for 1 min, with a final extension step at 72 °c for 8 min with
0.2 µM 5' primer (5'-GATCTGTGGGGTGTGTGGAGA-3')

and 3' primer (5'-

CTGGGAGTGTGTCTGGAGTTG-3 ') which correspond to nucleotide positions 181-
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201 and 625-645 in Genbank access NO. 103258, respectively. The amplified PCR
products were then visualized by 1.2% agarose gel electrophoresis.

E. ANTISENSE OLIGODEOXYNUCLEOTIDE (ODN) TRANSFECTION
The phosphorothioate antisense ODNs used in this study were synthesized by Life
Technologies. The antisense ODN targeting the nuclear vitamin D receptor (nVDR) was
designed corresponding to the start codon region of translation initiation in nVDR, with
the sequence 5'-CTGGCCGCCATTGCCTCCAT-3'.

A random mutant sequence (5'-

A TTGACTCAAA TTCA TTCTT-3 ') was used as a control.

A lipofection kit, OLIGOFECTAMINE™ Reagent (Life Technologies), was used to
transfect the cells with antisense ODNs. Antisense or mutant ODNs were diluted with
OPTI-MEM I Reduced Serum Medium (Life Technologies) and mixed with
OLIGOFECT AMINE™ Reagent to give the final concentration 200 nM. Cells were
incubated in this medium at 37 °Cina CO2 incubator for 4 hr and then cultured in
medium containing normal serum.

F. STATISTICAL ANALYSIS
All data are expressed as mean ± SE. Data are evaluated for statistical significance by one
way Analysis of Variance (ANOVA), and significantly different group means were then
separated by the least Significant Difference (LSD) test using SPSS (SPSS Inc, Chicago,
IL). A p value< 0.05 is considered significant.
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IV.RESULTS
We first determined the effect of la,25-(OH)z-D 3 on adipocyte basal UCP2 expression.

Fig. 33 (left panel) shows that a 48 hr treatment of human adipocytes with 1 nM la,25(OH)z-D3 caused a 40% decrease in UCP2 rnRNA (p<0.003), while direct stimulation of
Ca 2+ influx with KCl, a cell membrane depolarization agent, exerted no effect. Similarly,
1 nM la,25-(OH)z-D 3 reduced UCP2 protein levels by 50% (p<0.002, Fig. 33 right
panel), while KCl stimulation of Ca2+ influx was without effect. We then assessed the
effect of la,25-(OH) 2-D 3 on isoproterenol-stimulated UCP2 expression. Fig. 34 (left
panel) illustrates that treatment with 10 nM isoproterenol caused a 2 fold increase in
adipocyte UCP2 rnRNA (p<0.002), which was completely blocked by 1 nM la,25(OH)2-D3, but only 20% by KCL Although treatment with KCl inhibited isoproterenolstimulated increases in UCP2 protein (p<0.006, Fig. 34 right panel), la,25-(OH) 2-D3
exerted a more potent effect, reducing UCP2 protein below the basal level. We next
evaluated the effect of la,25-(OH) 2-D 3 on free fatty acid-stimulated UCP2 expression.

Fig. 35 shows that free fatty acids (oleic acid and linoleic acid mixture) caused a ~2 fold
increase in UCP2 rnRNA, which was completely prevented by 1a,25-(OH)z-D 3. These
data indicate that la,25-(OH)z-D 3 inhibition ofUCP2 expression is largely independent
of its effects on Ca 2+ influx or fatty acid flux.

To study whether membrane vitamin D receptor (m VDR) mediates this inhibition of
la,25-(OH)z-D 3 on adipocyte UCP2 expression, la,25-dihydroxylumisteroh

(la,25-

(OH)z-lumisteroh), a specific mVDR agonist, and lP,25-dihydroxyvitamin D (lP,25382

Fig 33. The effect of la,25-(OH) 2-D 3 on basal UCP2 mRNA (left panel) and protein

level (right panel) in human adipocytes. Human adipocytes were treated with la,25(OH)2-D3 (1 nM) or KCl (10 mM). UCP2 mRNA and protein level were measured by
Northern blot and Western blot analysis, respectively. These measurements were
conducted as described in Materials and Methods. Left panel: The effect of la,25-(OH)zD3 on basal UCP2 mRNA in human adipocytes. Blot shown is representative of 4 similar
experiments. *p<0.003 vs. control. Right panel: The effect of la,25-(OH)z-D 3 on basal
UCP2 protein level in human adipocytes. Blot shown is representative of 3 similar
experiments. *p<0.002 vs. control.
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Fig 34. The effect of la,25-(OH) 2-D 3 on isoproterenol-stimulated UCP2 mRNA (left
panel) and protein level (right panel) in human adipocytes. Human adipocytes were
treated with or without isoproterenol (10 nM), isoproterenol plus 1a,25-(OH) 2 -D 3 (1 nM)
or isoproterenol plus KCl (10 mM). UCP2 mRNA and protein level were measured by
Northern blot and Western blot analysis, respectively. These measurements were
conducted as described in Materials and Methods. Left panel: The effect of la,25-(OH)

2-

D3 on isoproterenol-stimulated UCP2 mRNA in human adipocytes. Blot shown is
representative of 4 similar experiments. *p<0.002 vs. control, **p<0.003 vs.
isoproterenol. Right panel: The effect of la,25-(OH) 2 -D 3 on isoproterenol-stimulated
UCP2 protein level in human adipocytes. Blot shown is representative of 3 experiments.
*p<0.006 vs. control, **p<0.008 vs. isoproterenol.
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(OH) 2 -D 3), a specific mVDR antagonist, were used to treat human adipocytes. Fig. 36
demonstrates that 1a,25-(OH) 2 -lumisteroh failed to exert an inhibitory effect on UCP2
mRNA, while lj3,25-(OH) 2-D3 was unable to reverse la,25-(OH) 2-D 3-induced inhibition
on UCP2 mRNA. Consistent with this, la,25-(OH)z-lumisteroh failed to prevent
isoproterenol-stimulated UCP2 expression, while 113,25-(0H)z-D3 was unable to reverse
1a,25-(OH) 2 -D 3 inhibition of isoproterenol-stimulated UCP2 mRNA (Fig. 37). Similarly,
the m VDR agonist and antagonist exerted no effect on fatty acid-stimulated UCP2
expression. Fig. 38 shows that la,25-(OH) 2 -lumisteroh failed to block fatty acidstimulated UCP2 expression, while lj3,25-(OH)z-D3 was unable to prevent la,25-(OH)

2-

D3 inhibition of fatty acid-stimulated UCP2 mRNA. These data indicate that mVDR does
not mediate the inhibitory effect of la,25-(OH) 2-D 3 on adipocyte UCP2 expression

We next investigated the role of the nuclear vitamin D receptor (nVDR) in mediating the
inhibitory effect of la,25-(OH) 2-D3 on adipocyte UCP2 expression. Using RT-PCR, we
detected a 465 hp nVDR fragment in human adipocytes and preadipocytes, corresponding
to the nucleotide sequence region 181-645 in nVDR gene (Genbank access NO. J03258)
(Fig. 39 left panel). This was confirmed by western blot analysis; using an n VDR

monoclonal antibody, we detected a ~50 kD protein (Fig. 39 right panel). We then
performed a transient transfection of antisense ODN to knock out the nVDR. A time
course study shows that treatment with nVDR anti sense ODN inhibited nVDR protein
from 48 hr through 96 hr, while the mutant antisense ODN was without effect (Fig. 40
left panel), demonstrating that the antisense ODN targeting n VDR is specific. We then
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by Northern blot. This measurement was conducted as described in Materials and
Methods. *p<0.05 vs. control, n=3.
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Fig 39. Detection of the expression of nuclear vitamin D receptor (nVDR) in human
adipocytes by RT-PCR (left panel) and Western blot (right panel). RT-PCR and Western
blot were performed as described in Materials and Methods. Left panel: Detection of the
expression ofnVDR in human adipocytes by RT-PCR. The PCR product (designated by
arrow), a 465 bp nVDR fragment, was visualized by 1.2% agarose gel electrophoresis.
Each lane is as indicated in the figure. Right panel: Detection of the expression of nuclear
vitamin D receptor (nVDR) in human adipocytes by Western blot. A ~50 Kd protein
band (designated by arrow) was detected in the blot. Each lane is as indicated in the
figure.
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Fig 40. Nuclear vitamin D receptor (nVDR) knockout by antisense oligodeoxynucleotide
(ODN) prevented the inhibitory effect of la,25-(OH) 2-D 3 on adipocyte UCP2 expression.
Antisense ODN knockout was conducted as described in Materials and Methods. Left
panel: a time course ofnVDR knockout by antisense ODN; equal amount of protein
loading was achieved by sample DNA measurement and confirmed by SDS-PAGE
visualized with coomassie blue stain (upper left). Adipocytes were transfected with
nVDR antisense ODN or mutant ODN as indicated in the figure. Right panel: nVDR
knockout by antisense ODN prevented the inhibitory effect of la,25-(OH)2-D3 on
adipocyte UCP2 expression. nVDR knockout adipocytes or adipocytes transfected with
mutant ODN were treated with or without la,25-(OH) 2-D 3 as indicated in the figure.
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treated the nVDR knockout adipocytes with la,25-(0H)z-D
that la,25-(0H)

2-D 3

3•

Fig. 40 (right panel) shows

markedly inhibited UCP2 protein in either control adipocytes or

adipocytes treated with mutant ODN. However, la,25-(0H)

2 -D 3

was unable to exert the

inhibitory effect in nVDR knockout adipocytes, indicating that this effect is mediated by
the nVDR.

394

V. DISCUSSION
We previously reported that la,25-(0H)z-D

3

stimulates adipocyte [Ca2+]i, promotes

lipogenesis and inhibits lipolysis via a rapid non-genomic action (14). Data presented
here further demonstrate that la,25-(0H)i-D

3

exerts an inhibitory effect on adipocyte

UCP2 expression via a genomic action. Therefore, la,25-(0H)

2-D3

appears to play an

important role in modulating adipocyte lipid metabolism and energy homeostasis and
function via both genomic and non-genomic actions.

It is now well recognized that la,25-(0H)i-D

3,

the biologically active form of the

vitamin D, generates biological responses via both genomic and nongenomic pathways.
la,25-(0H)i-D

3

is a highly conformationally flexible molecule and is able to rotate

around its 6, 7 carbon-carbon bond of the Bring. This rotation allows generation of a
continuum of potential ligand shapes ranging from the steroid like 6-s-cis conformation
to the extended 6-s-trans conformation (22, 23). Thus, this conformational flexibility of
la,25-(0H)

2 -D 3

in a structure and function context underlies the mechanism whereby

la,25-(0H)

2 -D 3

generates both genomic and non-genomic cellular responses.

la,25-(0H)i-D

3

generates genomic actions via a nuclear receptor in a manner similar to

the other members of steroid hormone superfamily (8). 1a,25-(0H)i-D

3

binds to and

activates a specific nuclear hormone receptor, nVDR, and nVDR knockout exhibits a
vitamin D deficient phenotype (24, 25). However, several studies demonstrated that
la,25-(0H)i-D

3

is able to induce rapid non-genomic effects in nVDR-null cells or cells
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from nVDR knockout mice (26, 27), indicating that the genomic model of la,25-(0H)

2-

D 3 action is not complete.

Instead, la,25-(0H)z-D 3 also generates rapid, nongenomic signal transduction via a
putative membrane vitamin D receptor (mVDR) in a wide variety of cells (9). These
effects include modulation of calcium channels (10-13, 28-33), production of diacyl
glycerol and inositol triphosphate induced by activation of phospholipase (34), activation
of protein kinase C (35), and stimulation of MAP kinase (36-38). Most importantly,
recent effort of pursuing physical existence of the putative mVDR provides the further
evidence to strengthen these findings. Several studies have identified membrane proteins
which function as membrane vitamin D receptors (32, 35, 39).

Our previous and present data further extend these observations by demonstrating that
la,25-(0H) 2-D 3 elicits both genomic and non-genomic action in adipocytes, resulting in
modulation of lipid and energy metabolism. In this study, we demonstrated that 1a,25(0H)2-D3 exerts an inhibitory effect on basal, isoproterenol and fatty acid stimulated
UCP2 expression via a genomic action. We confirmed that this inhibition is mediated by
nVDR using both pharmacological and molecular approaches. The mVDR agonist and
antagonist fail to exert their actions to either mimic or prevent thela,25-(0H) 2-D3
inhibitory effect on UCP2 expression, while nVDR knockout by antisense ODN
prevented the inhibitory effect of la,25-(0H)z-D 3 on adipocyte UCP2 expression.
Therefore, our data demonstrate a novel role ofnVDR in regulating adipocyte energy
metabolism. Moreover, a recent report demonstrated that nVDR gene polymorphism is
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associated with the susceptibility to obesity in humans with early-onset type II diabetes
(40). These findings indicate that nVDR may play a role in energy homeostasis and
obesity.

UCP2, a homolog ofUCPl, is 56% identical to UCPl and is ubiquitously expressed, with
the highest level found in white adipose tissue (17, 18). UCP2 has been shown to
decrease the mitochondrial potential in transformed yeast. Expressing UCP2 in yeast
causes a 50% increase in state 4 respiration, a respiration in the absence of ADP (17),
demonstrating that this protein may act on proton leaking. This was subsequently
confirmed by demonstrating that UCP2 expressed in Escherichia Coli inclusion body and
then reconstituted into liposomes is able to catalyze electrophoretic proton flux (41). Like
UCP 1, a well-characterized uncoupling protein, UCP2 requires fatty acid to mediate this
proton transport activity (41). Consistent with these findings, a recent study demonstrated
that UCP2 reconstituted into vesicles is a highly active proton transporter (42). The UCP2
mediated proton transport activity requires fatty acid and coenzyme Q, an obligatory
cofactor for proton transport by UCPl (43). Moreover, this proton transport process is
highly sensitive to purine nucleotides (42). Therefore, all these proton transport
properties for UCP2 resemble those for UCP 1.

Various physiological states and many nutritional and hormonal factors have been shown
to regulate UCP2 expression (see reviews 44-46). Administration ofthermogenic
hormones such as thyroid hormone (T3) and leptin to rodents increases UCP2 expression
(44-51). Moreover, PPARy agonist (thiazolidinediones) and retinoic acids are potent
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stimulators ofUCP2 expression (44-46, 52-56). In addition, fatty acids and J3-adrenergic
agonists are also able to induce UCP2 expression in vitro and in vivo (44-46, 51, 57-60).
Functional characterization ofUCP2 promoter region has demonstrated several potent
cis-acting regulatory elements including 2 PP ARy responsive elements (PPRE), 3 cAMP
responsive elements (CREB-1 ), 2 putative thyroid hormone responsive elements (TRE)
(61-63). These responsive elements could provide mechanisms of the positive regulation
ofUCP2 expression via PPARy agonists, fatty acids (ligands of PPARy), thyroid
hormones, J3-adrenergic agonists (isoproterenol). However, little is known regarding
negative regulatory factors ofUCP2 expression. Here we report that la.,25-(OH) 2-D3
exerts an inhibitory effect on UCP2 expression. The mechanism of this n VDR mediated
inhibition of UCP2 is not known. However, the human UCP2 promoter region does
contain several cis-acting negative regulatory elements, which strongly repress promoter
activity (61), although it is not clear whether nVDR acts on one of these silencers.
Alternatively, n VDR may also compete with other positive transcriptional factors
containing similar DNA binding domains on the responsive element binding or similar
protein-protein interaction domain (such as PPARy) on heterodimerization with the same
transcriptional factor (RXR). Further studies are required to address the mechanism
whereby la.,25-(OH)i-D 3 inhibits UCP2 expression.

The proposed physiological functions ofUCP2 include control ofthermogenesis and energy
homeostasis, regulation of insulin secretion, regulation of reactive oxygen species (ROS) and
regulation of fatty acid utilization as substrates (see reviews 44-46). UCP2 in different tissues and
physiological states may exhibit various functions. A recent study ofUCP2 knockout mouse
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demonstrated that UCP2-ablated mouse exhibits increased ROS production in macrophage (64).
Moreover, studies of UCP2 expression during fasting and re-feeding in rodents have led to a
proposal that UCP2 may function in the regulation oflipid as a fuel substrate (65, 66). Most
importantly, several lines of evidence show that UCP2 is involved in regulating metabolic rate and
adiposity in vivo. A high fat diet increased WAT UCP2 gene expression in obesity-resistant A/J
strains but not in obesity-prone C57B6 mice, indicating UCP2 also plays a role in preventing
obesity (67). In human study, a positive correlation between UCP2 mRNA expression in WAT
and resting metabolic rate (RMR) has been reported (68). In addition, UCP2 expression has also
been shown to decrease by 28% in skeletal muscle of obese subjects (69). Consistent with this
finding, a reduced UCP2 expression in visceral adipose tissue in morbidly obese subjects has been
reported recently (70). A number of genetic linkage studies have also documented association
between genetic markers and variants ofUCP2 gene and human metabolic rate and/or adiposity
(71, 72). A recent study showed that a common GIA polymorphism in the UCP2 promoter region
is associated with increased white adipocyte UCP2 mRNA level and reduced adiposity (73).
Moreover, this promoter polymorphism results in an increased transcription of a reporter gene in a
human adipocyte cell line (73). Recently, many studies have demonstrated that UCP2 is involved
in regulating insulin secretion in pancreatic J3cells (74-77). Increased UCP2 in pancreatic J3cells
decrease ATP/ADP ratio and thereby reduce glucose-stimulated insulin secretion (74-77). As
la,25-(OH)z-D

3

has been previously shown to induce insulin secretion in pancreatic J3cells (78,

79), it is tempting to speculate that la,25-(OH) 2-D 3 may induce insulin secretion, in part, by
inhibiting UCP2 in pancreatic J3cells. Indeed, our previous studies showed that inhibition of
circulating la,25-(OH)z-D

3

by increasing dietary calcium reduce insulin level in aP2-agouti

transgenic mice (15, 16).
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Regulation of adipocyte metabolism via la,25-(OH)z-D

3

signaling pathways may play an

important role in the development of obesity in vivo. Several lines of evidence
demonstrate that circulating la,25-(OH)z-D

3

level is elevated in obese humans (80-83).

Previous studies showed that increasing dietary calcium suppressed la,25-(OH)z-D

3

levels (84, 85). Accordingly, we tested the hypothesis that dietary calcium suppression of
la,25-(OH) 2 -D 3 would reduce adipocyte [Ca2+]i, increase lipolysis, inhibit lipogenesis,
increase UCP2 expression and thereby reduce adiposity in aP2-agouti transgenic mice.
Our data demonstrated that suppression of la,25-(OH) 2 -D 3 by increasing dietary calcium
decreases adipocyte intracellular

ca2+,
stimulated

lipolysis, inhibited lipogenesis,

increased adipocyte uncoupling protein 2 (UCP2) expression and core temperature in
aP2-agouti transgenic mice and that dietary calcium not only attenuated diet-induced
obesity but also accelerated weight loss and fat mass reduction secondary to caloric
restriction (15, 16). Recent epidemiological data demonstrate comparable effects in
humans (15, 86).

In summary, these data indicate that la,25-(OH)z-D

3

exerts an inhibitory effect on white

adipocyte basal, isoproterenol and fatty acid-stimulated UCP2 expression and that this
effect is mediated via a genomic action. Thus, suppression of la,25-(OH)z-D

3

and

consequent up-regulation ofUCP2 may contribute to our previous observation of
increased thermogenesis in mice fed with high calcium diet. This effect, coupled with
decreased lipogenesis and increased lipolysis secondary to decreased [Ca2+]i mediated by
nongenomic action may contribute to an anti-obesity effect of dietary calcium.
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SUMMARY AND CONCLUSIONS
In summary, we have evaluated the role of adipocyte [Caz+]i in modulation of adiposity.

We demonstrated that increasing (Caz+]iexerts a biphasic regulatory role in human
adipocyte differentiation, serving to inhibit the early stages of differentiation, while
promoting the late stages of differentiation and lipid filling. To antagonize adipocyte Caz+
influx by blocking Caz+ channels, we identified a potential receptor target, adipocyte
sulfonylurea receptor (SUR), which mediates adipocyte (Caz+]i signaling and
corresponding alterations in lipogenesis and lipolysis. Antagonism of this receptor
reverses all these actions. We extended this approach to dietary regulation of adipocyte
(Caz+]i.We demonstrated that la,25-(0H)z-D

3,

which is regulated by dietary calcium,

also stimulates adipocyte (Caz+]i,promotes lipogenesis, and inhibits lipolysis, thereby
resulting in triglyceride accumulation, via a rapid non-genomic action mediated by a
putative membrane vitamin D receptor (mVDR). These actions can be mimicked by
la,25-(0H)z-lumisteroh,

a specific agonist for mVDR, and completely prevented by

1/J,25-(0H)z-D 3, a specific antagonist for the mVDR. Dietary calcium suppression of
la.,25-(0H)z-D

3

was used as strategy to reduce adipocyte [Caz+]i and inhibit triglyceride

accumulation in transgenic mice over-expressing agouti specifically in adipose tissue.
Our data demonstrated that suppression of la.,25-(0H)z-D

3 by

increasing dietary calcium

decreases adipocyte (Caz+]i, stimulates lipolysis, inhibits lipogenesis in aP2-agouti
transgenic mice and that dietary calcium not only attenuated diet-induced obesity but also
accelerated weight loss and fat mass reduction secondary to caloric restriction. Notably,
high calcium diets also increase white adipose tissue uncoupling protein 2 (UCP2)
414

expression and core temperature. We therefore further evaluated the role of la,25-(0H)

2-

D3 in regulating human adipocyte UCP2 expression. We demonstrated that la,25-(0H)iD3 exerts an inhibitory effect on white adipocyte UCP2 expression and that this effect is
mediated via a genomic action (nuclear vitamin D receptor nVDR). Accordingly, these
data demonstrate that SUR-mediated Ca2+ signaling and la,25-(0H)

2-D 3-mediated

genomic and non-genomic pathways play important roles in regulation of adipocyte lipid
and energy metabolism, thereby contributing to modulation of adiposity, and that
antagonism of adipocyte [Ca2+]i by blocking these pathways may represent an effective
approach for development of therapeutic interventions in obesity.
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